Genetic investigation of both complex and Mendelian disorders: neural tube defects and Native American myopathy by Stamm, Demetra Serena
  
 
 
 
Genetic Investigation of both Complex and Mendelian Disorders: 
Neural Tube Defects and Native American Myopathy 
  
 
 
 
 
Demetra Serena Stamm 
 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Curriculum of Genetics. 
 
 
 
 
 
Chapel Hill 
2007 
 
 
 
 
Approved by: 
 
Kari North 
 
Cynthia Powell 
 
Stephen Crews 
 
Karen Mohlke 
 
John Gilbert 
ii 
 
 
 
 
 
 
ABSTRACT 
 
Demetra Serena Stamm 
 
Genetic Investigation of both Complex and Mendelian Disorders: Neural Tube Defects 
and Native American Myopathy  
(Under the direction of Dr. Marcy Speer) 
 
This dissertation seeks to map genes for two disorders: one complex and one 
Mendelian. The first project investigated the genetic basis of neural tube defects (NTDs) 
in one large multiplex family (8776).  NTDs are among the most common debilitating 
birth defects occurring in ~1/1000 live births in the U.S. and are considered complex 
disorders with both genetic and environmental factors implicated. Linkage analysis using 
a genomewide single-nucleotide polymorphism (SNP) screen in family 8776 identified 
maximum LOD* scores of ~3.0 mapping to 2q33.1- q35 and 7p21.1-pter.   
Ascertainment of another branch of this family further supported linkage at these two loci 
providing a ~3.3 LOD* score, and decreased the linkage interval for 7p by 7.8 Mb. 
Further haplotype analyses narrowed the minimum candidate intervals, with the new 
regions mapping to 2q33.1-q35 (20.3 Mb) and to 7p21.1-21.3 (8.3 Mb). Within these 
regions, sequencing of exons in eighteen candidate genes did not identify a causative 
mutation and chromosomal abnormalities were undetected.  Identification of an NTD 
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gene in this family may aid in a directed search for a disease gene for more typical NTD 
families. 
The second project studied Native American myopathy (NAM), a rare congenital 
disorder observed in the Lumbee population. In this dissertation, shared clinical features 
are described among 14 individuals of Lumbee Indian descent with Native American 
myopathy.  Notably, in these 14 subjects, we observed a 36% mortality rate and 29% had 
MH episodes. The Lumbee population is relatively isolated with evidence of 
consanguinity suggesting that homozygosity mapping methods may be employed for 
identifying the NAM disease locus.  To this end, we conducted a genomewide SNP 
screen which demonstrated five regions of shared homozygosity (≥ 3 contiguous SNPs) 
in individuals with NAM.  Genotyping microsatellites in these five regions lead to only 
one 5.6 Mb region of shared homozygosity amongst the NAM patients mapping to 
12q13.13 to 12q14.1. Sequencing of four genes within this region did not identify a 
functional mutation.  
Ultimately, the goal of these projects was to identify disease loci for NTD family 
8776, and for NAM, to facilitate a targeted search of candidate genes for these 
debilitating congenital disorders.  
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CHAPTER 1  
 
Introduction 
1.1 Overview of dissertation projects 
This dissertation includes two projects that both study congenital birth defects 
employing two different gene mapping approaches commonly applied to genetic 
epidemiological research.  Neural tube defects (NTDs) are considered complex, involving 
many genes and environmental factors, and a component of my thesis focused on one large 
multiplex family that demonstrated a strong genetic effect.  The other project studied a 
Mendelian disorder, Native American Myopathy (NAM), which is a rare congenital 
myopathy. Chapter 2 discusses the linkage findings obtained from a SNP-based genomic 
screen of one large NTD multiplex family, 8776. Additional ascertainment in this family 
facilitated further linkage and haplotype studies presented in Chapter 3. Chapter 4 
describes the natural history and clinical observation in patients with NAM. Finally, Chapter 
5 discusses homozygosity mapping data for five individuals with NAM. 
 
1.2 Neural Tube Defects are a Complex Group of Genetic Disorders 
The neural tube is part of the central nervous system and is formed during embryonic 
development. The process of neural tube closure occurs through neurulation beginning in the 
third week of gestation. Failure of appropriate neural tube closure by the 4th week of 
gestation leads to a neural tube defect and these defects often arise before a woman is aware 
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of her pregnancy. The etiology of neural tube defects is considered complex with both 
genetic and environmental factors implicated.  
 
1.2.1 Neural Tube Defects: Clinical Impact 
Birth defects are the leading cause of death in neonates. The risk of an infant being 
born with a significant congenital abnormality in body structure or function is approximately 
3-4%.  NTDs occur at a rate of 1/1000 live births in the US [1], representing the second most 
common type of birth defects after congenital heart defects and the most common congenital 
malformation of the central nervous system. NTDs are phenotypically heterogeneous and are 
classified as either an open or closed defect based on either the absence or presence of a layer 
skin that covers the spinal defect.  Open NTDs are brain and/or spinal tissue that are 
uncovered by skin tissue and therefore exposed at birth.  In contrast, closed NTDs are 
covered by a layer of skin and consequently have less risk of infection. 
The most common forms of NTDs are the open NTDs: anencephaly and spina bifida 
cystica.  Anencephaly is the failure of the formation of the brain and back of the skull, and all 
infants with anencephaly are stillborn or die shortly after birth.  Two types of spina bifida are 
commonly described, spina bifida occulta (SBO, closed) and spina bifida aperta (open). 
Spina bifida occulta is a vertebral defect without protrusion of any spinal contents.  SBO 
patients are usually asymptomatic. The most common NTD, open spina bifida also called 
myelomeningocele, involves a defect in the vertebral arches leading to herniation of spinal 
tissue (spinal cord and meninges) at the base of the spine, resulting in deleterious neural 
deficits below the level of the lesion. Craniorachischisis, which is always incompatible with 
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life, is a rare severe form of open NTDs with fetuses having an entirely open neural tube 
(encompassing both the cranial and spinal regions).  
For closed NTD defects, such as spina bifida occulta, often the only indication of the 
NTD is a cutaneous finding such as a skin tag, midline dimple, or hemangioma. 
Encephalocele is a closed NTD with a defect in the skull that leads to the protrusion of the 
brain outside of the skull into an enclosed sac of skin.  Children affected with open spina 
bifida often receive surgery to close the defect within 48 hours after birth, and may require 
frequent surgical intervention for hydrocephalus. Surgical closure of an open neural tube is 
performed shortly after birth for the following two reasons: 1) to prevent possible infection of 
the neural tissues that could lead to meningitis; and 2) to help preserve neurological function 
of the tissues in close proximity to the open defect.  
Hydrocephalus, which is an enlargement of the cerebral ventricles, is caused by an 
obstruction along the pathway of the cerebrospinal fluid (CSF) flow from the ventricles to the 
arachnoid villi.  Ninety percent of children born with open spina bifida will have 
venticulomegaly, and 70% of these children will require shunt placement [2].  Interestingly, 
most patients with myelomeningocele also have Chiari II malformation with four potential 
sites of obstruction for the cerebral spinal fluid pathways including at the aqueduct of 
sylvius, cork in bottle, foramen of magendie, and venous outflow obstruction. This condition 
includes downward displacement of the medulla, fourth ventricle, and cerebellum into the 
cervical spinal canal, as well as elongation of the pons and fourth ventricle, probably due to a 
relatively small posterior fossa.  
The Chiari II malformation is a complex congenital malformation of the brain and is 
nearly always associated with myelomeningocele. This co-occurrence of spina bifida and 
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Chiari II malformation may in part be explained by the disrupted cerebral spinal fluid 
pathways caused by the Chiari II malformation.  For instance, the presence of disrupted CSF 
flow in the spine may have deleterious effects on appropriate neural tube formation and 
closure at the base of the spine, thereby leading to the associated spina bifida.  
Patients affected with a spinal defect commonly have an impaired ability to walk and 
often need to use a wheelchair, and they may have little or no bowel and/or bladder control. 
The extent of impairment for the patient is dependent on the position of the spinal lesion.  For 
example, a child with a cervical lesion may not be able to breathe on his or her own whereas 
a child with a lumbosacral lesion –the most common location for spina bifida—may have 
nerve damage affecting ambulation, bladder, and bowel function. In 1990, the estimated 
annual medical and surgical costs for persons with spina bifida exceeded $200 million [3]. 
However, the psychosocial and emotional toll for the family and child with NTD is 
immeasurable. These significant medical and personal costs have lead to several 
collaborative studies to investigate NTDs to better understand the genetic and environmental 
etiologies. 
 
1.2.2 Epidemiology of Neural Tube Defects 
Since a large percentage of fetuses affected with a NTD are likely to be 
spontaneously aborted before diagnosis, estimates of NTD incidence may be underestimated. 
Therefore, in a study of congenital birth defects, it is generally recommended to report 
prevalence estimates, often reported as live births, since there may be elected abortions and 
early fetal demise in the first few hours to days of life.  Across the world, the prevalence of 
NTDs varies widely showing significant geographic and ethnic variation in NTD risk. 
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Prevalence studies and registries have been designed for epidemiological surveillance of 
birth defects in order to identify particular exposures in different geographical locations and 
populations which may either have protective mechanisms or potential teratogenic risks.  In 
the US between the years of 1991-2004, the frequency of spina bifida was 19.56 per 100,000 
live births and the frequency of anencephaly was 10.39 per 100,000 live births [4]. The 
highest US prevalence rates are noted in the South-East, particularly in the Appalachian 
region [2]. Using data reported to the National Birth Defects Prevention Network (NBDPN) 
for the years between 1999-2000, it was found that Hispanics had the highest prevalence of 
NTDs in the United States with ~5.8 per 10,000 live births, Caucasians were the next most 
frequent with 5 per 10,000 live births, followed by African Americans with ~3.8 per 10,000 
live births [5]. More specifically, populations of Mexican descent along the Texas-Mexico 
border of the United States have a high prevalence of NTDs [6]. The high prevalence 
observed in this group may be due to any number of factors including genetic susceptibility, 
inadequate dietary folate levels, an occupational exposure such as pesticides on farms, and/or 
an environmental exposure such as fumonisin B1 (FB1). FB1 is a naturally occurring 
mycotoxin in corn—a dietary staple of this Hispanic population—and FB1 has been shown 
to reduce cellular folate uptake [6]. Moreover, an association between fumonisin exposure 
and NTD prevalence has been observed in women living along the Texas-Mexican border 
[7]. 
Other countries exhibit higher rates of spina bifida or anencephaly prevalence in 
comparison to the United States. For example, both Mexico and Guatemala have high 
prevalence rates of NTDs, rates that may also be attributed to FB1 exposure.  The prevalence 
of NTDs in Mexico from the years of 1996-2000 was 13.5 per 10,000 live births for 
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anencephaly and 14.4 per 10,000 live births for spina bifida [8]. In India, a higher prevalence 
of NTDs are noted in the North (Punjab, Delhi) in comparison to Eastern cities [9]. For 
example, a retrospective study in Punjab, India reported an anencephaly prevalence of 36 per 
10,000 live births [10].  Northern China’s Shanxi Province has one of the highest prevalence 
of NTDs in the world, and during 2003 the birth frequency of NTDs was 138.7 per 10,000 
live births [11]. Importantly, only 4.2% of mothers with children having NTDs used folic 
acid supplements during the periconceptional period, suggesting folic acid deficiency as a 
possible explanation for the high prevalence, although, other factors likely contribute to this 
high prevalence, for example teratogenic exposures and/or genetic effects.   
Currently, it is unclear whether these observed differences in NTD risk are related to 
population-specific differences in genetic risk, environmental factors, or a combination of the 
two.  
 
1.2.3 Syndromic versus Nonsyndromic NTDs 
The etiology of NTDs is heterogeneous [12,13] both in phenotypic characteristics as well 
as the genetic predisposition. For instance, the majority of infants with NTDs are 
nonsyndromic (isolated cases without any other associated phenotypic features) and likely 
result from multifactorial etiologies.  Different studies have reported that most cases of spina 
bifida and anencephaly (approximately 80-90% [14-17]) are nonsyndromic.  Other patients 
with NTDs may have additional birth defects, and these NTDs are either considered part of a 
syndrome with a presumed cause (single gene mutation, chromosomal abnormality, or 
teratogen exposure) or if not part of syndrome, the child may be described as having multiple 
birth defects. The genetic mechanisms responsible for nonsyndromic NTDs versus multiple 
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birth defects and syndromic NTDs are likely to be different; however, it is also possible that 
there are pleiotropic effects of genes, or in the case of chromosomal abnormalities, that 
several genes may be altered leading to more tissues and organ systems to be adversely 
affected.   
 
1.2.4 Chromosomal Abnormalities in NTDs 
Chromosomal abnormalities are observed in both syndromic and nonsyndromic 
NTDs. Neural tube defects can be caused by chromosome rearrangements.  Chromosomal 
abnormalities can include translocations, deletions and insertions/duplications, and the 
cytogenetic breakpoint may disrupt genes involved in neural tube development.  Such 
chromosomal abnormalities are present in 5-17% of NTD cases; however, this estimate may 
not accurately predict live birth frequency since many of the studies were conducted 
prenatally and therefore also describe chromosomal abnormalities of stillbirths and 
spontaneous abortions [18-20]. For example, Sepulveda et al. conducted a prospective study 
of fetuses with open neural  tube defects that underwent prenatal chromosome analysis [21], 
and found that trisomy 18 and 13 were the most common chromosomal abnormalities and 
both of these aneuploidies have high rates of fetal mortality.  They collected cytogenetic data 
on 144 fetuses with open NTDs, and found that 10 fetuses (7%) had chromosomal 
abnormalities, 7 fetuses with trisomy 18 and 2 fetuses with trisomy 13. Characterizing the 
chromosomal abnormality in individuals affected with an NTD could be informative for 
identifying potential NTD candidate genes that either fall within the cytogenetic breakpoint 
or are in the deleted and/or amplified chromosomal segments.  
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The majority of NTDs are nonsyndromic and 2-16% of the individuals with 
nonsyndromic NTDs also carry chromosomal abnormalities [22]. However, if NTDs are 
observed with other congenital anomalies the frequency increases up to 24% [18]. The 
reported frequency may be even higher in spontaneously aborted fetuses, with approximately 
53% of spontaneously aborted fetuses with an NTD having a cytogenetic abnormality [22].  
Trisomy 18 is the most common aneuploidy associated with various forms of NTDs 
including spina bifida, anencephaly, craniorachischisis, encephalocele; trisomy 13 is also 
associated with spina bifida and encephalocele [22]. Other commonly associated 
chromosomal aberrations observed in NTDs include other trisomies and tetraploidy, 
duplication of 2p23-2pter, ring chromosomes 13 and 18 (formed by fusion of ends of 
chromosome), and deletions in chromosomes 13q and 22q, among many others.   
There is variable presentation of NTDs with chromosomal abnormalities that may 
implicate a multifactorial nature of NTD manifestation even in syndromic cases, such that 
numerous genetic abnormalities in combination with particular environmental exposures may 
lead to expression of different NTD phenotypes.  
  
1.2.5 Environmental Components to NTD Predisposition 
The predisposition to and development of NTDs is complex, with both environmental 
and hereditary factors implicated. There are a vast number of exogenous risk factors 
correlated to the development of NTDs including maternal insulin-dependent diabetes 
mellitus, obesity, maternal use of anti-epileptic (valproic acid) and cholesterol (statins) 
medications, maternal elevated homocysteine levels, smoking, Agent Orange exposure, and 
mycotoxin fumonisin (a fungus toxin found on maize) [23-29]. 
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The antiepileptic medications valproic acid (VPA) and carbamazepine have been 
associated with an increased risk for NTDs in both human studies and experimental animal 
models [24,30-36]. VPA has been associated with a variety of major and minor 
malformations, including neural tube defects, cleft lip and palate, cardiovascular 
abnormalities, genitourinary defects, developmental delay, endocrinological disorders, and 
limb defects. It has been estimated that 1-2% of all infants exposed to VPA during early 
pregnancy will have spina bifida aperta, a 20-fold increased prevalence over that observed in 
the general population [31].  VPA may cause these defects by interfering with retinoic acid 
metabolism [37].  With carmazepine, another anti-epileptic medication, the risk for exposed 
infants presenting with a NTDs ranges between 0.5% and 1% [25,32,38]. Lower blood folate 
concentrations in women treated for epilepsy have also been associated with increased 
congenital malformations [39].  However, folic acid supplementation in women with 
epilepsy is not always associated with protection against NTDs, suggesting maternal 
exposure of antiepileptic meds may be an underlying pharmacogenetic susceptibility[40].  
 A study of pregnant epileptic women revealed significant changes in drug 
metabolism enzymes with specific decreases in P450 1A2, xanthine oxidase and n- 
acetyltransferase activities, and a significant increase in hydroxylation activities during 
pregnancy [41]. These findings demonstrate that metabolism of antiepileptic drugs will be 
altered during pregnancy. And it is also possible that genetic polymorphisms in drug 
metabolizing genes in either the mother or infant can further change the pharmacokinetics of 
antiepileptics which may contribute to the 20-fold increased NTD risk in particular 
pregnancies.  
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Epigenetic factors may also influence susceptibility to NTDs, for example the 
maternal genetic background combined with environmental exposure may indirectly affect 
the development of the fetus in the intrauterine environment. 
The main environmental intervention that has had a significant impact on preventing 
NTDs is maternal periconceptional supplementation with folic acid, which has been shown to 
reduce the recurrence risk for having a child with an NTDs by 70% [42] and estimated to 
reduce the risk in the general US population by 50% [43]. Fortification of the U.S. food 
supply with 140 mcg of folic acid per every gram of enriched grain products, since January 
1998, has been estimated to reduce the prevalence of NTDs by 20-30% [44,45].  It was also 
shown that the post-fortification the newborn hospitalization rates for spina bifia decreased 
by 21% from the 1993-1997 to 1998-2002 which reflects the reduction in prevalence 
estimates [46]. Additionally, maternal serum alpha fetoprotein values have decreased by 32% 
since fortification, roughly mirroring the decreased prevalence estimates of NTDs [47].  
However, the magnitude of folic acid’s protective effect varies between different studies 
which may reflect differences in study design and/or genetic heterogeneity from differences 
in population-specific responsiveness to folic acid during pregnancy.  
 
1.2.6 Evidence for a Genetic Contribution to NTDs 
NTDs are likely caused by a complex interaction between environmental influences 
and genetic susceptibility. The significant reduction in NTDs with periconceptional 
supplementation with folic acid demonstrates that folate has a protective effect.  This NTD 
protective effect may represent a maternal or fetal genetic susceptibility that can be 
modulated by gene-environment interactions. Several lines of evidence support a genetic 
11 
 
factor in NTDs [48].  Firstly, NTDs are associated with established genetic syndromes such 
as CHILD, Fraser, Jarcho-Levin, Meckel-Gruber, and Waardenburg syndromes [49]. As 
mentioned previously, NTDs are also associated with chromosomal rearrangements such as 
trisomies 13 and 18 [22]. Moreover, NTDs tend to breed true, meaning if there are multiple 
affected individuals within a family, they will tend to have the same phenotype [50-55] 
suggesting familial predisposition to particular phenotype may be due to similar genetic 
etiologies.  Also, twin studies demonstrate a higher risk of NTD phenotype [56,57]. 
However, the twin studies compare like (monozygotic and dizygotic) versus unlike-sex (only 
dizygotic) instead of comparing the zygosity of the twin pairs (monozygotic versus dizyotic), 
which confounds the ability to estimate the degree of twin concordance.  The limited twin 
data available, which is based on small sample sizes, claims concordance ranging from 3.7% 
to 18% [56].  Also, there are currently 155 mouse models with known genetic mutations 
causing an NTD phenotype, and these NTD mouse models provide further evidence in 
support of a genetic component underlying the formation of human NTDs [58]. 
 Family history of more than one individual affected with an NTD [59-61] or familial 
clustering of NTDs is one of the strongest lines of evidence for a genetic contribution.  In 
addition, there is a higher risk of recurrence of NTDs in offspring of parents with previous 
NTD pregnancies is higher, with a sibling recurrence risk of 2-5%, which is ~ 25-50 fold 
increase compared to what is observed in the general population [62,63].   
Segregation analysis evaluates multiplex families with a particular disorder, such as 
NTDs, and attempts to fit a genetic model to the disease based on the transmission patterns 
observed in the families. In 1982, two formal segregation analyses were reported for NTDs.  
One family-based segregation analysis study suggested a genetic contribution by showing a 
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higher likelihood that the NTD phenotype was caused by a dominant gene with 75% 
penetrance than sporadic occurrence or recessive inheritance [64]. The other segregation 
analysis study in 298 nuclear NTD families observed results consistent with either a 
recessive major gene or environmental effects or a combination of both [65].  These 
differences in patterns of inheritance may reflect different family structures with likely 
different genes and modes of transmission. Since we believe NTDs to be multifactorial in 
etiology it is possible that many different forms of inheritance are contributing to disrupted 
neural tube closure during early embryogenesis.  
 Genetic gender differences in children born with anencephaly provide additional 
evidence for a genetic contribution to NTDs.  In the United States it was observed that 
approximately 68% of anencephaly cases are female and 56% of open spina bifida cases are 
female [56].  Several theories have been proposed for the female preponderance of 
anencephaly cases such as there may be differences in spontaneous abortion rates in males 
more than females, sex-linked genetic effects that may be protective for females and/or 
deleterious for males, and that sex specific products, like hormones, might be affecting 
disease risk. The latter, seems less likely since neurulation precedes gonadal development. 
Cranial NTDs in mice have shown a female excess with approximately two-thirds of the 
exencephalic embryos being female in the SELH/Bc strain and in the Cd, crn, ct, Efna5, 
Hipk1/Hipk2, Marcks, and xn mouse mutants [58].  The molecular basis for the higher risk of 
females for cranial NTDs in both human and mice is currently unknown [58].  However, it 
has been proposed that the higher risk observed in female embryos may be explained by the 
higher demand of methyl groups required for appropriate cellular X-inactivation [66]. Further 
support of X-chromosome involvement in NTDs is from known X-linked conditions 
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associated with neural tube defects including CHILD syndrome, focal dermal hypoplasi, X-
linked laterality sequence, X-linked midline defect, and X-linked neural tube defects[2]. 
While several lines of evidence suggest human NTDs have a genetic component, a 
major genetic factor has not been identified. 
 
1.2.7 Challenges to Identifying a Genetic Component 
 The genes that contribute to inherited risk for having a child with a NTD are not well 
established. Due to the reduction in NTDs with folic acid supplementation, candidate genes 
in the folate metabolism pathway have been extensively investigated [67-69].  There have 
been conflicting data in human genetic studies on the folate metabolizing genes, specifically 
with regards to 766C-> T thermolabile isoform of (MTHFR), with some studies 
demonstrating an association and others not [68,69].  This discrepancy in human studies 
investigating association with the MTHFR polymorphism and NTD risk is likely caused by 
the differences in the study designs or statistical approaches, along with population specific 
differences in risk.  For example, many of the studies showing significant association 
between MTHFR and NTDs are case-control studies, which are subject to sampling biases 
and population stratification [70-72]. Such confounding factors can lead to false positive 
associations; consequently, case-control studies need to be conducted with careful attention 
to possible bias and confounding by ethnicity and demographics. Family-based designs can 
be a reliable approach to analyzing the genetic contribution in human disease because they 
are robust to population stratification and the transmission of alleles from parents to proband 
can be traced.  
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Even though genes involved in folate metabolism are biologically plausible 
candidates, 30-50% of NTD cases are not responsive to nutritional folate [73] suggesting 
there may be other genetic mechanisms for folate-resistant NTDs. Undertaking the study of 
the genetic basis of human NTDs presents several complicating factors. First, multiplex 
families are relatively rare and traditional linkage studies using multiplex pedigrees to 
identify regions of interest based on identical by descent sharing have been limited. The 
majority of NTDs are sporadic, meaning that it is easier to ascertain simplex families (one 
affected individual in a family).  Second, collection of affected individuals is challenging 
because of the increased spontaneous abortion and perinatal deaths associated with NTDs, 
low parent-to-child transmission due to decreased reproductive capacity in affected cases, 
and early termination of pregnancies detected prenatally [48,74,75]. 
 
1.2.8 Why Investigate a Genetic Component for NTDs?  
Any insights into one or more genes predisposing to the development of NTDs would 
lend itself towards more accurate genetic counseling for families and ideally prevention of 
these frequently disabling birth defects.  Three different prenatal diagnostic methods are 
currently available to assess a pregnant women’s risk of having a child affected with an open 
NTD and these include MSAFP, amniocentesis to test AFP, and ultrasound. Typically, the 
first prenatal test for levels of maternal serum alpha-fetoprotein (MSAFP) takes place from 
16-20 week gestation.  Fetal AFP is a protein produced by fetal yolk sac, gastrointestinal 
tract and liver and a small amount can cross the placenta moving into the mother’s blood 
stream. Fetal serum concentrations of AFP decline exponentially between the 14th to 32nd 
week gestation.  MSAFP is a screening test for both open NTDs and Down Syndrome.  An 
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increased risk of open NTDs is associated with high levels of MSAFP whereas an increased 
risk of Down Syndrome is associated with low level of MSAFP. An MSAFP cutoff level of 
2.5 MoM or greater has a 73% detection rate for open spina bifida at 17 weeks gestation with 
false-positive rates of 1% when the AFP values are corrected for maternal age [2].  If a 
woman has an elevated MSAFP during pregnancy, an amniocentesis and ultrasound are 
suggested.  Because the MSAFP is not a specific diagnostic tool but an associated metabolic 
marker, it can lead to false positive results. This can be anxiety provoking for the mother [76] 
and family and can lead to unnecessary medical procedures that increase risk for pregnancy 
loss.  The identification of causative gene(s) for NTDs can enhance our prenatal testing 
capabilities generating more accurate screening tools. More importantly, preconceptional 
interventions may be implemented based on the familial genetic susceptibility, such that 
periconceptional folate supplementation may be more relevant for only a subset of pregnant 
women whereas other medical intervention(s) may be more efficacious for other individuals. 
 
1.2.9 Normal Human Embryology of Neural Tube Development 
The process of neurulation leads to the formation of the neural tube and is a key 
morphogenetic event in human neurodevelopment. The neural tube gives rise to the brain and 
the spinal cord to form the central nervous system. The central nervous system (CNS) is the 
first adult organ system to appear during vertebrate development and formation of the human 
neural tube occurs in the very early stages of fetal development.  Different regions of the 
neural tube form through two distinct processes: primary neurulation and secondary 
neurulation. Primary neurulation is the process by which a flat neural plate forms a 
cylindrical neural tube, resulting from the neural plate folding into the midline until the 
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neural folds (or edges of the neural plate) contact and fuse. Secondary neurulation is 
complete by the 8th week of gestation and is the process by which the neural tube forms at the 
most caudal end involving canalization of a dense mass of cells in the tail bud to form a 
hollow tube. Secondary neurulation is considered a mechanistically different process than 
primary neurulation since it occurs over several weeks as opposed to several days and does 
not require elevation and fusion of the neural plate.  
As mentioned, the neural tube closure occurs early in the process of embryogenesis, 
and the early stages of fetal development during primary neurulation demonstrate distinctive 
morphological features [77].  Embryologists use these distinctive morphological findings in 
the human embryo to approximate the stage of development or embryonic Carnegie Stages 
(CS) because often it is difficult to determine the exact dates of conception [77].  This 
description of the Carnegie Stages focuses specifically on stages involving neural tube 
closure and are therefore postulated stages when anencephaly and spina bifida arise; these CS 
10-13 are illustrated in Figure 1.1.  
 
At CS 10 (22 days gestation) 4-10 somites (giving rise to vertebrae) and 
the neural folds fuse in the midline.  
 
 
At CS 11 (24 days gestation) both ends of the neural tube are open 
evidenced by rostral and caudal neuropores. Once 20 somites are 
present, the rostral neuropore closes within a few hours and failed 
closure may lead to anencephaly.  
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By CS 12 (26 days gestation) 21-29 somites are present and the caudal 
neuropore closes taking about 24 hours for complete closure of the 
neural tube and any disruption of this process may lead to spina bifida.   
 
By CS 13 (28-32 days gestation) 30 somites are present and the neural 
tube has completely closed. 
 
 
 
 
Adapted from UNSW Embryology website by Mark Hill 
http://embryology.med.unsw.edu.au/wwwhuman/Stages/CStages.htm 
 
  Closure of the neural tube prevents high levels of α –fetoproteins accumulating in 
amniotic fluid and thus forms the basis for MSAFP screening for open neural tube defects.  
Since closure takes place in the first few days of life, often well before a woman is even 
aware of her pregnancy, it is often impossible to take preventive measures, such as 
consuming folic acid.  Closure of the caudal and rostral neuropores occurs at different stages 
of development and requires different amounts of time, suggesting there may be different 
underlying molecular mechanisms for each neuropore to close appropriately.   These 
differences may result from spatial and temporal heterogeneity in molecular mechanisms 
involved in transformation of neural fold morphology to produce neural tube closure. 
Since rostral and caudal neuropore closure takes place at different times, it seems 
possible that there may be different genetic risk factors involved with a cranial or spinal 
defect. To this end, a question commonly debated in the NTD community is whether 
Figure 1.1 Human neural tube closure and Carnegie Stages 10-13. 
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different NTD phenotypes have the same or different underlying genetic and/or 
environmental risk factors. Phenotypic classification of NTD mouse models have revealed 
that approximately 20% of mutants have either exencephaly or spina bifida aperta or both, 
70% only have exencephaly, 5% have spina bifida aperta , and 5% have craniorachischsis 
[58].  These observations in mice suggest that particular genetic risk factors will only 
primarily affect a particular region of the neural tube whiles other genes may be involved 
with formation of the entire neural tube.  
 
1.2.10 Role of Folate in Development and Sufficient Maternal Folic Acid 
Consumption 
It is not currently understood why some NTDs are folate-sensitive while others are 
folate-resistant. Folic acid is involved in several biochemical pathways including nucleoside 
biosynthesis and production of methyl groups necessary for homocysteine metabolism [78].  
Moreover, folate is crucial for the maintenance and production of cells, especially during 
periods of rapid cell division, as would be expected during neurodevelopment.  Folate 
deficiency leads to impaired folate metabolism, and folic acid supplementation has beneficial 
effects on several developmental defects and diseases including neural tube defects (NTDs), 
cleft lip and cleft palate, omphalocele, congenital heart disease, cardiovascular disease, and 
cancer [5,78].  However, the exact process by which folic acid is protective against 
congenital birth defects is still unknown.  
Folate derivates are involved in single-carbon transfer for many essential metabolic 
reactions.  During early development many methylation reactions are taking place such that 
any impairment of the folate and methionine metabolic cycles involving the methylation 
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pathway may disrupt neurodevelopmental processes. For example, folate metabolism 
involves homocysteine (Hcy) remethylation to methionine integral for formation of Ado Met, 
a substrate for many transmethylation reactions including DNA methylation (shown in 
Figure 1.2).  DNA methylation undergoes rapid changes during embryogenesis, especially 
during the first stages, so small delays or impairment in remethylation of genes could affect 
expression of important genes needed for closure of the neural tube.   
Elevated plasma homocysteine levels have been observed in women with affected 
NTD children [79,80]; these elevated homocysteine levels have been shown to normalize 
when women are given adequate folic acid  [80]. It is currently unknown why high 
homocysteine levels and low folate levels have been associated in women with NTD 
pregnancies. The elevated homocysteine may be a metabolic marker with a direct effect on 
NTD development or indirectly may reflect low folate status. Elevated homocysteine levels 
have been proposed to disrupt embryogenesis through several different mechanisms 
including: 1) toxic mechanisms to the fetus; or 2) disrupted methylation reactions in the 
fetus; or 3) increased oxidative stress in the fetus [81].   
The widely studied MTHFR enzyme converts 5, 10- methylene THF to 5-methylTHF 
and consequently this enzyme regulates the balance between folate derivates being used for 
either DNA synthesis or methionine/adoMet synthesis involved in methylation reactions 
(shown in Figure 1.2).  Many checks and balances are in place to ensure proper homeostasis 
between folate and methionine metabolic pathways; for example, adoMet inhibits the 
MTHFR enzyme.  
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Substrates are shown in rectangular boxes while enzymes are shown in ellipses.  Adapted 
from Nijhout, 2004; Reed, 2004 [82,83]. 
 
 
Folate is a water-soluble, B-complex vitamin acting as a coenzyme for single carbon 
transfers and nucleotide biosynthesis. In the United States, a woman may consume folate or 
folic acid in three ways: through food folate, folic acid from fortification, and/or through 
supplemental folic acid either from multivitamins or from a prescription of folic acid.  The 
difference between folic acid and food folate is based on its bioavailability, and consumption 
of food folate on an empty stomach has approximately the same bioavailability as 
supplemental folic acid [84]. A way to estimate the degree of folate derivates consumed by 
women around the time of conception through the first month of pregnancy is by 
administering questionnaires that address their multivitamin use, folic acid supplementation, 
and specific diet. Unfortunately, these types of questionnaires are subject to recall bias.   
Ideally, to reduce the problem of recall bias, a study should be designed prospectively before 
a woman is pregnant to obtain a more accurate reflection of folate/folic acid intake. Further 
Figure 1.2 The folate and methionine metabolic cycles. 
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quantification issues in estimating maternal folic acid intake comes from variability in folic 
acid dosage in different multivitamin formulations. 
Despite the significant public health impact folic acid has had in the prevention of 
NTDs, the protective mechanism of action remains unclear [85]. Folic acid may be protective 
in the mother or the fetus or both. There may be varying reasons why certain women require 
a higher folic acid intake to protect against NTDs, such as some may have poor folate 
absorption, others may have increased excretion of folate, while others may have abnormal 
folate metabolism either from genetic mutations in the folate metabolism genes or from 
environmental disturbances.  Studies have found that folate receptors have an important role 
in embryogenesis and NTD development [86,87].   
Based on the observation that administering antiserum to folate receptors in pregnant 
rats caused developmental abnormalities [88], Rothberg and colleagues speculated that 
autoantibodies against folate receptors in women could also cause neural tube defects [89]. 
As they predicted, autoantibodies to folate receptors were found in 9 of the 12 women who 
had NTD-affected pregnancies and only in 2 of the 20 control subjects.  The authors had two 
different explanations as to why supplemental folic acid may have a protective effect in 
relation to autoantibodies to folate receptors: 1) supplemental folic acid may bypass the 
folate receptors by being alternatively transported in the cell by the reduced folate carrier; 
and 2) according to their work, folic acid appeared to have a higher affinity to the folate 
receptor than the autoantibodies did, suggesting that high folic acid levels may displace the 
autoantibodies from the folate receptor. The sample size for this study was rather small, 
including only 12 women with a current or prior pregnancy affected with an NTD and 20 
control women (pregnancy not affected by an NTD); therefore, replication of folate-
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autoantibodies in a larger NTD dataset is warranted to determine the degree of reliability and 
generalizability of this finding.   
 
1.2.11 Epigentic Effects and Parental Effects on Neural Tube Defects 
Parental effects such as genomic imprinting may play a role in early developmental 
processes such as during neural tube closure. Epigenetic alterations acquired in utero can be 
inherited mitotically in somatic cells that change gene expression without altering the DNA 
sequence.  The process of imprinting is re-established in each successive generation, and 
imprinted genes have varying temporal and spatial expression patterns. For example, 
imprinted genes may be monoallelically expressed from one parental chromosome in specific 
tissues and during particular developmental stages while having biallelic expression patterns 
in other parts of the body. Most imprinted genes are expressed in fetal and placental tissues 
[90,91], supporting the idea that monoallelic expression patterns may play a role in early 
developmental processes. Imprinting occurs through specific patterns of cytosine-phospho-
guanine (CpG) dinucleotide sequence methylation that are established de novo by Dnmt3a 
(DNA-methyltransferase) and Dnmt3b in early development and then propagated during 
DNA replication by Dnmt1 [92].  
Since one-carbon metabolism from the folate and methionine metabolism cycles 
provide methyl groups for biological methylation reactions, early human nutrition may 
influence DNA methylation patterns or epigenetic programming of the fetus in utero [93]. 
The large role maternal folic acid consumption has had in preventing NTDs suggests that 
there may be a maternal contribution to NTD susceptibility through the intrauterine 
environment.   
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A few human genetics studies have suggested a role for imprinting or parental sex 
effects in NTD risk. One study evaluated fifty families with individuals affected with 
nonsyndromic spina bifida [94] and observed twice as many unaffected female transmitting 
members than males, after excluding ascertainment bias, simple X-linked or mitochondrial 
inheritance and male infertility.  Two other groups studying nonsyndromic NTDs in distant 
affected relatives also observed an increase in maternal transmission, and the authors 
discussed the possibility that maternally imprinted developmental genes may explain the 
female preponderance of normal transmitters [95,96].  Moreover, a recent study in 48 Irish 
NTD families observed that maternal first cousin pregnancies were more likely to end 
adversely (defined as premature children, stillbirths, and miscarriages) when compared to 
paternal first cousin pregnancies, and that excess risk with maternal line was associated to 
spina bifida occulta families [97].   
 
1.2.12 Theories of Neural Tube Closure Sites 
It has been postulated that the different forms of NTDs in both humans and mice 
could result from different fusion sites of the neural folds in the last stage of primary 
neurulation. Since the early 1990’s different investigators have proposed varying theories on 
the number and location of these fusion sites in humans.  The original “zipper theory” 
proposed that the first site of neural fold fusion occurred in the cervical region of the 
developing fetus with subsequent fusion of neural folds progressing bidirectionally in rostral 
and caudal directions [98]. This simplistic model was refuted by other later theories.  For 
example, four sites of initiation of neural fold fusion were originally reported in the mouse by 
Sakai et al in 1989 [99] and later only three closure sites were corroborated by other groups 
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[100,101]. Based on this mouse work and observation of therapeutic abortuses and still born 
fetuses (19 embryos total) with different fusion defects along the neural tube, Van Allen et al 
in 1993 proposed that human embryos have five fusion sites with four corresponding 
neuropores [102]. The basis for this multi-site model was to explain the variety of NTDs that 
may result from failure of these closure sites [102,103]. Although Van Allen study did 
accurately predict the existence of multiple closure sites in humans,  the five site model was 
not supported by later studies conducted in human embryos [104-106].  In 2000, Nakatsu et 
al evaluated 68 normal embryos of Carnegie stages 10-12 and 98 NTD embryos of Carnegie 
stages 11-23.  Within these human embryos they observed three closure sites described as A, 
B, and C.  The first closure site A was located at the upper cervical region and progressed 
both rostrally and caudally. The second closure site B occurred at the rhombenecephalon-
mesencephalon junction; however, this closure site B only was observed in 10 embryos so it 
was not a widely accepted to be an actual closure site. And the third closure site C was 
observed occurring at the rostral tip of the neural groove. In 2002, O’Rahilly and Muller 
observed only two sites of initiation of neural fold fusion (α and β) in nighty-eight paraffin 
sections of Carnegie Stages 8-13 from the Carnegie collection of human embryos.  Fusion 
site α was found in the rhombocephalon and fusion site β localized to the rostral tip of the 
prosenephalon [106] as illustrated in Figure 1.3. They also observed additional accessory 
sites of neural fold fusion but they were inconsistently observed and did not reveal a specific 
pattern of position. Thus, it is possible that closure site B observed by Nakatsu and 
colleagues (2000) was also an accessory site that is not always present. These accessory 
closure sites may reflect the complexity of molecular events involved in neural tube closure 
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and underlying genetic differences and environmental exposures that contribute to variable 
morphological events during neurodevelopment.  
Mice only have three proposed sites of neural fold fusion localized to the cranial 
neural tube which further refuting the idea of the 5 site model proposed by Van Allen [107]. 
As illustrated in Figure 1.3 , mice have been proposed to have the following three neural tube 
closure sites: closure 1 occurs first and is initiated at the hindbrain/cervical boundary and 
then closure continues bidirectionally, closure 2 occurs at the forebrain/midbrain boundary, 
and finally, closure 3 occurs at the rostral end of the forebrain [107].  Interestingly, closure 
site 2  in mice appears to vary in location along the rostrocaudal axis and timing of closure 
and this polymorphic presentation was observed inbred mice, outbred mice, and backcrosses 
of splotch (sp2H) mice to DBA2 mice and NZW mice [108]. Although the location of closure 
site 2 is polymorphic, the closure locations and timing of 1 and 3 appear to remain the same 
among different mice [107].   This morphological variation in closure site 2 is consistent with 
the two human embryo studies described whereby one study observed a closure site 2 while 
another study did not [105,106].  
 
26 
 
 
 
The depiction uses an outline of an human embryo at Carnegie Stage 12 for observation in 
both mouse and human a) the human two-site closure model (designated by α and β) b) the 
human three site model (designated by A,B, and C) c) the mouse three closure site model, d) 
the mouse four closure site model. Adapted from O’Rahilly and Muller 2002 [106] 
 
1.2.13 Key Molecular Process Underlying Neural Tube Closure 
Neural tube closure is a dynamic process that requires a network of  
protein-protein and protein-DNA interactions in order to orchestrate the  
appropriate spatial and temporal expression of various factors involved in  
neurulation. Briefly, at the edge of the neural plate, neural folds form and  
then elevate and fuse in the dorsal midline to form the closed neural tube.  
Currently, the underlying processes thought to be involved with human neural tube closure 
have been elucidated from animal models, and the mouse model system is one of the most 
widely used animal models for studying NTDs. The plethora of mouse models have 
demonstrated dysregulation of numerous proteins that may result in a NTD, which is not 
Figure 1.3 Regions of human and mouse neural tube closure sites. 
a 
c d 
b 
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surprising given the incredible molecular complexity involved in the formation of the neural 
tube. Several of the gene products are transcriptional regulators and molecules  
involved in signal transduction. These products may regulate several  
different molecular pathways and could explain why some of the mouse models  
are not 100% penetrant. 
The active processes known to be involved with  neural tube closure include 
convergent extension cell movements, expansion of the cranial mesenchyme, contraction of 
actin microfilaments, regulated bending of the neural plate, balance of proliferation and 
programmed cell death of neuroepithelium and adhesion of neural folds [107].  A 
comprehensive evaluation of all the molecular mechanisms involved in  
neural tube closure is outside the scope of this dissertation, but since genes related to the 
planar cell polarity (PCP) pathway were preferentially selected as candidate genes for 
sequencing efforts described in Chapter 3, the PCP pathway is further described.  The PCP 
pathway involving the highly conserved non-canonical Wnt-frizzled-dishevelled signaling 
pathway is required for initiation of neural tube closure.  In Xenopus, it was first shown that 
an absence of  PCP-dependent convergent extension causes neural folds to be widely spaced 
apart preventing apposition and fusion of the neural folds, and consequently producing 
embryos with short broad neural plates and failed neural tube closure [109,110].  Convergent 
extension movement is a process mediated through the planar cell polarity pathway through 
non-canonical Wnt signaling leading to inter-digitation of cells in the midline, in turn causing 
the neural plate to narrow and lengthen as shown in Figure 1.4.  The PCP pathway requires 
binding of the Wnt ligand to the receptor Frizzled (Fz),  triggering recruitment of 
cytoplasmic transducer Dishevelled (Dvl) to the plasma membrane to form a complex with 
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Fz; the PCP pathway signals are then transduced to the cytoskeleton through the activation of 
small Rho GTPase and JNK pathways [111].  Drosophilia genetics identified other signaling 
molecules for the PCP pathway whose interactions have not been identified and these 
include: Flamingo (Fmi), Strabismus (Stbm)/Van Gogh (Vangl), Prickle (Pk), Diego and 
Scribble (Scrbl)[111].   Moreover, PCP mutations in mice (Vangl2, Fzd3 and Fzd6 double 
mutants, Dvl1 and Dvl2 double mutants, Celsr1, and Scrbl) have been shown to result in 
widely spaced neural folds preventing neural tube closure (leading to craniorachischisis 
[112].) Overall, the PCP pathway appears to be an integral signaling cascade for appropriate 
neural tube closure during embryogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This process involves convergence of cells in the dorsal midline and mediolateral 
intercalations of cells whereby the tissue narrows in one axis and elongates in a perpendicular 
axis leading to an extension of the body axis. Adapted from De Marco et al 2006 [111].  
Figure 1.4 PCP-dependent convergent extension movements. 
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1.2.14 Translation of Mouse Models to Human NTDs   
The human homologues to several of the candidate genes gleaned from mouse models 
have been studied in human populations [58,69]. It is hypothesized that early developmental 
processes such as primary and secondary neurulation are conserved across vertebrate species, 
suggesting that genetic mutations in mice or other animal models may implicate important 
candidate genes for human NTDs. Although the number of mouse models with a known 
genetic mutation exhibiting NTD phenotypes is now at 155, the human homologs of these 
mouse genes have not, until recently, been particularly informative for human NTD studies 
[58,66,69,107].  Kibar and colleagues recently discovered three mutations in the VANGL1 
gene, with two mutations observed in two familial forms of spinal NTDs (V239I and R274Q) 
and one patient with a sporadic spinal NTD (M238T). The authors additionally demonstrated 
that the familial V239I mutation confers functional changes in VANGL1’s protein-protein 
interactions with dishevelled-1,-2,-3 proteins [113]. Notably, the Lp mouse with a Vangl2 
mutation has craniorachischisis which is incomplete formation of both cranial and spinal 
neural tube [58]. Not only does this finding with VANGL1 further support that there is a 
genetic contribution to NTDs but it also provides functional evidence of a rare genetic 
mutation associated with human familial NTDs.   
Unfortunately, no other NTD mouse models have led to the discovery of human NTD 
genes, possibly because of the complex multifactorial etiology of NTDs.  For example, 
phenotype disparity between mouse and humans manifests because the majority of NTD 
mouse models have exencephaly (which is equivalent to anencephaly phenotype in humans) 
whereas the majority of association analysis studies have samples from individuals with 
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lower open NTD lesion (myelomeningocele) with very little inclusion of anencephalic cases.  
Anencephaly is incompatible with life making collection of DNA samples for genetic 
analysis more challenging.   Another factor that may complicate the mouse-human 
correlation is that most human NTDs are nonsyndromic and are likely due to multiple genes 
and environmental factors, while most NTD mouse models with null mutations are 
embryonic lethal having multiple other associated anomalies [114].  In order to emulate 
common complex human NTDs, an ideal mouse model of NTDs, would be nonsyndromic, 
have low penetrance of the NTD phenotype, and a reduced or increased NTD risk with 
environmental factors such as folic acid.   
Only a few NTD mouse models exhibit similar multifactorial etiologies as is seen in 
human NTDs, with both genetic and environmental factors involved [58,66]. For example, 
the SELH/Bc mouse strain and curly tail mutation have oligogenic inheritance patterns. In 
SELH/Bc mice 5-30% have nonsyndromic forms of exencephaly and the genetic risk is 
caused by four loci (Exen 1, 2, 3, and 4) acting additively with the frequencies of NTDs 
dependent on maternal diet as shown in Table 1.1 [58]. The curly tail (ct) mouse mutant may 
have a curled tail, spina bifida aperta, and exencephaly; three modifier genes have been 
shown to increase risk of having an NTD.  Though SELH/Bc and curly tail (ct) have 
oligogenic inheritance patterns, neither appear to have decreased risk of NTDs with maternal 
folate supplementation [66]. Table 1.1 illustrates some mouse NTD models that have 
decreased frequency of NTDs with maternal nutritional supplementation of various factors 
including folic acid, folinic acid and methionine, among others, demonstrating a 
multifactorial etiology to these mouse models.  Specifically, the folate-responsive NTD 
mouse mutants include Cart1, Crooked, Folbp1, and Splotch as shown in Table 1.1.  
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Table 1.1 Responses to maternal nutrition in mouse models for NTDs. 
Mutant or strain  NTD % NTD Supplement  
 
 Control Treated 
 
Axial defects (Axd)  Spina bifida  30 15 Methionine  
Cartilage homeo-protein 1 
(Cart1)  
Exencephaly/Facial Defect 100 
 
20 
 
Folic acid  
 
Crooked (Cd)  Exencephaly  20 15 Folic acid 
Curly tail (ct)  Spina bifida  
 
15 5 Inositol  
Folate binding protein 1 
(Folbp1)  
Exencephaly 100 10 Folinic acid  
Splotch (Sp, Pax3)  Exencephaly/Spina bifida  
 
100 60 Folic acid or 
thymidine  
 
SELH/Bc strain  Exencephaly  25 10 Purina #5001 
 (vs #5015)  
Adapted from Juriloff  2000 [66]. 
 
1.3 Approaches for Identifying Genes Related to Human Neural Tube Defects 
 Linkage mapping can be used in complex diseases such as NTDs to identify 
underlying genes only with prior knowledge that the trait is inherited. Linkage is a powerful 
tool to help identify disease genes without having any prior information about the molecular 
mechanisms or biological properties of the disease.  One of my dissertation projects involved 
the genetic basis for the neural tube defects and the linkage techniques described in this 
section focus on the linkage methods used for NTD family 8776 (Chapters 2 and 3). 
 
1.3.1 Parametric Linkage Analysis 
Linkage analysis is a traditional approach to mapping genes in families with more 
than one individual affected with a Mendelian disease. Linkage is a gene mapping tool used 
to evaluate co-segregation of a locus and a particular trait within families. Genetic linkage 
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measures the tendency for two or more genetic loci that are usually in close physical 
proximity on a chromosome to segregate together in a family. In 1955, Morton originally 
described likelihood-based methods for scoring recombinants and non-recombinants to 
determine linkage using a parametric or model-based approach.  Using this method, the 
degree of linkage can be measured by the number of recombination events between two loci 
based on the total observed meioses, and with a recombination fraction designated as θ. 
Complete linkage occurs when there is no recombination at a θ = 0, and a lesser degree of 
linkage between the loci when the number of recombinants has a θ < 0.5. The evidence of no 
linkage is when the observed recombination fraction is 50% (θ = 0.5). These recombination 
events take place during meioses when homologous chromosomes pair and crossover. The 
frequency by which the alleles segregate together is a factor of the distance between them 
along a chromosome. The proximity of alleles to each other can be described by genetic 
linkage which is measured using centiMorgan (cM), where 1 cM represents 1% 
recombination. The marker maps used for linkage analysis are derived from mathematical 
formulas to determine genetic map distance developed by Haldane in 1991 [115]  and 
Kosambi in 1944 [116]. These genetic maps are based on the frequencies of recombination 
events between marker alleles. The more commonly used Kosambi map function accounts 
for interference, a phenomenon whereby crossovers of homologous chromosomes at a 
specific chromosomal location interferes with crossover events within the same location.  
The LOD score serves as a test of the null hypothesis of no linkage versus the 
alternative hypothesis of linkage. The equation for the parametric LOD score is illustrated in 
Figure 1.5.  
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LOD = log10
(1−θ)NRθR
(1/2)NR +R = log10
(Likelihood for linkage)
(Likelihood for no linkage)  
Figure 1.5 Logarithm of the Odds (LOD) score equation. 
NR representing non-recombinant events and R indicating recombinant events. 
 
To score recombinant and non-recombinant individuals within a pedigree, the genetic 
mode of inheritance is used to assign the disease locus based on individuals’ affection status, 
and then phase of the marker and disease alleles can be determined. If phase is unknown 
within a pedigree and there is no a priori expectation to assign phase to a particular phase 
arrangement, then the LOD score will be estimated over the various possible phases.  The 
ability to establish phase is often dependent on whether both parents are genotyped and if 
they have different heterozygous alleles at each marker.  Linkage analysis using parametric 
linkage methods assumes a genetic model based on Mendelian inheritance patterns, such as 
specifying whether the disease is autosomal dominant, recessive, or an X-linked.  Model-
based linkage methods also require knowledge of disease allele frequency, marker allele 
frequency, and penetrance of trait of interest. Allele frequencies are commonly calculated 
from the existing dataset being tested for linkage; however, these frequencies may not reflect 
true population frequencies, particularly when allele frequencies are estimated using a small 
set of families. Misspecification of any of these parameters, especially the genetic model can 
decrease the power to detect linkage [117-120].   
Full pedigree analysis includes all available phenotypic and genotypic data and also 
allows specification of a penetrance model. In complex diseases, like neural tube defects, 
often an affecteds-only or low-penetrance approach is employed. In this affecteds-only 
approach the phenotypic information for unaffected individuals is not used because they may 
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carry the disease locus but not exhibit the phenotype due to a myriad of potential causes such 
as incomplete penetrance of the gene, absence of another susceptibility gene and/or 
environmental exposure. Therefore, an affecteds-only linkage approach only uses the 
phenotypic information from those individuals who express the trait of interest. In this 
model, the genotypic data from the unaffected individuals can be used to infer missing 
genotypes and establish phase, although phenotypic data from unaffecteds will not directly 
contribute to the LOD score. This type of an analysis can be more powerful for detecting 
linkage when reduced penetrance or subtle non-specific phenotypic findings may lead to 
misdiagnosis. In addition, phenocopies -- when a phenotype mimics disease but has 
nongenetic etiology -- may also decrease the power to detect linkage, and may be accounted 
for by using liability classes based on estimated phenocopy rates. 
Two-point linkage analysis compares one marker locus to the disease locus, and 
estimates the recombination fraction one marker at a time. Multipoint linkage analysis is an 
extension of two-point analysis in which linkage of a disease locus to a marker is tested over 
several markers at a time. In a single pedigree, the multipoint results will show co-
segregation of many marker haplotypes with the trait of interest through the pedigree. 
Multipoint analysis can be more informative in situations when there is an uninformative 
marker or missing genotypic data that can be inferred from the haplotype structure of other 
family members. Multipoint LOD scores can be helpful for gene mapping when an affected 
individual is recombinant for the region of interest because this crossover event will provide 
a negative LOD score along the curve, decreasing the evidence in favor of linkage at that 
particular location.  
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Genomewide screens are used to identify novel loci for both Mendelian and complex 
diseases, and with any statistical test, there is the possibility for false positive results and 
thresholds for significance.  Morton defined a LOD score of > 3.0 (odds are 1000:1 that loci 
are linked at θ rather than unlinked) to be considered a “significant” linkage result, and a 
LOD score of 2 to 3 was “suggestive” of linkage, whereas a LOD score < -2 provides 
evidence to exclude linkage. Scores between -2.0 and 3.0 are often considered inconclusive 
linkage findings suggesting that additional informative family members or families and/or 
more informative markers need to be included. Lander and Kruglyak later defined 
genomewide significance for linkage studies using more conservative estimates. Their new 
estimates require a parametric LOD score of 3.3 and nonparametric, allele sharing methods, 
to have a LOD score of 3.6. The underlying assumption of these significance thresholds is 
that there will be one false positive outcome in 20 genome scans for a type I error rate of 5%. 
These criteria for genomewide scan significance levels are shown in Table 1.2.  
 
Table 1.2 Genomewide Linkage Significance 
 
 
 
 
 
Estimates based on work by Lander and Kruglyak in 1995 [121] 
 
Mapping Method LOD 
Score 
Level of 
Significance 
3.3 Significant Parametric 
LOD score analysis 
1.9 Suggestive 
3.6 Significant Nonparametric 
Allele sharing method 
2.2 Suggestive 
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1.3.2 Nonparametric Linkage Analysis 
Many common diseases are heritable but do not have a classic Mendelian pattern of 
inheritance.  These diseases are often complex with multiple genetic and environmental 
components involved, making it difficult to model the mode of inheritance appropriately. 
Nonparametric linkage analysis methodologies, also known as model-free approaches, do not 
require prior knowledge of the mode of inheritance or the disease model.  Since 
misspecification of the mode of inheritance in parametric linkage methods can lead in a 
decrease in power to detect linkage, these model-free approaches are often used for complex 
diseases for which the mode of inheritance is unknown. Methods designed to map complex 
human diseases using a nonparametric approach with relative pairs will quantify the degree 
to which related individuals share alleles at the marker loci. These relative pair allele-sharing 
methods either evaluate alleles that are identical by state (IBS) or alleles that are identical by 
descent (IBD).  Specifying alleles as IBS or IBD between relative pairs can be established 
through examining the inheritance of markers in families. Alleles that are IBD can be shown 
in pedigrees to be inherited from a common ancestor; in contrast, alleles that are IBS are the 
same alleles but cannot be conclusively proven to be inherited IBD.  Nonparametric methods 
evaluate whether affected relatives share alleles identical by descent at a particular locus 
more frequently than expected by chance alone to localize the disease locus. One of the first 
nonparametric approaches was the affected sib pair (ASP) method that calculates the sharing 
of alleles identical by descent between sibling pairs [122,123]. Each relative pair will be 
expected to share a certain proportion of their alleles IBD. For example the Mendelian 
expectation is that siblings will share 0 alleles IBD with a probability of 0.25, 1 allele with 
probability 0.5, or 2 copies of an allele IBD at an expected frequency of 0.25. In ASP, if two 
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affected siblings share particular alleles IBD greater than expected by chance, then this 
finding suggests that the marker allele may be linked to the disease trait of the siblings. 
Although the ASP methods are useful and easy to calculate they did not account for other 
relative pairs within extended multiplex families. Later, an affected relative pair (ARP) 
method which maximizes information over all affected family members and uses the  
nonparametric linkage analysis (NPL) statistic was established [124,125] and implemented in 
the Genehunter, Allegro and Merlin linkage programs.   
The NPL statistic calculates the inheritance vector by specifying the founder alleles 
inherited by each of the individuals that are non-founders in the pedigree. In some cases, the 
inheritance vector cannot be estimated perfectly since there may be missing genotypic data or 
there may be uninformative markers with low heterozygosities. To address the issue of 
inheritance uncertainty, the NPL statistic calculates a probability distribution that assigns a 
prior and posterior probability to estimate the probability of inheritance vectors. The 
inheritance distribution is calculated using the hidden Markov models (HMMs) that are 
implemented in the Lander-Green algorithm [124].  The prior probability of each inheritance 
vector is equally as likely without genotypic data; however, as genotype data is added the 
inheritance distribution selects more likely inheritance vectors.  Once the inheritance vector 
is estimated, the program calculates linkage scores for both parametric and nonparametric 
methods.  The NPL scores are calculated using the scoring functions Spairs or Sall. [126], 
which compare the degree of IBD sharing to expected IBD estimates for the relationship pair. 
 
Spairs counts the degree of alleles shared IBD by each affected relative pair and compares this 
to the expected degree of IBD sharing. On the other hand, the Sall statistic evaluates 
permutations of the inheritance vectors of each allele to count the number of identical shared 
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permutations for the affected relative pairs, and this statistic gives increasing weight as the 
number of affected relative pairs share more alleles IBD. Generally speaking, Sall works best 
for additive and dominant diseases, whereas Spairs is best for recessive diseases.  The 
normalized Spairs or Sall score is described as the Z score or the NPL. Of note, NPL is a 
conservative test that is more towards the null hypothesis of no linkage due to an 
overestimation of the variance from the assumption that all markers are completely 
informative. Also a likelihood-based measure of linkage is available, referred to as the LOD* 
statistic that incorporates the NPL score as part of its estimate and is considered comparable 
to a standard LOD score [127]. Unlike the traditional LOD score, the LOD* score is always a 
non-negative result and so may not be informative for exclusion of linkage.  
Two commonly used computing algorithms for linkage analysis include the Elston-
Stewart and Lander-Green algorithms. The Elston-Stewart algorithm, which was  introduced 
in 1971 [128], does not require phase to be completely known for each pedigree, because this 
algorithm can estimate phase using maximum likelihood estimates; additionally, this 
algorithm allows for computational speed linear with an increasing number of individuals, 
but the algorithm becomes exponentially more time consuming with more markers. The 
Elson-Stewart Algorithm is implemented in such programs as Linkage, Mendel and Vitesse 
[129-132].  The Lander-Green algorithm [124] uses inheritance vectors (described in the 
nonparametric linkage methods section) in a family to estimate linkage. For example, at 
every marker, the observed marker phenotypes and genotypes are used to assign probabilities 
for each possible inheritance vector. The Lander-Green algorithm allows for computational 
speed linear with an increasing number of markers and is exponential with the number of 
individuals in the pedigree.  With the advent of denser genotyping platforms, linkage 
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programs with the Lander-Green algorithm are more commonly used since the computational 
time is linear with increasingly more markers. The Lander-Green algorithm is implemented 
in Genehunter and Allegro linkage programs [125,133]. Allegro, which was developed after 
Genehunter, allows for more extended pedigrees (20-30% larger) with a bit size of 24 [133]. 
The bit size is calculated by 2n-f with n representing the number of non-founders and f is the 
number of founders in the pedigree. Often trimming of large extended pedigrees is performed 
in which the most informative individuals are retrained within the pedigree.  For example, 
trimming was required for the linkage analysis conducted in the large multiplex NTD family 
8776, and the individuals included in linkage analysis are described in Chapters 2 and 3. 
 
 
1.3.3 Linkage Screen in 44 Multiplex NTD Families 
In 2005, one of the first linkage screens of NTDs was reported in 44 multiplex 
families [134].  The linkage screen included 402 microsatellite markers spaced on average ~ 
10 cM apart and the majority of the families were Caucasian (n=41).  A total of 292 
individuals were included in this genomic screen with a total of 89 sampled affected, of 
which 50 had lumbosacral myelomeningocele. The other affected individuals had other types 
of NTDs including anencephaly, cervical myelomeningocele, craniorachischisis, 
encephalocele, lipomyelomeningocele, rachischisis, and thoracic myelomeningocele. To 
control for potential genetic heterogeneity underlying different NTDs, the phenotype for 
linkage analysis was first narrowly defined as only those individuals with lumbosacral 
myelomeningocele, and also a broader phenotypic definition was used leading to inclusion of 
all individuals affected with an NTD.  The study population was composed of 21 affected 
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sibling pairs, 12 affected avuncular pairs, and 35 other affected relative pairs. Multipoint 
parametric and nonparametric analyses using Allegro identified regions of interest on 
chromosomes 7 and 10. The highest LOD score of 2.45 was on chromosome 7 under the 
parametric model, and the linked region spanned a 24 cM interval between D7S3056 and 
D7S3051. Further investigation of the genomic screen data identified a single large family, 
8776, as primarily driving the linkage results on chromosome 7; on its own generating a 
parametric LOD score of 2.40. This screen revealed that family 8776 clearly demonstrates a 
strong genetic effect, and additional gene mapping analyses in family 8776 are described in 
Chapters 2 and 3.  
 
1.3.4 Approaches to Candidate Gene Selection in Human NTDs 
After a region of interest has been defined by linkage studies, candidate genes can be 
prioritized for further evaluation. The human genome project has provided a rich sequence 
dataset for candidate gene selection. Several bioinformatics sites compile extensive 
information on gene annotation, expression profiles in various tissues, and protein structure 
and function; commonly used sources for human candidate gene evaluation studies include: 
UCSC Genome Bioinformatic Site, National Center for Biotechnology Information (NCBI), 
and Ensembl Genome Browser.  These complementary bioinformatics websites can be used 
to compile a comprehensive list of genes residing in positional target regions.   
Candidate gene studies can select genes either that map to regions identified by 
positional cloning methods or based solely on the gene’s biological plausibility without any 
gene mapping information.  Alternatively, candidate gene selection can also preferentially 
use many converging lines of evidence to choose a particular gene; this approach has been 
41 
 
previously termed “genomic convergence” [135-137].  For example, studying neural tube 
defects may use any of the following three converging lines of evidence for selection of 
candidate genes: 1) positional candidates from promising linkage or whole genome 
association analysis results; 2) known biological mechanisms that may affect neural tube 
closure such as genes involved in folate metabolism and early developmental neurobiology 
and genes from NTD mouse models; and 3) gene expressed in tissue of interest. The genomic 
convergence model is illustrated in Figure 1.6; this approach was applied for candidate gene 
selection in family 8776 as described in Chapter 3.  
Once a candidate gene is selected, a way to interrogate the gene may include use of 
known variants (such as SNPs) and genotype using either Taqman SNP allelic discrimination 
methods or SNP arrays designed by such biotechnology companies as Illumina and 
Affymetrix that can be used for association analysis.  To capture additional variation in the 
population of interest, resequencing may be done to identify novel variants that may reveal 
functional variants and/or other variants that may also be used for association analysis or 
tested for functional characteristics.  
 
42 
 
 
Figure 1.6 Genomic Convergence 
Combination of multiple sources of information for candidate gene selection. The genes of 
highest priority to follow-up are those that fall into the region defined by the intersecting 
lines of evidence as illustrated by the red arrow; NTD candidate gene selection is used as an 
example.  
1.3.5 The Future for Gene Mapping Studies in Complex Disease 
Linkage analysis studies depend on the number of informative meisoses from families 
to estimate recombination. The informativeness of the marker set used in whole genome 
linkage analysis will be based on the heterozygosity of the genetic markers and the spacing 
of the markers across the genome; however, even dense marker sets will still lead to large 
intervals of interest spanning ~10-20 Mb.  In humans, single nucleotide polymorphisms are 
the most common type of genetic variation and several million SNPs have been documented 
in the dbSNP database [138]. The development of efficient high-throughput SNP platforms 
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have catapulted the world of human genetics into a whole genome association analysis 
paradigm, where ideally the disease loci and/or variants can be mapped at a finer scale than 
linkage methods. In addition, these dense oligonucleotide microarrays, along with array-
CGH, have identified copy number variants in the presumed normal population [139-144]. 
These recently identified known copy number variants (CNVs) leading to amplification or 
deletion of portions of chromosomes may confer risk to common complex disease. As each 
year passes, the density of arrays increases, now dense 500K or 1M SNP chip arrays not only 
allow the potential for whole genome association analysis but also allow for fine resolution 
detection for either known or novel copy number variants. However, many of the 
characteristics of the CNVs in the human population are currently unknown including the 
total number, expected frequencies for particular populations, genomic content, gene content, 
and patterns of linkage disequilibrium [145].  Perhaps in the future CNVs will be informative 
for the study of NTDs, and Chapter 6 comments on the feasibility and rationale behind WGA 
in the study of NTDs.  
1.4 Native American Myopathy: Defining the Phenotype and Genetic Analysis  
Native American Myopathy (NAM) is a congenital myopathy [MIM 255995] first 
described in the Lumbee American Indian population a multiracial group indigenous to 
Robeson County, south-central North Carolina [146].  NAM is a congenital myopathy 
characterized by cleft palate and a susceptibility to malignant hyperthermia provoked by 
anesthesia.  NAM likely segregates in an autosomal recessive manner. The Lumbee people 
are a relatively isolated population with a high rate of consanguinity suggesting that 
autosomal recessive diseases in this population may be inherited through a common ancestor. 
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Despite the high mortality and morbidity seen in NAM, little is known about the clinical 
presentation or the genetic mutation causing the disease. 
 
1.4.1 The Lumbee Population 
The Lumbee people are a Native American Indian tribe from south-central North 
Carolina. The “Lumbee” name is derived from the Lumber River that passes through 
Robeson County, the region in which the Lumbee population is concentrated. Currently, the 
Lumbee Tribe of North Carolina is estimated to have more than 45,000 members making 
them the largest tribe east of the Mississippi River [147].  The Lumbee population is 
considered a relatively isolated population with three different ethnic backgrounds including 
a mixture of American Indian, European, and African American ancestry [148]. 
The origin of the admixed Lumbee population has many theories. One commonly 
repeated theory, proposed by Hamilton McMillian in 1885, is that the Lumbee people are 
descendents of Sir Walter Raleigh’s “Lost Colony” who mixed with the Croatan Indians, an 
Algonquin-speaking tribe from the North Carolina coast [149]. The “Lost Colony” saga 
commenced in 1587, when under the authority of Sir Walter Raleigh, John White and 120 
men and women embarked on expedition to establish a colony on Roanoke Island [148].  
Once the colony was established, John White returned to England for additional supplies, and 
upon his return in 1591 the colony had disappeared.  It is unclear what happened to the 
colony, they may have died of starvation or disease or perhaps intermarried with the Croatan 
Indians.  Interestingly, in the 1730’s when the first English and Scotch settlers arrived in 
Robeson County, they described encounters with individuals of mixed race and speaking an 
English dialect [148].  Two other theories of the Indian origin of the Lumbee people exist. 
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One is that the Indian ancestry is derived from the Cherokee, a powerful Iroquois-speaking 
tribe who dominated the Western Carolinas prior to European settlement, and the other 
theory is the Indian ancestry may be from the Catawaba, a Siouan-speaking tribe, from the 
Piedmont Carolinas [150]. 
In the 1960’s, William Pollitzer, an anthropologist at the University of North Carolina 
at Chapel Hill, studied the origins of the Lumbee people. He described the Lumbee 
population as a “tri-racial isolate” that dates back as far as the American Revolution [151].  
He further reported: “Considerable phenotypic variation is found within the isolate today, 
with extremes of skin color from light to dark and of hair from very curly to straight. The 
morphology of the face also suggests broad racial backgrounds” [150].  In order to estimate 
the degree of admixture in the “tri-racial isolate”, Pollitzer investigated the type of blood 
factors and hemoglobin within 1273 individuals in the Lumbee population. He estimated, 
based on three loci (ABO genes, Rh, and hemoglobin pattern), that the racial composition of 
the Lumbee was ~34% Caucasian, ~53% African American, and ~13% American Indian.  
These estimates were suggestive of a small amount of American Indian ancestry, and not 
surprisingly, the Lumbee tribe, who identify primarily with their Native American ancestry, 
did not appreciate the implications of this study (Cynthia Powell, personal observation). 
Whatever the original pattern of ancestry, the Lumbee people are now a relatively 
isolated population [148].  Indeed, Pollitzer speculated that the large number of individuals 
with the same last name suggests a pattern of historical inbreeding. For example, Pollitzer 
described the marriage records from 1800 to 1860’s of 132 men who had 12 surnames 
common to the current day tribe, and of these 132 men, 23 married women with the same 
surname. More current observations of common surnames and consanguinity within families 
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also support Pollitzer’s previous studies (Cynthia Powell, personal observation). Pollitzer 
believed the Lumbee’s social isolation may have resulted from members of the population 
not wanting to marry outside of their tribe [151]. This social isolation was probably 
heightened by low socioeconomic status within this group limiting their ability to migrate to 
other regions and to marry outside of their group. 
The Lumbee people have a very active tribal community evidenced by many tribal 
organizations, community events celebrating their Native American Indian ancestry, and 
Lumbee websites dedicated to preserving their history and describing their struggle for 
federal recognition as a bona fide Native American tribe [152]. The Lumbee people, who 
identify strongly with their Native American ancestry, have been attempting to obtain federal 
recognition as an Indian tribe to request benefits since 1888. In 1885, the State of North 
Carolina first recognized the population to be Croatan Indians (the former name for the 
Lumbees). This state recognition allowed the Croatan Indian to petition for a school system 
for the exclusive use of tribal members.  Much later, in 1956, the United States House of 
Representatives passed the Lumbee Act, that recognized the Lumbee people as a Native 
American tribe. However, the Lumbee Act did not provide full federal recognition as an 
American Indian tribe, thus preventing the tribe from full tribal benefits such as for health 
care and housing from the Federal Government. In 1987, the Lumbees petitioned the U.S. 
Department of the Interior for federal recognition to gain federal monetary benefits reserved 
for American Indian tribes, and this petition was denied.  
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1.4.2 Clinical Description of Native American Myopathy 
In 1987, Bailey and Bloch first described Native American Myopathy in a 3-month 
old of Lumbee descent with multiple congenital anomalies and a malignant hyperthermia 
episode under general anesthesia for placement of a gastrostomy tube [153].  In 1988, 
Stewart et al described six Lumbee children affected with congenital myopathy, 
kyphoscoliosis, and cleft palate. Two of these children had documented malignant 
hyperthermia during cleft palate repair [146].  The 6 children ranged in age from 5 to 13 
years old and two were siblings, and one of the patients was a cousin to this sib-pair. All 
children had normal baseline creatine kinase levels and three of the six muscle biopsies had 
nonspecific myopathic changes.  The one male enrolled in the study had undescended testes 
(cryptorchidism).  The typical clinical presentation of NAM (abnormal facies with ptosis and 
low-set ears, muscle wasting and kyphoscoliosis) is illustrated in Figure 1.7. Overall, clinical 
features described for NAM include short stature, cleft palate, high arching palate, myopathic 
facies (malar hypoplasia, ptosis), scoliosis, congenital joint contractures, clubbed feet, 
normal baseline creatine kinase,and susceptibility to malignant hyperthermia [146,153-156]. 
These descriptions highlight both shared NAM characteristics as well as the phenotypic 
heterogeneity in the presentation of NAM. The phenotypic heterogeneity seen in NAM 
patients may be explained by several different mechanisms including different environment 
exposures, pleiotropic effects of the NAM gene, epigenetic influences on disease progression 
and expression, and/or potential misdiagnosis. Chapter 4 provides a more in depth 
description of the clinical presentation of 14 patients with NAM. 
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Panel A: Dysmorphic facies with low-set ears and ptosis. Panel B: Kyphoscoliosis and 
cachexia with muscle wasting. Reprinted from Pediatric Neurology, 4(6), Stewart CR, Kahler 
SG, Gilchrist JM, Congenital Myopathy with Cleft Palate and Increased Susceptibility to 
Malignant Hyperthermia: King Syndrome?, 371-374., Copyright (1988), with permission 
from Elsevier.  
 
1.4.3 Malignant Hyperthermia Susceptibility in the Lumbee Population 
Susceptibility to malignant hyperthermia is common in Lumbee people even in the 
absence of congenital myopathy [154]. The prevalence of MH in the Lumbee population is 
likely to be much higher than ~1:30,000 observed in the general population [157].  Because 
of the known MH susceptibility risk within the Lumbee people, clinicians in the Lumberton 
region and surrounding areas will often use non-halogenated non-volatile anesthetics in 
patients of Lumbee descent.  Several mechanisms may be causing MH to be more frequent in 
B 
Figure 1.7 Dysmorphic facies and skeletal abnormalities of NAM. 
A B 
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the Lumbee people; for instance, the presence of MH without congenital myopathy may be 
associated with individuals that are heterozygous for the NAM genetic mutation whereas 
individual with all the features of NAM may be homozygous for the genetic mutation. 
Another possibility is that some individuals homozygous for the NAM genetic mutation may 
have reduced penetrance leading to a milder phenotype such as MHS only. Alternatively, 
another genetic mutation may be segregating though the population that confers 
predisposition to MH only. Particular gene-gene and gene-environment interactions may also 
determine whether NAM and/or MHS will be expressed.   
1.4.4 Clinical Complexity of NAM 
The phenotypic presentation of NAM is not well characterized evidenced by a lack of 
clinical information in the literature. Dissecting the unique clinical characteristics of NAM 
has been complicated by the phenotypic heterogeneity in the presentation of NAM and by 
King-Denborough Syndrome (KDS) and Noonan Syndrome (NS) that have similar 
phenotypic characteristics to NAM.   A key distinction is that both KDS and NS tend to be 
inherited as autosomal dominant disorders whereas NAM appears to be inherited in an 
autosomal recessive manner. KDS is a disorder that appears markedly similar to NAM, with 
both features of myopathy and susceptibility to malignant hyperthermia. However, we 
believe NAM to be clinically distinct from KDS because patients with KDS have increased 
baseline CK levels and they lack cleft palate, contractures, and clubbed feet.  In addition, 
Noonan syndrome affected individuals have short stature and dysmorphic features that 
resemble NAM.  Such clinical resemblance led one patient with NAM to be initially 
diagnosed with Noonan Syndrome (S. Kahler, personal communication). However, NS can 
be clinically distinguished from NAM, because patients with NS tend to have structural 
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cardiac defects and they do not have congenital myopathy, cleft palate or congenital joint 
contractures as seen in NAM. In addition, Froster-Iskenius and colleagues described an 
autosomal recessive form of congenital contractures with similar features to NAM including 
myopathic face, arthrogryposis, ptosis, cleft palate, and susceptibility to malignant 
hyperthermia, but these patients also had congenital torticollis and neck and axillary 
webbing, which are not observed in NAM [158].   Thus, although these other diseases may 
resemble NAM, the differences in phenotype suggest NAM to be clinically distinct as shown 
in Table 1.3. 
Table 1.3  Differential diagnosis for NAM 
Disease Inheritance pattern Disease 
Locus 
Gene Traits common to NAM Dissimilar to NAM 
King-
Denborough 
Syndrome 
majority autosomal 
dominant; 
Some cases 
autosomal recessive 
19q13.1 RYR1 congenital myopathy, 
short stature, scoliosis, 
cryptorchidism, myopathic 
facies, MH 
below average 
intelligence, high 
CK; No cleft palate 
or arthrogryposis 
Noonan 
Syndrome 
Autosomal dominant 12q24.1 PTPN11 short stature, dysmorphic 
facies with ptosis, feeding 
difficulties as a newborn 
cardiac defects; No 
MH, cleft palate or 
arthrogryposis 
Froster-Iskenius Autosomal recessive Unknown Unknown myopathic face, 
arthrogryposis, ptosis, 
cleft palate, MH 
congenital 
torticollis, neck and 
axillary webbing 
Gordon 
Syndrome 
Autosomal dominant Unknown Unknown short stature, cleft palate, 
equanovarus deformities, 
camptodactyly 
pterygium colli, and 
vertebral 
anomalies; No MH 
This a partial list of the diseases and known loci presenting with similar features to NAM. 
 
1.4.5  Clinical Manifestations of Malignant Hyperthermia 
Malignant hyperthermia (MH [MIM 145600]) is a potentially life-threatening 
pharmacogenetic disorder of the skeletal muscle that is triggered in genetically susceptible 
individuals exposed to inhaled anesthetics and/or depolarizing muscle relaxants. MH crisis is 
a hypermetabolic response to potent inhaled anesthetic agents that may result in any of the 
following symptoms: tachypnea, tachycardia, unstable arterial blood pressure, increased 
carbon dioxide production, increased oxygen consumption, acidosis, muscle rigidity, 
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rhabdomyolysis, hyperthermia, elevated creatine kinase and hyperkalemia [159].  If MH 
crisis is not reversed, severe tissue damage and death may result.  Treatment of MH involves 
discontinuing the eliciting anesthetic agent, hyperventilation with 100% oxygen, and 
administration of dantrolene sodium, a muscle relaxant acting to depress excitation-
contraction coupling of skeletal muscle [160,161].  Dantrolene is the most effective 
pharmacologic agent used to halt the progression of MH [160,161]. The use of dantrolene as 
a main treatment intervention of MH has decreased the risk of mortality from 80% in the 
1960s to less than 10% of cases today [162]. MH susceptibility in patients can be determined 
by applying the standardized European in vitro contracture test (IVCT) that evaluates a 
muscle biopsy specimen for the degree of muscle tension in response to halothane and 
caffeine [163].  However, the IVCT is invasive, requiring skeletal muscle biopsy and 
consequently is not widely available or performed [164]. 
 
1.4.6 Malignant Hyperthermia Susceptibility Loci and Associated Genes 
Predisposition to malignant hyperthermia is commonly inherited as an autosomal 
dominant trait and has been reported to be genetically heterogeneous with six different 
malignant hyperthermia susceptibility (MHS) loci identified: MHS1-6 (Shown in Table 1.4).  
Two MHS genes have been identified, including the ryanodine receptor type 1 (RYR1) , 
which is a calcium release channel of skeletal muscle sarcoplasmic reticulum; CACNA1S,  
which encodes the α1-subunit of the human skeletal muscle dihydropyridine-sensitive L-type 
voltage-dependent calcium channel (VDCC) (Table 1.4).  The SCN4A gene which encodes 
the sodium channel voltage-gated type IV alpha is a potential MHS gene but only linkage to 
this gene has been observed thus far [165,166].  MHS1 [MIM 145600] maps to 19q13.1 and 
52 
 
may be caused predominantly by dominant mutations in the RYR1 gene [167-169]. King-
Denborough Syndrome is also included as part of MHS1. MHS2 [MIM 154275] maps to 
17q11.2 - q24 [170], and  two studies provided marginal evidence for linkage of MHS2 to the 
SCN4A gene but no genetic mutation has been identified [165,171]. MHS3 [MIM154276] 
maps to 7q21-22 near the CACNA2D1 gene and evaluation of coding regions in affected 
patients did not identify any pathogenic mutations [172,173], MHS4 [MIM 600467] maps to 
3q13.1 [174], and MHS6 [MIM 601888] maps to 5p [175].  MHS5 [MIM 601887] was 
shown in three European families to map to 1q32 locus [175], and a 3333G-A transition in 
the CACNA1S gene, resulting in an Arg1086His amino acid substitution in the protein, was 
identified in a single large French family [176].  Later, mutations in the CACNA1S gene were 
also observed in a large North American family [177].  However, Stewart and colleagues 
observed that only 1% of the North American MHS population of 112 people had the 
Arg1086 His mutation [177].  Mutations in CACNA1S gene are associated with either 
malignant hyperthermia susceptibility or hypokalemic periodic paralysis; however, the 
CACNA1S mutation for MHS is localized to a different part of the alpha-1-subunit of the 
skeletal muscle voltage-dependent calcium channel compared with mutations for 
hypokalemic periodic paralysis [176].  Notably, the CACNA1S and CACNA2D1 genes 
encode subunits of the dihydropyridine receptor which is functionally coupled to the 
ryanodine receptor. Overall, the CACNA1S gene is considered to be rarely associated with 
MHS and instead the majority of mutations identified in families with malignant 
hyperthermia have been in the RYR1 gene. Although the majority of RYR1 mutations are 
autosomal dominant, a few autosomal recessive mutations have recently been identified 
[169].   Given the allelic and locus heterogeneity of MH, susceptibility to malignant 
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hyperthermia may be dependent upon the effects of more than one gene. For example, a 
small association analysis study (77 UK nuclear families) of several MH candidate loci 
suggested that the MH phenotype is influenced by RYR1 as the major locus and also by 
additional modifier genes [178].  
 
Table 1.4 Malignant hyperthermia susceptibility loci 
MHS locus Location Associated Gene Mutation 
MHS1 19q13.1 RYR1 Yes, multiple 
MHS 2 17q11.2-q24 SCN4A No 
MHS 3 7q21-22 CACNA2D1 No 
MHS 4 3q13.1 - - 
MHS 5 1q32 CACNA1S Yes, rare 
MHS 6 5p - - 
 
1.4.7 RYR1 Mutations and Associated MH and/or Congenital Myopathies 
The mechanism of MH involves increased intracellular calcium ions in skeletal 
muscle resulting in protracted muscular contraction and hypermetabolism [179].  Porcine 
animal models susceptible to MH have been useful for characterizing the genetics of MH; 
these animal models exhibit an autosomal recessive form of disease and sequencing of the 
RYR1 gene in these pigs revealed a missense mutation (Gly614Arg) [180].  Identifying this 
mutation in pigs stimulated a search for RYR1 mutations in MH-susceptible human families, 
and both missense mutations and deletions [181] have also been reported in humans affected 
with MH.  MH-susceptible porcine breeds also demonstrated that mutated RYR1 receptors 
allowed for greater efflux of calcium ions [182].  
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Susceptibility to MH appears to be from abnormal calcium ion balance in skeletal 
muscle, and many cases have been shown to result from mutations in the RYR1 gene product 
in the sarcoplasmic reticulum.  The skeletal muscle ryanodine receptor (RYR1) gene 
comprises 106 exons and encodes a protein of 5,038 amino acids.  The RYR1 protein 
functions as the main calcium opening channel of the sarcoplasmic reticulum involved in 
excitation-contraction coupling in skeletal muscle, whereby the opening of RYR1 leads to an 
efflux of calcium ions into the myoplasm. The released calcium ions activate muscle 
contraction by attenuation of troponin C inhibition of the contractile proteins myosin and 
actin.  
Congenital myopathies, sometimes associated with malignant hyperthermia, are a 
phenotypically heterogenous group of neuromuscular disorders that are characterized by 
specific histopathologic findings in skeletal muscle from muscle biopsy. The key histological 
feature seen in skeletal muscle samples has been used in the naming of these myopathies, 
which include: central core disease, nemaline myopathy, multiminicore disease, and 
centronuclear myopathy.  These congenital myopathies overlap in phenotypic, genotypic, and 
histopathologic characteristics [183] suggesting that different forms of the same myopathic 
disease process may exist. For example, malignant hyperthermia susceptibility (and King-
Denborough disease), central core disease, and multi-minicore disease have all been 
associated with RYR1 mutations [184]. The majority of RYR1 mutations in CCD and MHS 
cause the RYR channel to be leaky leading to depletion of calcium stores in the sarcoplasmic 
reticulum and elevated levels of calcium in the cytosol [185]. Over 100 mutations in RYR1 
have been described [157] with only 9 of these reported in multimincore disease, and the 
majority of the RYR1 mutations are present in MHS and CDC. General patterns in the 
55 
 
phenotypic effects of RYR1 mutations are becoming more clear; for instance, dominant RYR1 
mutations disrupting either the cytoplasmic -terminal or the central domains of the RYR1 
protein predominantly lead to a MHS phenotype, while dominant mutations in the C-terminal 
region of the RYR1 protein cause the CDC phenotype [169].  Even though more RYR1 
mutations have been elucidated and associations between these mutations and the 
development of congenital myopathies and/or malignant hyperthermia have been well 
documented, the exact molecular mechanism underlying the various associated phenotypes 
still remains undetermined.  
 
1.4.8 Homozygosity Mapping Approach to Identify the NAM Disease Locus 
In 1987, Lander and Bostein proposed using a homozygosity mapping approach to 
identify rare sharing of homozygous regions for recessive diseases born from 
consanguineous matings [186]. Homozygosity mapping identifies genomic segments shared 
identical-by-descent inherited from a common ancestor (also referred to as autozygosity) by 
patients with recessive diseases from populations with limited migration into or out from the 
population and/or with high rates of consanguinity, allowing characterization of a genomic 
region that harbors the causative genetic mutation [186,187].  Moreover, homozygosity 
mapping is a form of linkage disequilibrium (LD) mapping whereby the disease gene is in 
LD with a conserved haplotype that arises from founder effects [187].  However, these 
conserved homoyzygous haplotypes can be large segments complicating gene discovery, but 
recombination events over several years within the population may lead to smaller segments 
of the original founder chromosome facilitating more productive homozygosity mapping 
studies. While individuals in the general population can share small regions of homozygosity 
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that are either identical by state (IBS) or identical by descent (IBD), inbred individuals are 
more likely to share longer stretches of homozygous alleles inherited IBD from a common 
ancestral haplotype.  However, contrary to this assumption,  it has recently been shown that 
presumable outbred populations can also have long stretches of homozygous segments that 
are considered ancestral haplotypes with alleles inherited identical-by-descent [144,188-190].  
Homozygosity mapping is typically performed using linkage analysis methods in 
multiplex consanguineous families and has facilitated the identification of causal genetic 
variants of recessive diseases from consanguineous populations [191-193].  Similarly, the 
genetic basis of NAM could be investigated by utilizing homozygous mapping methods 
based on the observation that Lumbee people are a relatively isolated population with a high 
degree of consanguinity (Cynthia Powell, personal observation). Our hypothesis underlying 
the genetic analysis of NAM was that affected individuals with NAM would share a region 
of homozygosity flanking the NAM disease gene that was inherited IBD from a common 
ancestor.  Genetic mapping results using homozygosity mapping methods to map the NAM 
disease locus are described in Chapter 5.  
 
1.4.9 Potential Pitfalls in Homozygosity Mapping  
In a highly inbred population like the Lumbee population, one may observe several 
autozygous chromososmal regions, such that identifying the true disease-associated 
haplotype may be difficult. Moreover, even though homozygosity mapping may be a 
powerful tool to map novel loci in rare autosomal diseases, the actual disease locus may not 
be detected if any degree of allelic heterogeneity is present within the population.  
Exemplifying this potential issue, two studies of rare autosomal recessive disease in isolated 
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consanguineous populations identified different mutations in the same disease gene, such that 
a few individuals were either heterozygotes for a mutation or compound heterozygotes [194-
196].  This observed allelic heterogeneity within consanguineous kindreds then obscured the 
actual disease locus due to loss of homozygous markers flanking the disease mutation [194-
196].  Additionally, when using linkage methods for homozygosity detection, the presence of 
hidden consanguinity in pedigree founders may inflate the likelihood estimate, which may 
lead to identifying spurious homozygous segments [195].  These potential issues in the 
genetic analysis of NAM are further addressed in Chapter 6. 
 
  
 
 
 
CHAPTER 2  
 
SNP screen in a large multiplex neural tube defect family refines linkage to loci at 7p21-
pter and 2q33.1-35 
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2.1 Abstract 
Neural tube defects (NTDs) are considered complex with both genetic and 
environmental factors implicated.  To date, no major causative genes have been identified in 
humans despite several investigations.   The first genomewide screen in NTDs (Rampersaud 
et al. 2005) demonstrated evidence of linkage to chromosomes 7 and 10.  This screen 
included forty-four multiplex families and consisted of 402 microsatellite markers spaced 
approximately 10 cM apart.  Further investigation of the genomic screen data identified a 
single large multiplex family, pedigree 8776, as primarily driving the linkage results on 
chromosome 7.  To investigate this family more thoroughly, a high-density single nucleotide 
polymorphism (SNP) screen was performed.  Two-point and multipoint linkage analyses 
were performed using both parametric and nonparametric methods.  For both the 
microsatellite and SNP markers, linkage analysis suggested the involvement of a locus or loci 
proximal to the telomeric regions of chromosomes 2q and 7p, with both regions having 
nonparametric LOD* scores of ~3.0, yielding very similar evidence in favor of linkage.   In 
addition to mutations and/or variants in a major gene, these loci may harbor a microdeletion 
and/or translocation; potentially, polygenic factors may also be involved.  This single family 
may be promising for narrowing the search for NTD susceptibility genes. 
 
2.2 Introduction 
2.2.1 Neural Tube Defects: Clinical Impact 
Birth defects are the leading cause of death for neonates in the United States; the risk 
of an infant being born with significant congenital abnormality in body structure or function 
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is approximately 3-4%.  Neural tube defects (NTDs) occur at a rate of 1 per 1000 live births 
in the United States [1,197], representing both the most common congenital malformation of 
the central nervous system and the second most common type of birth defect.  Neural tube 
closure occurs during the first three to four weeks of development.  NTDs are due to failure 
of closure of the neural tube during early embryogenesis, typically before a woman is aware 
of her pregnancy.  NTDs can present clinically with large phenotypic variation.  The most 
common presentations are spina bifida (spina bifida cystica, open spina bifida) and 
anencephaly.  These phenotypes represent the classic definition of NTDs and whether they 
are caused by the same underlying genetic basis remains controversial.   
Neural tube defects can frequently be disabling.  Children affected with spina bifida 
often undergo surgery to close the defect within 48 hours after birth, and may require 
frequent surgical intervention for complications such as hydrocephalus.  Affected patients 
commonly have an impaired ability to walk and often need to use a wheelchair, and they may 
have little or no bowel and/or bladder control.  Severely affected NTD cases may require 
aggressive surgical, medical, and rehabilitative care.  Thus, for a child and their family 
affected with an NTD, the psychosocial and emotional tolls are immeasurable.  These 
significant medical and personal costs have lead to several collaborative studies to investigate 
NTDs to better understand the genetic and environmental etiologies. 
 
2.2.2 Evidence for genetic and environmental components 
 NTDs are caused by a complex interaction between genetic and environmental risk 
factors.  Several exogenous risk factors are correlated with the development of NTDs, 
including maternal insulin-dependent diabetes mellitus, obesity, maternal use of anti-
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epileptic (valproic acid), and and maternal consumption of the mycotoxin fumonisin [23-29].  
An important environmental intervention for NTDs is periconceptional supplementation with 
folic acid, which has been shown to reduce the recurrence risk for NTDs by reducing the 
recurrence risk for NTDs by 50-70% [43,85,198].  However, folate supplementation has not 
entirely eliminated the risk of NTDs, suggesting that there are additional underlying genetic 
factors that may contribute to the development of NTDs.   
Several lines of evidence support a genetic component to NTDs [48].  The most 
compelling evidence for a genetic factor is the higher recurrence risk for NTDs among 
offspring from parents with previous NTD pregnancies [62,63].  Notably, the NTD 
recurrence risk for siblings is 2-5%, representing a 25-50 fold increased risk above that 
observed in the general population [199].  NTDs are also associated with established genetic 
syndromes including Meckel-Gruber syndrome, anterior sacral meningomyelocele, anal 
stenosis, trisomies 13 and 18, and other chromosomal aberrations [18,19,22].  Furthermore, a 
plethora of mouse models with mutations leading to NTDs have been identified [200].  
Overall, these observations support a genetic component to the development of NTDs.   
 
2.2.3 Initial genomic screen results 
Results from the first genome screen of NTDs were recently reported [201].  This 
screen included 44 multiplex families and considered 402 microsatellite markers with 
approximate 10 cM spacing.  The genomic screen identified regions of interest on 
chromosomes 7 and 10, with the highest LOD score of 2.45 on chromosome 7 using 
parametric linkage analysis.  Further investigations of the genomic screen data identified a 
single large family 8776, a multigenerational Caucasian family with lumbosacral 
62 
 
myelomeningocele segregating, as primarily driving the linkage results on chromosome 7.  
Additionally, this family revealed a region on chromosome 2 with evidence in favor of 
linkage (unpublished data).    
In this study of family 8776, the microsatellite genomic screen was followed up with 
a whole-genome high-density SNP screen to confirm the previously identified region on 
chromosomes 7 and 2 and narrow the minimum candidate interval for each.  In addition, the 
SNP screen could identify previously unidentified regions of linkage.  The utility of SNPs 
over microsatellites for genomewide screens has been validated, with studies demonstrating 
increases in information content with SNP screens being dependent on family structure, 
previous marker density, and other factors [202-205].  However, this increased density comes 
at a cost:  simulation-based studies have lead to concern regarding inter-marker linkage 
disequilibrium (LD) in dense SNP-genomic screens.  These simulations demonstrated that 
dense SNP data can cause false positive elevation of multipoint LOD scores, especially in the 
presence of missing parental genotypes [206,207].   
 
2.3 Materials and Methods 
2.3.1 Clinical data collection and power analysis 
NTD family 8776 was identified by self-referral through the NTD Collaborative 
Study.    First-degree relatives and relatives connecting related affected individuals were 
ascertained in this extended family.  A detailed family history [208] was obtained and 
medical records including operative reports and pre-surgical x-ray films were collected for 
review of diagnosis by a neurosurgeon (TMG).  Of the affected individuals in the pedigree, 
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three were diagnosed with lumbosacral myelomeningocele and a fourth individual was 
diagnosed with congenital dermoid cyst with tethered cord. 
Certified phlebotomists obtained blood samples from affected individuals and related 
family members at medical centers, clinics, or by visiting participants' homes.  Some 
participants sent in mailer kits with their enclosed samples.  This study was conducted under 
the oversight of Duke University Medical Center Institutional Review Board and informed 
consent was obtained from all participants.   
Power analysis of family 8776, under the broad phenotypic classification, was 
performed for the microsatellites screen by using the program SIMLINK [209,210].  The 
assumptions for the power studies included an autosomal dominant inheritance pattern with 
low penetrance (affecteds-only) model, a disease allele frequency of 0.001, and a marker 
with 75% heterozygosity linked at 5% recombination with the disease allele.  These power 
studies generated an average parameric LOD score for family 8776 at a recombination 
fraction θ = 0.05 of 1.063 ± 0.02 and a maximum LOD score of 2.515.  These power 
estimations are based on two-point parametric analysis with a specified dominant mode of 
inheritance; therefore this analysis may underestimate power to detect linkage when using a 
high density SNP approach.   
 
2.3.2 Genotyping methods 
Blood samples were collected on four affected individuals and 27 unaffected 
individuals in family 8776.  DNA was extracted from whole blood using the Puregene 
system (Gentra Systems, Minneapolis, MN).  Whole genome SNP typing was performed 
using the Affymetrix 10K SNP Chip (Affymetrix, Santa Clara, CA).  In brief, the 10K SNP 
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Chip requires only 250 ng of genomic DNA and yields genotypes for approximately 10,644 
SNPs from the SNP Consortium database with an average heterozygosity of 0.37, and 
covering on average approximately one SNP every 210 kb.  Microarrays were scanned by 
using the GeneChip Scanner 3000 according to the manufacturer's protocol (Affymetrix).  
Data acquisition was performed by using the GeneChip GCOS software.   
 
2.3.3 Whole genome linkage analyses   
The integrity of the family’s pedigree structure was confirmed as previously reported 
[211] using data generated from the genomewide microsatellite screen with the program 
RELPAIR [212,213].   
All marker information from the genomic screen was databased using the 
PEDIGENE system [214].  Data were evaluated for Mendelian inconsistencies using 
PedCheck [215].   Markers were retained in the map files for linkage analysis if they 
demonstrated at least 85% efficiency.  Allele frequencies for the SNP markers were 
estimated based on 126 unrelated Caucasian individuals that were genotyped on the 10K 
SNP chip.  Map order for the SNP markers was generated from sequence data provided by 
Translational Genomics (Phoenix, AZ).  To account for potential inter-marker LD in the 
dense SNP screen, LD Select was used [216] with pairwise r2 > 0.16 (Boyles et al. 2005) to 
generate map files that contained only tagging SNPs.   
Linkage analysis was performed using the program Allegro [133] for both two-point 
and multipoint analysis.  Because the exact inheritance pattern of NTDs is unknown, 
different analytic approaches were applied to these data, including parametric (assuming 
dominant inheritance and a disease allele frequency of 0.001) and nonparametric analysis.  
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For the nonparametric analysis, an identity-by-descent relative pair sharing method LOD* 
was assessed between all pairs of affected individuals using Spairs [126] and the exponential 
model [127] as implemented in Allegro.  Since the unaffected individuals in the pedigree 
8776 could represent asymptomatic gene carriers or have undiagnosed NTDs, a low 
penetrance affecteds-only parametric model was applied such that unaffected individuals 
contributed no information to the LOD score other than to infer missing genotypic data on 
unsampled individuals.  Size limitations in Allegro’s computational capability allowed 
inclusion of only 24 individuals from family 8776 in the linkage analyses, so the least 
informative individuals were eliminated from the analysis.   Phenotypic criteria included both 
broad (all 6 affected individuals) and narrow (only 5 affected individuals with lumbosacral 
myelomeningocele), with the narrow phenotypic definition excluding individual 100, who 
has a congenital dermoid cyst.  The two affected individuals 102 and 1075 who were not 
sampled were included in the analyses, because the genotypic information on their siblings 
and/or parents using maximum-likelihood estimation techniques can help to infer the affected 
individual’s missing genotypes.   
To confirm segregation of a disease-linked haplotypes within regions of interest, 
haplotype analysis was performed using both visual inspection and a statistical approach with 
Simwalk [217].   
 
2.3.4 Sequencing of Candidate Genes 
Several genes mapping to the regions of interest were identified using an internally 
developed bioinformatics tool Genominator2 that operates via Ensembl [218].  Primers were 
designed using Primer 3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) on 
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genomic sequence from UCSC’s database (http://genome.ucsc.edu/).  Primers were designed 
to flank the exons and include the splicing region to account for splice variants.  PCR 
products covered all the coding exons and respective intronic boundaries.  PCR product was 
purified using Sephadex G-50 fine (Amersham Biosciences, Piscataway, NJ) and QuickStep2 
SOPE Resin (Edge BioSystems, Gaithersburg, MD).  Samples were sequenced using the 
BigDye Terminator v3.1 Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster 
City, CA) and purified using Sephadex G-50 fine.  Both forward and reverse strands were 
sequenced.  The sequence data was analyzed to evaluate for putative polymorphisms using 
ABI 3100 Data Collection Software Version 1.01 and ABI Sequencing Analysis 3.7.  All 
sequences for candidate genes MEOX-2 and FZD7 were visually inspected with this software 
to evaluate noteworthy variants such as a premature termination codon, a frameshift 
mutation(s) or a missense mutation(s).  The sequence data were compared to unaffected 
parents to ascertain if a variant was transmitted or a de novo mutation.   
 
2.4 Results 
2.4.1 Linkage Results for Family 8776 
The individuals included in the linkage analyses using Allegro are indicated in Figure 
2.1.  The regions of interest were defined by a one LOD unit drop support interval from the 
peak LOD to approximate 95% confidence intervals.  Table 2.1 summarizes the linkage 
findings for the SNP data based on the results from Allegro multipoint LOD scores > 2.5 and 
with two-point LOD scores > 1.8; plots for these regions are shown in Figure 2.2.  The 
strongest evidence for linkage occurred near the telomeres of chromosomes 7 (7p21.1-pter) 
and 2 (2q33.1-q35).  Specifically, the maximum multipoint nonparametric LOD* score was 
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3.01 on chromosome 2 in the region spanning rs1379007-rs1992235.  For chromosome 7, the 
maximum multipoint nonparametric LOD* score was 2.99 in the region spanning rs2353788-
rs1368215.  These results provide an approximate 10% increase in information content over 
the maximum multipoint scores in the microsatellite genomic screen.      
When individual 100, who has a closed NTD, was included as affected (under the 
broad phenotype), her genotypic information increased the overall LOD score under both 
parametric and nonparametric analyses. 
2.4.2 Haplotyping 
Preliminary haplotyping using Simwalk [217] and hand-haplotyping confirmed the 
linkage regions identified in Table 2.1.  The haplotype results are consistent with autosomal 
dominant transmission with reduced penetrance.  Individual 100, who has the closed NTD 
variant of congenital dermoid cyst, also carried the disease-associated haplotypes on 
chromosomes 2 and 7.  Visual inspection of marker data for chromosome 2 expanded the 
candidate interval to span markers D2S1776 to D2S1363 approximating a 55.2 cM region.  
For chromosome 7, marker coverage of 7pter extended only to the middle of 7p22.3; as a 
result, the flanking marker for the 7pter end of the disease-associated haplotype could not be 
determined.  Thus, the minimum candidate interval for chromosome 7 spans from D7S3051 
to 7pter approximating a 32.3 cM region.  The presumed unaffected individual 126 carried 
the chromosome 7 disease-associated haplotype and showed a crossover between D7S2201 
and D7S641.  If individual 126 is truly “unaffected”, the crossover could reduce the 
minimum candidate interval to 17.4 cM. 
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2.4.3 Candidate genes 
Several biologically plausible candidate genes reside in the regions of interest defined 
by haplotyping results.  Using Ensembl (http://www.ensembl.org/index.html), a list of 
candidate genes for chromosomes 2 and 7 was assembled for mutational analysis.  For 
chromosome 2, the frizzled 7 receptor (FZD7) gene that maps to 2q33.1 was sequenced.  
Members of the frizzled gene family encode 7-transmembrane domain proteins that are 
receptors for Wnt signaling proteins.  The highly conserved Wnt-frizzled signal non-
canonical transduction pathways have been shown in several animal models to be involved in 
convergent extension, the process that leads to elongation of the neural plate during neural 
tube development [107,110,219].  Human mesenchyme homeobox 2 (MEOX 2), located at 
7p21.3-p22.1, is a homeobox gene involved in formation, patterning, and differentiation of 
somites. The mouse homolog Meox-2 is required for migration of limb bud and null Meox-2 
mice have decreased limb muscle mass and demonstrate downregulation of Pax3 [220].  
Both genes evaluated (FZD7 and MEOX-2) did not show any novel genetic polymorphisms 
within the coding exons.  
 
2.5 Discussion 
For some complex diseases, traditional linkage analysis approaches in rare families 
with Mendelian or near-Mendelian inheritance patterns has identified susceptibility loci.  For 
example, investigators who studied rare multigenerational families with early-onset fully 
penetrant Alzheimer's disease identified linkage to chromosome 14 and subsequently 
identified the amyloid precursor protein (APP) gene [221].  Later investigations identified a 
second locus and the genetic risk gene presenilin 1 (PSEN 1) [221].  Other examples using 
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single large families to identify linkage regions that influence disease susceptibility include 
familial focal segmental glomerulosclerosis [222], coronary artery disease [223], dementia 
[224], tonic-clonic seizure [225] sensoineural hearing loss [226,227], among others.   This 
focused approach of genetic analysis is advantageous for minimizing genetic heterogeneity, 
thereby increasing the investigator’s ability to identify areas of allele sharing in large 
multiplex families.   
Using a high-density SNP genomic screen, linkage of Family 8776 was confirmed for 
the previously reported locus at 7p21.1- pter.  Additionally, a locus at 2q33.1-q35 yielded 
increased evidence in favor of linkage over that from the earlier microsatellite genomic 
screen [228].  These two regions of interest exhibit similar statistical support for an NTD 
susceptibility locus, which may reflect multiple distinct genetic effects.  Haplotype analysis 
verified these regions of interest and demonstrated that the high-risk haplotypes segregate in 
a pattern consistent with autosomal dominant inheritance and reduced penetrance, or 
alternatively, an environmental factor that triggers disease presentation.  As with any genetic 
linkage study, these results could represent a spurious finding.   
An avenue for further investigation involves more precise phenotypic definition in the 
presumptively unaffected individuals.   For instance, determining whether these unaffected 
individuals have subtle dysraphic changes such as spina bifida occulta may stimulate 
broadening of the NTD phenotype, increase the power for future linkage analyses, enhance 
the ability to minimize a candidate interval, and identify individuals at high risk to conceive a 
pregnancy with an NTD.  Alternatively, the failure to identify radiographic changes in 
presumptively unaffected “transmitting” individuals may reflect a non-penetrant allele or a 
susceptibility locus in the absence of an eliciting environmental insult.  Studies to elucidate 
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the phenotype involve radiographic confirmation by x-ray and/or magnetic resonance 
imaging and may be difficult to obtain in a research setting due to increased risk to the 
subject.  Any detected differences in affected individuals’ NTD phenotype from family 8776 
may potentially be explained by pleiotropic effects of a common underlying gene, different 
genetic backgrounds containing a modifier gene, and/or different environmental exposures at 
a critical developmental time point.  Two individuals in family 8776 demonstrate the 
importance of accurate phenotypic definition. 
For instance, when individual 100, who has an NTD variant of congenital dermoid 
cyst, was included in the analyses as affected, the LOD scores for the 7p and 2q regions were 
increased.  Individual 100 also carries the same high-risk haplotype as other affected 
individuals with lumbosacral myelomeningocele in the family.  
And, haplotype analysis also revealed that individual 126, who appears 
phenotypically unaffected, to be recombinant for the disease-associated chromosome 7 
haplotype.  Since individual 126 is a minor, radiographic studies are not available for 
clarification of the phenotype.  If individual 126 demonstrated no evidence for a radiographic 
abnormality, the 7p interval could potentially be narrowed by 14.9 cM to a 17.4 cM region 
between D7S641-7pter.  However, this crossover for the unaffected individual should be 
interrupted cautiously because she may harbor a subtle dysraphic variant which would lead to 
a change in her affection status, thereby modifying the minimum candidate interval.   
Several promising candidate genes reside in the regions of interest for chromosomes 2 
and 7.  FZD7, CASP8, CASP10, PAX3, and a cluster of HOXD genes map to the region of 
interest on 2q.  MEOX2 and TWIST1 genes map to 7p.  Sequence data for FZD7 and MEOX2 
genes did not reveal any potential causal variants for this family; however, the promoter 
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regions for these genes have yet to be evaluated.  In addition to evaluation of candidate 
genes, family 8776 is also under investigation for potential chromosomal abnormalities using 
both comparative genomic hybridization (CGH)-arrays and fluorescent in situ hybridization 
(FISH).   
Overall, the highest linkage results for family 8776 map near the telomeric regions of 
chromosomes 2 and 7.  Telomeric regions typically are difficult to map due to limited marker 
density, and in fact, the chromosome 7 region of interest could be narrowed with an 
increased marker density.   Regions proximal to the telomeres tend to have a high degree of 
interchromosomal recombination, so it is plausible that a microdeletion and/or translocation 
event has taken place in one or both of these regions.  Chromosomal abnormalities are 
associated with NTDs, and reports suggest 2-16% of nonsyndromic NTDs have detectable 
cytogenetic abnormalities [22].  The 2q region of interest for family 8776 includes the PAX3 
gene, for which an interstitial de novo microdeletion of 2q35-q36.2 has been previously 
reported for two patients with Waardenburg syndrome type III and myelomeningocele 
(OMIM 148820) [229].   PAX3 is a member of the Paired Box transcription factor gene 
family that has been extensively studied for its role in early development.  Pax3 is expressed 
in the mouse neural tube and mutant Pax3 mice (Splotch) embryos have neural tube defects, 
including spina bifida and exencephaly, (the equivalent of human anencephaly).   
Focusing on rare Mendelian-like families for linkage studies can identify 
susceptibility loci that may later be shown to alter risk in the non-Mendelian forms of the 
disease.  Family 8776, as one of the largest reported NTD families, may represent an 
important resource for narrowing the search for NTD candidate genes since it provides a 
unique opportunity for identification of a single major locus.  However, evaluation of this 
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one family may or may not be generalizable to all NTDs, so any putative high-risk 
haplotypes, genetic variant(s) and/or chromosomal abnormalities may or may not be unique 
to this family.  Consequently, any results identified in family 8776 must be characterized in 
other families to determine generalizability.    
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Table 2.1 Multipoint LOD scores (>2.5) for regions of interest on chromosomes 2 and 7. 
 
n represents the number of affected individuals included in each analysis. 
  
    Parametric Nonparametric 
Cytogenetic 
Band 
Marker Region 
Spans 
One LOD unit (CI) 
(Total distance, cM) 
 
Broad 
n=6 
Narrow 
n=5 
Broad 
n=6 
Narrow 
n=5 
SNPs rs1437872-
rs2888386 
196.5 – 213.6 
(17.1 cM) 
2.69 2.39 3.01 2.41 Chrom. 2 
2q33.1-q35 
Microsat. D2S2978-
D2S1363 
186.0 – 229.2 
(43.2 cM) 
2.32 2.02 2.64 2.04 
SNPs rs2389831- 
7pter 
0 – 31.68 
(31.7 cM) 
2.66 2.36 2.99 2.38 Chrom. 7 
7p21.1-pter 
Microsat. D7S3051-
7pter 
0 – 32.34 
(32.3 cM) 
2.31 2.02 2.63 2.03 
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Figure 2.1 Pedigree diagram of family 8776 
Condensed version of extended family 8776.  Fully shaded symbols represent individuals 
affected with lumbosacral myelomeningocele.  The half shaded circle for individual 100 
represents congenital dermoid cyst.  The quarter shaded circle denotes the 5 individuals who 
are affected by history alone.  + indicates sampled (DNA) individuals.  § refers to individuals 
included in linkage analysis.  Individuals 102 and 1075 are reported to have lumbosacral 
myelomeningocele; however, the medical records and radiographic studies are not currently 
available to confirm this diagnosis.   
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Figure 2.2 Multipoint LOD score curves for regions of interest in family 8776 
Both SNP and microsatellite marker linkage results using parametric and nonparametric linkage 
methods are plotted for chromosomes 2(A) and 7 (B).  The total genetic distance covered by the 
analyzed markers is given on the X-axis in cM.   
 
 
  
CHAPTER 3  
 
Refinement of 2q and 7p loci and genomic convergence for candidate gene selection in a 
large multiplex neural tube defect (NTD) family 
 
 
 
3.1 Abstract 
Neural tube defects (NTDs) are considered complex disorders that arise from an 
interaction between genetic and environmental factors. NTD family 8776 is a large 
multigenerational Caucasian family that provides a unique resource for the genetic analysis 
of NTDs.  Linkage analysis using a genomewide SNP screen in family 8776 and multipoint 
nonparametric methods mapping previously identified maximum LOD* scores of ~3.0 
mapping to 2q33.1- q35 and 7p21.1-pter.  We ascertained an additional nuclear branch of 
8776 and conducted additional linkage analysis, fine mapping and haplotyping  
We observed increased evidence for linkage with LOD* scores of ~3.3 for both regions. 
Haplotype analyses narrowed the minimum candidate intervals to a 20.3 Mb region in 
2q33.1-q35 between markers rs1050347 and D2S434, and a 8.3 Mb region in 7p21.1-21.3 
between a novel marker 7M0547 and rs28177. Within these candidate regions, 16 genes were 
screened for mutations; however, no obvious causative NTD mutation was identified. 
Evaluation of chromosomal aberrations using array-CGH, subtelomeric fluorescent in situ 
hybridization, and copy number variant detection techniques within the 2q and 7p regions did 
not detect any novel chromosomal abnormalities.  This large NTD family has identified two 
77 
 
genomic regions that may harbor NTD susceptibility genes. Ascertainment of another branch 
of family 8776 and additional fine mapping permitted a 9.1 Mb reduction of the NTD 
candidate interval on chromosome 7 and 37.3 Mb on chromosome 2 from previously 
published data.  Identification of one or more NTD susceptibility genes in this family could 
provide insight into genes that may affect other NTD families. 
 
3.2 Introduction 
3.2.1 Human Neural Tube Defects 
Neural tube defects (NTDs) are among the most serious congenital birth defects 
occurring at a rate of 1 per 1000 live births in American Caucasians [1,197].  NTDs result 
from failure of closure of the neural tube during the first three to four weeks of fetal 
development. NTDs are phenotypically heterogeneous disease with a large spectrum in the 
clinical presentation and degree of impairment. The most common NTD presentations are 
anencephaly and lumbosacral myelomenginocele (also known as spina bifida). Anencephaly 
occurs when the rostral neural tube fails to form and is associated with 100% mortality of 
anencephalic fetuses whereas spina bifida occurs when the caudal neural tube fails to close 
appropriately. The majority of NTDs are non-syndromic [15,16] that is, the failed closure of 
the neural tube in the cranial or spinal location, or both, is the only defect present at birth. 
Non-syndromic NTDs are thought to have a multifactorial etiology with a complex 
interplay of several genetic and environmental factors [230].  A number of these 
environmental risk factors have been associated with maternal risk of having a child affected 
with an NTD.  Most significant among these has been the impact that periconceptional folate 
supplementation has made a on NTD prevalence in the US population, decreasing the risk of 
78 
 
having a child with an NTDs by 50-70% [43,85,231]. Approximately 30-50% of NTDs are 
not prevented by folic acid supplementation, suggesting that additional factors including 
genetic risk factors, may contribute to the development of NTDs.  The most compelling 
evidence for a genetic factor is a 2-5 % recurrence risk for NTDs among offspring from 
parents with previous NTD pregnancies [199].  Interestingly, syndromic NTDs are also 
associated with established genetic syndromes including Meckel-Gruber syndrome, anterior 
sacral meningomyelocele, anal stenosis, trisomies 13 and 18, and other chromosomal 
aberrations [18,19,22].  Furthermore, 155 mouse models with known genetic mutations 
leading to NTDs have been characterized -- one of these is the Lp mouse with 
craniorachischisis caused by a Vangl2 mutation [58]. Recently, Kibar and colleagues 
discovered two mutations in the VANGL1 gene in two patients with familial forms of non-
syndromic NTDs (V239I and R274Q) and the V239I mutation abrogated protein-protein 
interactions with disheveled binding partners [113].  Not only does the VANGL1 finding 
support a genetic contribution to NTDs, but it also provides functional evidence of a rare 
genetic mutation associated with human familial NTDs.  This work demonstrates that family-
based genetic studies can illuminate rare genetic effects and further our understanding of the 
complex molecular mechanisms underpinning human neural tube closure.  
 
3.2.2 Previous NTD Gene Mapping Studies  
A whole genome screen performed on 44 multiplex families using 402 microsatellite 
markers at ~ 10 cM spacing identified linkage peaks on chromosomes 7 and 10 with 
parametric LOD scores of 2.45 and 2.08, respectively [134].  One large family, 8776, was 
found to be primarily responsible for the chromosome 7p linkage peak.  
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Further genetic analysis of family 8776 alone revealed similar evidence of linkage on 
chromosome 2, with both linkage regions  in 7p21.1-pter and 2q33.1-q35 having a 
nonparametric Spairs LOD* scores ~3.0 assuming a broad phenotypic definition for NTDs in 
which all affected individuals with a broad spectrum of NTDs were considered affected [61]. 
The 2q and 7p linkage regions were confirmed by haplotype analysis, and we also 
determined that the 2q and 7p NTD associated haplotypes segregated in a pattern consistent 
with autosomal dominant inheritance with reduced penetrance.   
In this current genetic analysis, we have ascertained a new branch of the family 8776 
that led to the refinement of the previous linkage interval on 7p. Additional fine mapping and 
haplotype analysis further narrowed the minimum candidate gene interval for both the 2q and 
7p loci. We have used convergent methodologies to identify to prioritize candidate genes for 
mutational screening and have investigated the possibility of chromosomal abnormalities 
within family 8776 as a mechanism for NTD development.  As family 8776 is one of the 
largest known multigenerational NTD families showing evidence of a strong genetic effect, it 
provides a unique opportunity for identification of a novel NTD gene. 
3.3 Materials and Methods 
3.3.1 Clinical Data Collection and Biological Samples 
NTD family 8776 was identified by self-referral through the NTD Collaborative 
Study.  First-degree relatives and relatives connecting related affected individuals were 
ascertained in this extended family.  A detailed family history [208] was obtained, and 
medical records including operative reports and pre-surgical x-ray films were collected for 
review of diagnosis by a neurosurgeon.  A total of 5 affected and 29 unaffected individuals 
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were available for genotyping.  Of the sampled affected individuals with non-syndromic 
NTDs in the pedigree, four were diagnosed with lumbosacral myelomeningocele and 
individual 100 was diagnosed with congenital dermoid cyst with tethered cord.  A sixth 
affected individual (1075) is reported by family history to be affected with lumbosacral 
myelomeningocele.  
Certified phlebotomists obtained blood samples from affected individuals and related 
family members at medical centers, clinics, or by visiting participants' homes.  Some 
participants sent in mailer kits with their enclosed samples.  This study was conducted under 
the oversight of Duke University Medical Center Institutional Review Board and informed 
consent was obtained from all participants.   
Power analysis of family 8776 for the SNP screen was performed using the program 
SIMLINK [209,210].  The five newly sampled individuals affected with an NTD were 
included in the power analysis. The assumptions for the power studies included an autosomal 
dominant inheritance pattern with low penetrance (affecteds-only) model, a disease allele 
frequency of 0.001, and a SNP marker with 50% heterozygosity linked at 5% recombination 
with the disease allele. These power studies generated a maximum parametric LOD score of 
2.07 at θ = 0.05. SIMLINK assumes an underlying Mendelian inheritance pattern, which may 
not accurately represent the complexity of NTDs.  
 
3.3.2 Genotyping Methods 
Since the previous publication [61] blood samples were collected on one nuclear 
branch in family 8776 including affected individual (102) and 2 unaffected individuals 
(1006, 103) .  DNA was extracted from whole blood using the Puregene system (Gentra 
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Systems, Minneapolis, MN). Individual genotyping was performed on the Affymetrix 10K 
version 2 chip (Affymetrix, Santa Clara, CA) using the standard Affymetrix protocol. This 
SNP chip provides genotypes for approximately 11,500 SNPs that have an average 
heterozygosity of 0.37 and average spacing of one SNP every 210 Kb.   Microarrays 
handling and data acquisition methods are the same as previously reported [61].  All marker 
information from the genomic screen was databased using the PEDIGENE system [214].    
 
3.3.3 Error Checking 
Mendelian pedigree inconsistencies present within the SNP data were identified using 
PedCheck [232] and were removed prior to genetic analysis. Using 685 SNP markers 
genotyped across the genome, intra-familial relationships for family 8776 were inferred using 
a maximum likelihood approach implemented in RELPAIR [233,234] in order to verify the 
genetic relationships for the newly ascertained 8776 branch containing individuals 1005, 
1006, 102, and 103.  
 
3.3.4 Whole Genome Linkage Analyses   
3.3.5 Marker Maps 
Map order for the SNP markers was generated from sequence data provided by 
Translational Genomics (Phoenix, AZ).  SNPs with at least 85% genotyping efficiency for 
family 8776 were retained for linkage analysis.  Allele frequencies for the SNP markers were 
estimated based on 126 unrelated Caucasian individuals’ DNA also genotyped on the 10K 
Affymetrix SNP chip.  To account for potential inter-marker LD in the 10K SNP screen, LD 
82 
 
Select was used [216] with a pairwise r2 > 0.16 (Boyles et al. 2005) to create map files with 
only tagging SNPs. After efficiency and inter-marker linkage disequilibrium (LD) were 
incorporated, the markers maps used for linkage analysis included 5871 SNPs.  The rationale 
behind accounting for inter-marker LD in multipoint linkage analysis is based on simulation 
work demonstrating that dense SNP data can lead to false positive elevation of multipoint 
LOD scores, particularly when there are missing parental genotypes [206,207]. 
 
3.3.6 Linkage Analysis 
We used similar linkage approaches as previously reported for this family [61].  
Briefly, linkage analysis was performed using the program Allegro [133] for both two point 
and multipoint analysis.  Since the inheritance pattern of NTDs is unknown, different 
analytic approaches were applied to these data, including parametric (assuming dominant 
inheritance and a disease allele frequency of 0.001) and nonparametric analysis (model-free).  
It is possible that unaffected individuals in the pedigree 8776 could represent asymptomatic 
gene carriers or have undiagnosed NTDs; thus, a low penetrance affecteds-only parametric 
model was applied such that unaffected individuals did not affect the LOD score other than 
to help infer missing genotypic data on unsampled individuals.  Phenotypic criteria included 
as affected all six individuals with lumbosacral myelomeningocele, as well as individual 100 
who has an NTD variant of congenital dermoid cyst.  Previous linkage findings demonstrated 
that individual 100 contributed to the LOD score for both 2q and 7p. Individual 1075, who is 
affected by historical account only and not sampled, was also included in the analyses, 
because the genotypic information from siblings and/or parents can help to infer the affected 
individual’s missing genotypes.  For the nonparametric analysis, an identity-by-descent 
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relative pair sharing method LOD* was assessed between all pairs of affected individuals 
using Spairs and Sall  [126] and the exponential model [127] as implemented in Allegro. The 
regions of interest were defined by a 1 LOD/LOD* unit support interval from the peak 
LOD/LOD* to approximate 95% confidence intervals. The LOD score reflects the parametric 
linkage results and the LOD* is the linkage results from the nonparametric methods.   
The same 24 individuals were retained in the current linkage analysis as previously 
reported [61].  The nuclear branch with individuals 1006, 1005, and 102 was included in this 
original linkage set based on the rationale that the genotypic data from 1005 could help to 
infer affected individual 102’s potential genotypes. In this current study, the new genotypic 
data for individual 102, who is affected with lumbosacral myelomeningocele, provided 
additional power (estimated increase in parametric LOD score by 0.3) to detect linkage.   
 
3.3.7 Fine mapping  
An additional 19 microsatellite repeat markers in 2q and 11 (including two novel 
variants) microsatellite repeat markers in 7p were genotyped to further refine the linkage 
regions. Microsatellite markers were prioritized based on high heterozygosity and spacing (~ 
2 Mb) within the region. We also used UCSC Bioinformatics Table Browser 
(http://genome.ucsc.edu/cgi-bin/hgTables?command=start) to identify additional repetitive 
regions for the development of novel genetic markers as the chromosome 7 interval had a 
paucity of known microsatellites. Primers were designed in Primer 3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and the novel microsatellite 
markers were named 7M0546 and 7M0547.  7M0546 maps to chr7: 14043894-14044124 
(NCBI Build 35); the forward primer is 5’CATTGTTGGCTGACGAATTG 3’ and the 
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reverse primer is 5’ CTAGGGGCACAGGTGAGAAG 3’.  7M0547 maps to chr7: 
16053379-16053552 and a forward primer of 5’GAATGGAACAGGGATTTGGA 3’ and the 
reverse primer is 5’ CACTGCATCCATATTGGGTTT 3’.  Microsatellite genotyping 
methods are the same as previously published [61].  
 
3.3.8 Haplotype analysis 
To confirm segregation of haplotypes with disease status and to further evaluate 
haplotypes from fine mapping, haplotype analysis was performed using both visual 
inspection and a statistical prediction using Simwalk [217],  
 
3.3.9 Chromosomal Aberration Detection Methods 
We carried out genomewide copy number profiling to identify genomic gain or loss 
that could be associated with NTD within family 8776. as previously described [235].  
Briefly, PCR representations of 30,000 overlapping 100-200 Kb clones generated from the 
Human Genome Project are used as array probes. NTD DNA and sex-mismatched control 
DNA were differentially labeled with Cy3 or Cy5 and co-hybridized to the genomic tilepath 
array [236].  Hybridization signals were visualized using an Axon 4100A dual laser scanner 
and output data uploaded into BlueFuse (www.cambridgebluegnome.com/) for signal 
normalization and clone filtering prior to log2 ratio calculation (as previously reported by 
[235]). Array-CGH was conducted on DNA of 8 individuals from family 8776; specifically, 
CGH arrays were run on 4 sampled affected individuals (001, 100, 128, 129), 2 mothers 
transmitting the 7p and 2q high-risk haplotypes (1001, 1023), an unaffected not carrying the 
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high-risk haplotypes (131), and an unaffected individual (126), who carries the 2q and 7p 
haplotype. 
SNP data available from the Affymetrix 10K SNP Chip was also used to test for 
potential copy number variants (CNV) and loss of heterozygosity (LOH). More specifically, 
the .cel files which provide the intensity information for a given probe on an array were 
utilized in two different analysis tools that both compare cases versus controls for copy 
number changes and loss of heterozygosity.  The first was DChip 
(http://biosun1.harvard.edu/complab/dchip/) and the second tool was CNAT 4.0 
(http://www.affymetrix.com/products/software/specific/cnat.affx).  In each case the SNPs 
were first viewed in groups of 5 in both a smoothed median and a Hidden Markov model. 
The SNP threshold was then gradually lowered to a single SNP using both algorithms. 
   Subtelomeric FISH (fluorescent in situ hybridization) analysis on family 8776 was 
performed using ToTelVysionTM Multicolor DNA probe mixtures (Abbott Laboratories, 
Abbott Park, IL) per the manufacturers recommended protocol.  FISH analysis was 
performed on two nuclear, branches of family 8776; more specifically, in individuals 1000, 
1001, 001, 100, 1024, 1023, 126, 127, and 128.  
 
3.3.10 Candidate Gene Prioritization 
We identified 89 and 9 RefSeq genes mapping to the 2q and 7p disease-associated 
haplotype regions, respectively, using the UCSC genome browser (http://genome.ucsc.edu/). 
To focus our mutational sequencing efforts we prioritized candidate genes based on each of 
the gene’s following characteristics: 1) biological plausibility (e.g. NTD mouse model, 
involved in folate or glucose metabolism); 2) expressed in brain or fetus; and 3) differential 
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expression in immortalized lymphoblast cells lines from three NTD cases of family 8776 
(individuals 1, 100,128) compared to 9 Coriell control cell lines (GM03797, GM07535, 
GM03714, GM03798, GM12497, GM13072,  GM08336, GM10958 , GM01207; Camden, 
NJ). The control cell lines were selected to roughly age match (the age of the subject when 
cell lines were immortalized) for the cases and controls—the cases had an mean age of 4.2 
years old + 2.8 (SE) at age of immortalization and the control cell lines were 7.9 years old + 
1.5 (SE).  
 
3.3.11 Expression Analysis 
The whole genome expression work was performed on the Illumina’s Sentrix® 
Human-6 version 1 Expression BeadChip (San Diego, CA) using the standard Illumina 
protocol for these RNA chips. These chips allow for assessment of six independent RNA 
samples in parallel on a single chip containing probes for 46,000 transcripts with 24,000 
being annotated genes. Each transcript has a full-length 50mer oligo probe that is present on 
average 30 times in order to increase the reproducibility and reliability of the expression data 
generated.  Illumina’s Bead Studio 2.3 was used for expression analysis. The rank invariant 
normalization method was performed (rank invariant genes have expression values with 
consistent order in different samples when compared to other genes on the expression panel).  
The Illumina custom error model was applied to the data; this model assumes the target 
signal intensity is normally distributed among replicates and takes into consideration three 
components of variation: sequence biological variation, nonspecific biological variation, and 
technical error. Differentially expressed genes with p values < 0.05 residing in the 2q and 7p 
haplotypes were prioritized for candidate gene selection.  
87 
 
 
3.3.12 Sequencing of Candidate Genes 
Exon locator and eXtractor and Resequencing (ELXR) were used to select primer sets 
for resequencing (http://mutation.swmed.edu/ex-lax/index.html).  If primers failed to produce 
PCR products, then primers were redesigned using Primer 3 on genomic sequence from the 
UCSC genome browser. PCR amplicons covered all exons and respective intronic 
boundaries.  First, we conducted a screen for potential variants by sequencing eight 
individuals (four affected individuals: 001, 100, 128, 129; two parents: 1000, 1001; one 
unaffected individual 126, who carries 2q and 7p haplotype; and a sample from the Centre 
d'Etude du Polymorphisme Humain (CEPH) genotyping database (Family 1331, individual 
2).  PCR products and corresponding primers were sent to Agencourt’s Genomic Service 
(Beverley, MA) for sequencing.  In the initial screen, only the forward direction was 
sequenced. Subsequent sequencing was performed in both forward and reverse directions to 
contiguate sequence from several overlapping PCR products.  Sequence data were visually 
inspected to identify nucleotide variants using ABI 3100 Data Collection Software Version 
1.01 and ABI Sequencing Analysis 3.7. The sequence data were compared to unaffected 
parents to ascertain if a variant was either transmitted to their two affected individuals (001 
and 100) or a de novo mutation.  
Variants observed in the mutational screen were further prioritized for resequencing 
in the remaining individuals of NTD family 8776.  The decision for additional re-sequencing 
efforts in family 8776 was based on the following features of each variant identified in the 
screen: 1) whether all four affecteds share the same variant; 2) potential functional 
significance of variant (coding or UTR); 3) degree of conservation; 4) whether novel or 
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known variant; and 5) when available, allele frequencies. Cross-species conservation 
predictions were based on the UCSC genome browser’s conservation track. Sequencing the 
entire family included DNA from 34 NTD 8776 family members and 2 CEPH controls.  
All novel mutations identified in this study were named according to the 
recommendations of the Human Genome Variation Society (HGVS) described by [237] with 
the ATG translation start codon assigned +1.   Gene names were assigned based on the 
HUGO-approved gene symbol (http://www.gene.ucl.ac.uk/cgi-bin/nomenclature/). 
 
3.4 Results 
3.4.1 Linkage Results for Family 8776 
Intra-family relationships for NTD family 8776 were verified using RELPAIR and 
the pedigree structure of 8776 is shown in Figure 3.1. The individuals included in the current 
linkage studies (Figure 3.1) are the same set as previously reported [61],  but with the 
addition of genotypic data for individuals 1006 and 102. Figure 3.2 shows LOD plots for the 
regions with the strongest evidence of linkage mapping to chromosomes 2 (2q33.1-q35) and 
7 (7p21.1-7p21.3). The maximum multipoint parametric LOD and nonparametric LOD* 
scores for chromosome 2 were 3.31 and 2.99 spanning the intervals between rs1961468 - 
rs956133 and rs1379007 - rs1912181, respectively; for chromosome 7, they were 3.29 and 
2.96 at rs2215949 - rs763534 and rs719680 - rs1368215, respectively. Specifically, the 1 
LOD support interval for chromosome 2 is rs1437872 to rs2888386, the same as previously 
published, whereas for chromosome 7 the region is flanked by markers rs2389831 to 
rs28177, a 9.7 Mb interval, leading to a narrowing of the 7p linkage region by 7.8 Mb (15.5 
cM).  Notably, both regions of interest had an increase in the LOD scores by 0.3 with the 
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additional genotypic data for individual 102.   The Spairs and Sall linkage results were the same 
within the 1 LOD* support interval. 
 
3.4.2 Haplotyping 
 We previously identified regions of linkage to chromosomes 2 and 7 within NTD 
family 8776 [61].  To further refine these loci we genotyped an additional 19 and 11 
microsatellite repeat markers on 2q and 7p, respectively, with inclusion of a new branch of 
family 8776 (Figure 3.3). NTD-associated haplotype analysis of the additional markers 
substantially decreased the minimal critical regions of interest on both chromosome 2 and 7.  
 For chromosome 2, the haplotype previously was reported to span D2S1776 to 
D2S1363, a 57.6 Mb interval mapping to 2q24.3-q36.3 [61]. Genotype analysis of the 19 
microsatellites on chromosome 2 substantially reduced the region to a 23.5 Mb interval 
between D2S425 to D2S434. We further refined this interval by sequencing exon 2 of the 
‘heat shock 60kDa protein 1’ gene (HSPD1 [MIM 118190]) within all family members of 
8776.  Sequence analysis revealed a recombination event within individual 129 for a coding 
synonymous SNP within HSPD1 (rs1050347) that reduced the chromosome 2 by 3.2 Mb, 
redefining the minimal critical region to 20.3 Mb between rs1050347 - D2S434 mapping to 
2q33.1-q35. Two presumptively unaffected individuals 103 and 126 also have the 2q high-
risk haplotype as shown in Figure 3.3. 
Our previously reported chromosome 7 NTD haplotype spanned a 17.4 Mb interval 
between D7S2508 to 7pter [61]. Genotype analysis of the additional 11 microsatellite 
markers within the additional branch of family 8776 identified cross over events within 
individual 1005, the father of 102 between novel markers 7M0546 and 7M0547 and affected 
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individual 102 between SNP markers rs28177 and rs2349775. The new data shows a 
conserved 7p haplotype segregating with affection status mapping to an 8.3 Mb interval 
between rs28177-7M0547 within 7p21.1-21.3 (Figure 3.3), a decrease of 9.1 Mb from our 
previous data [61].  Haplotype analyses also revealed two unaffected individuals, 103 and 
126, carry the 2q haplotype and are recombinant for the 7p haplotype.  Specifically, 
individual 103 is recombinant between D7S2547 and rs2215949 and individual 126 between 
rs725934 and D7S2514 (Figure 3.3).  
 
3.4.3 Candidate Genes 
Several biologically plausible candidate genes reside in the regions of interest defined 
by haplotyping results.  Using UCSC, a list of candidate genes for chromosomes 2 and 7 was 
assembled. Approximately 89 and 9 annotated genes for 2q and 7p minimum candidate 
intervals, respectively. Our decision to sequence genes was prioritized first on their 
biological plausibility based on what is known from animal models on neural tube closure. 
For instance, biologically plausible candidate genes include those involved in folate 
metabolism [58,68,69], in planar cell polarity pathway [109,110], and in apoptosis [58,200]. 
Thus, the genes FZD5, WNT10A and WNT6 were preferentially evaluated for their role in the 
planar cell polarity pathway; of note, only two exons were successfully sequenced in the 
WNT genes since the other exonic regions had high homology to many other genomic 
locations complicating primer design. Three genes involved in apoptosis were sequenced in 
family 8776 including CASP8, CASP10, and STK17B.    
Table 3.1 shows the genes that were selected for mutational sequencing and describes 
for each gene the particular variant evaluated with the corresponding total number of exons 
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successfully sequenced. The majority of exons were sequenced but for those exons that were 
not sequenced it was often due to the sequence being highly homologous to other regions of 
the genome making primer design challenging. There were 1372 differentially expressed 
transcripts in the 3 case to 9 control comparison, 4 of which mapped to the 2q and 7p 
haplotype intervals, and three were selected for sequence analysis; HSPD1, PECR and 
IGFBP2 (Table 3.1), and the other differentially expressed gene ICA-1 was not sequenced 
because it mapped near the end of the haplotype (13.6 kb from the flanking marker rs28177).  
Table 3.1 indicates of these 3 genes sequenced whether they had increased or decreased 
patterns of expression.   
All eight novel variants identified in our mutational screen by re-sequencing were 
non-coding (intronic or untranslated) polymorphisms (Table 3.2). Variants were prioritized 
for additional sequencing in the entire family based on whether > 3 of the 4 affected 
individuals shared the same variant since we would expect the same variant to be segregating 
with disease. Only two novel variants (NM_003468.2:c.-164 G>A and NM_177538.1: c122 
+ 129 G > A) were observed. We did not carry out further sequence analysis of 
NM_177538.1: c122 + 129 G > A in CYP20A1 since it was observed in all 8 individuals 
sequenced including the CEPH sample and the father 1000 who does not carry the 2q or 7p 
haplotype. Twelve variants detected in the screen were also sequenced in the entire family 
8776 (Table 3.3).  Following evaluation, no variant appeared to be specifically associated 
with disease status.  Hence, it was interpreted from this finding that these mutations are 
unlikely to be NTD susceptibility variants.  
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3.4.4 Chromosomal Abnormalities 
Copy number analysis by tilepath array-CGH of 8 members of family 8776 failed to 
identify copy number variation associated with NTD within the two regions of interest in 2q 
and 7p. Analysis of SNP data across the entire genome of these individuals also failed to 
identify copy number changes that may be associated with NTD. Subtelomeric FISH analysis 
for probes to 7p and 2q on two triads of family 8776 did not identify any chromosomal 
aberrations. Together, these findings provide evidence supporting normal chromosomal 
structure in family 8776 for the 2q and 7p regions of interest. 
 
3.5 Discussion 
In this study, fine mapping, haplotype analysis and pedigree expansion of NTD 
family 8776 lead to a substantial refinement of regions of interest previously identified at 2q 
and 7p. Pedigree expansion resulted in an increased LOD* from ~3.0 to ~3.3 for both 2q and 
7p linkage peaks and decreased the 7p linkage region to an interval that is 7.8 Mb (15.5 cM) 
smaller than previously described [61].  Moreover, fine mapping and haplotype analysis of 
these two regions led to a decrease in the region of interest in 2q by 37.3 Mb to a 20.3 Mb 
region and in 7p there was a 9.1 Mb decrease to a 8.3 Mb interval. 
 
Further narrowing of this 7p haplotype could be achieved if we were able to 
determine whether one of the presumed unaffected individuals 103 and 126 were truly not 
affected by an NTD.  When haplotypes of individuals 103 and 126 are combined they 
completely overlap with the 7p NTD-associated haplotype, so if both individuals were found 
to be definitively unaffected this region may be excluded altogether.  However, the 
93 
 
recombinant haplotypes for these two unaffected individuals should be interpreted carefully 
because these individuals may have a subtle NTD variant that has not been diagnosed. 
Radiographic studies (X-rays and MRI) used to diagnose NTDs are not currently available 
for either of these individuals, and even had such studies been available the utility of a 
negative imaging result is unclear. Of note, an X-ray on transmitting relative 1001 did not 
identify any bony defects. 
The chromosome 7 linkage interval localizes to the subtelomeric region of 
chromosome 7p. Telomeres have previously been shown to have a high degree of inter-
chromosomal recombination [238].  It is plausible, therefore, that a microdeletion and/or 
translocation event may have taken place in one or both of these regions and 2-16% of non-
syndromic NTDs have detectable cytogenetic abnormalities [22]. We evaluated family 8776 
for chromosomal abnormalities in the 2q and 7p regions and detected no evidence of 
abnormality using three independent techniques: 1) array-CGH; 2) subtelomeric FISH; and 
3) CNV analysis of the SNP mapping array data. Although none of these approaches 
identified loss or gain of genomic material, it is possible that a small chromosomal 
aberration(s) exists within these regions that may only be detected using denser genotyping 
chips or tiling path oligo-arrays.    
 
The chromosome 2 and 7 linkage regions exhibit similar statistical support for an 
NTD susceptibility locus which may reflect multiple distinct genetic effects or epistatic 
interactions associated with the disease. As with all gene mapping studies, there still remains 
the possibility that one or both of these haplotypes are shared by chance and do not harbor an 
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NTD high-risk variant.  However, this seems unlikely given the high evidence in favor of 
linkage for this family.  
NTDs are most likely caused by polygenic factors combined with a multitude of 
environmental factors. A multifactorial threshold model can be applied to diseases like NTDs 
with complex disease inheritance [239]. Within this model the presence of the complex 
disease phenotype is detected once the combined additive genetic and environmental effects 
coalesce to a particular liability threshold.  In family 8776, the liability threshold may not 
have been reached for the unaffected individuals that carry either the 2q or 7p or both 
haplotypes, such that certain genetic variants or environmental stimulus may not be present 
to reach the additive gene and environment threshold. Interestingly, individual 100, who 
carries the 2q and 7p haplotypes, has a different clinical presentation (congenital dermoid 
cyst) from the other 5 individuals affected with lumbosacral myelomeningocele. This 
different phenotype or lack of phenotype in “unaffecteds” carrying the high-risk haplotype(s) 
may be due to any of the following factors: 1) pleiotropic effects of the same susceptibility 
gene(s), 2) differences in genetic backgrounds with modifier gene(s), and/or 3) differences 
in-utero exposures at time of neural tube closure.   
 
Epigenetic mechanisms may also play a role in normal and dysregulated neural tube 
closure.  Methylation of cytosine nucleotides is an epigenetic modification of DNA that 
occurs during the early development of germ cells and pre-implanted embryos.  NTDs have 
been shown to develop in mutant mice that are null for DNA (cytosine-5)-methyltransferase 
3B (Dnmt3b) and DNA (cytosine-5)-methyltransferase 3L (Dnmt3l) [58], genes that are 
known to establish methylation of maternally imprinted genes throughout mouse 
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development [240]. These data suggest that aberrant methylation may play a role in neural 
tube defects within humans.  Interestingly, methylation patterning during fetal development 
has been shown to be affected by dietary methyl donors (methionine and choline) and critical 
co-factors (folic acid, B12 , pyridoxal phosphate) [92] . Thus, the nutritional status of the 
mother may affect essential methylation reactions such as establishment and maintenance of 
methyl marks on imprinted genes.   
In NTD multiplex family 8776, aberrant maternal imprinting may implicated in the 
disorder because the sex ratios for NTD transmitting unaffected members of the family to 
affected children is 5:2 female to male ratio, suggesting a stronger maternal transmission 
pattern.  Although this observation is not statistically significant and may reflect 
ascertainment biases toward maternal interviews, it illustrates that maternal imprinting in 
family 8776 and/or general DNA methylation patterns may increase the risk of having a child 
affected with an NTD.   
We selected 16 genes promising candidate genes from the refined linkage regions on 
chromosome 2 and 7 for mutational sequence analysis in family 8776.  Twelve variants 
identified within these genes were evaluated in the entire family, however, they were not 
specifically associated with disease status; therefore, it is our belief that the actual NTD 
susceptibility variant(s) from these intervals remain to be identified.  Despite this negative 
outcome, sequencing efforts for family 8776 are still underway. However, other avenues of 
research may also prove useful in identifying candidate genes. For instance, preliminary 
work in our laboratory evaluating expression patterns of human fetal embryos from SAGE 
(serial analysis of gene expression) libraries of human fetal neural tube tissue from Carnegie 
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Stage C12 (neural tube closing) and Carnegie Stage 13 (neural tube closed) may be a 
valuable tool for selecting additional candidate genes [241].   
There are likely many rare and common variant interactions coupled with 
environmental milieu that together predispose a child to an NTD.  Unraveling the separate 
components of this genetic complexity often requires focused study design and mapping 
approaches. Focusing on genetic mapping in rare Mendelian-like families, like family 8776, 
can help identify susceptibility loci and/or genes that may later be shown to confer risk in the 
non-Mendelian forms of the disease. Specifically, for this family, identification of the causal 
NTD gene(s) may allow for identification of individuals who are at an elevated risk of 
conceiving offspring with an NTD. However, such a causal variant(s) may or may not be 
generalizable to most subjects with NTDs, and therefore any promising variant(s) identified 
in this family will also need to be examined in a larger subset of families.  Even if a causal 
variant(s) is identified in this family and fails to be found in other NTD cases, the genetic 
information gleaned from 8776 is still valuable because the gene(s) identified in 8776 may 
provide insight into the pathogenesis of human NTDs and of early neurodevelopment in 
general. 
In summary, we have used one of the largest known multigenerational NTD families 
that show evidence of a strong genetic effect to substantially refine two regions of genetic 
linkage on chromosome 2 and 7. These data provides a valuable resource for identifying 
novel candidate genes implicated in the molecular etiology of NTDs. 
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Table 3.1 Genes Sequenced in NTD Family 8776 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key legend:  
DE =Differential expression of genes from lymphoblast cell lines comparing 3 NTD cases to 9 controls. UP denotes the gene was found to have increased expression levels in 
the cases and DOWN denotes decreased expression levels of the gene.  
#E = Number of exons present in the gene sequenced 
ES=Exons successfully sequenced 
*Only two exons were sequenced in the WNT genes because the other exonic regions had high homology to many other genomic locations complicating primer design.
gene chr molecular mechanism DE #E ES gene name 
ABI2 2 arg protein tryosine kinase 
binding protein 
 10 2-10 NM_005759.3|  abl interactor 2 
CASP10 2 apoptosis  10 10 NM_032977.2| caspase 10, apoptosis-related cysteine peptidase  
CASP8 2 apoptosis  9 9 NM_033355.2| caspase 8, apoptosis-related cysteine peptidase 
CYP20A1 2  drug metabolism; cholesterol 
synthesis 
 13 2-5, 
7-13 
NM_177538.1| cytochrome P450, family 20, subfamily A, 
polypeptide 1 
EEF1B2 2 translation elongation factor  6 6 NM_001959.3| eukaryotic translation elongation factor 1 beta 2 
FZD5 2 signaling; planar cell polarity 
pathway 
 2 2 NM_003468.2| frizzled homolog 5 (Drosophila) 
HSPD1 2 heat shock protein UP 12 12 NM_002156.4| heat shock 60kDa protein 1 
IGFBP2 2 Insulin growth factor DOWN 4 2, 3 NM_000597.2| insulin-like growth factor binding protein 2  
MAP2 2 microtubule-associated protein  17 17 NM_031846.1| microtubule-associated protein 2 
NRP2 2 vascular endothelial growth 
factor; axon guidance 
 16 16 NM_018534.3|  neuropilin 2, transcript variant 4 
PECR 2 peroxisomal trans-2-enoyl-CoA 
reductase 
UP 8 8 NM_018441.2| peroxisomal trans-2-enoyl-CoA reductase 
STK17B 2 apoptosis  8 1-7 NM_004226.2| serine/threonine kinase 17b (apoptosis-inducing) 
WNT10A 2 signaling; planar cell polarity 
pathway 
 4 2,3* NM_025216.2| wingless-type MMTV integration site family, 
member 10A  
WNT6 2 signaling; planar cell polarity 
pathway 
 4 2,4* NM_006522.3|wingless-type MMTV integration site family, 
member 6 
DGKB 7 regulate intracellular levels of 
diacylglycerol (DAG) 
 24 24 NM_004080.1| diacylglycerol kinase, beta 90kDa 
ETV1 7 transcription factor  12 12 NM_004956.3| ets variant gene 1 
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Table 3.2 Novel Variants Identified in Sequencing Screen of Family 8776 
 
                          
Gene Variation NCBI ss# Type of Variant 
Individual(s)  
with variant 
 
HSPD1 
 
NM_002156.4:c.606 + 42 G>T 
  
 
 ss77831713 
 
intronic SNP 
 
 
1,100, 126, 128, 
1000,1001, CEPH 
 
HSPD1 NM_002156.4:c.606 + 53 
delGTTTGAGTTATCTGATGATC
AAAA  
 
ss77831714 intronic deletion 
 (-GTTTGAGTTATCTG 
ATGATCAAAA) 
 
1, 100, 126, 128, 
1001, CEPH 
FZD5 NM_003468.2:c.-164 G>A ss77831715 5' untranslated SNP 
 
126,128,1000,1001 
 
STK17B NM_004226.2:c-130 C >T  ss77831716 5' untranslated SNP 
 
1, 129, 1000 
CASP8 NM_033355.2:c.550 + 63 G > A 
 
ss77831717 intronic SNP 
 
1001 
CYP20A1 NM_177538.1: c122 + 129 G > A 
 
ss77831718 intronic SNP 1, 100, 126, 128, 
129, 1000, 1001, 
CEPH 
 
DGKB NM_004080.1:c516 + 155 G > C 
 
ss77831719 intronic SNP 1,100,1000 
NRP2 NM_018534.3:c1786 + 122  C>A 
 
ss77831720 intronic SNP 001, 1000 
 100 
 
  
Table 3.3 Variants Sequenced in the Entire Family 8776 
Gene Variant Type of Variant 
Known/
Novel 
Variant Conserved 
Allele frequencies 
(Caucasian) 
CYP20A1 rs13015873 intronic SNP (C/T) known mild C=0.985; T=0.015 d 
CYP20A1 rs10586509 intronic deletion (-/TTAA) known yes 
Del=0.985;  
no Del=0.015 d 
CYP20A1 rs2351771 intronic SNP (T/G) known yes G= 0.986; T =0.014 d 
EEF1B2 rs11546386 
coding nonsynonymous 
SNP (G/A) known yes G= 0.917; A =0.083 d 
HSPD1 rs1050347 
coding synonymous SNP 
(C/T) known yes C= 0.08; T= 0.920 b 
NRP2 rs849526  
coding synonymous SNP 
(A/G) known yes A=0.5;G=0.5 b 
NRP2 rs2041808 intronic SNP (A/G) known mild C= 0.672; A =0.328d 
STK17B rs12478353 
coding synonymous SNP 
(A/T) known yes A=0.658; T= 0.342 a 
STK17B rs1054537 
coding synonymous  
(C/T) known yes C=0.62; T= 0.38 b 
CASP8 rs2141331 3' untranslated SNP (A/G) known no G=0.919; A=0.081 c 
ETV1 rs9639168 
coding nonsynonymous 
SNP (C/T) known yes C=0.267; T= 0.733 a 
HSPD1 
NM_002156.4
:c.606 + 53 
delGTTTGAG
TTATCTGAT
GATCAAAA 
intronic deletion 
 (-GTTTGAGTTATCTGA 
TGATCAAAA) novel no 
Del=0.371;  
no Del=0.629 d 
 
Allele frequencies are based on the following populations: a = HapMap CEU; b= CEPH; c= CAUC1; d= No publically 
available allele frequencies; allele frequencies are calculated from our sequencing efforts and are shown in bold 
italics. Del= deletions. Conserved: indicates regions of sequence conserved by alignment of 28 different species 
using USCS Genome Browser. 
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Condensed pedigree diagram of the extended multiplex Caucasian NTD family 8776.  
Fully shaded symbols represent individuals affected with lumbosacral 
myelomeningocele.  The half shaded circle for individual 100 represents congenital 
dermoid cyst.  The quarter shaded circle denotes the 5 individuals who are affected with 
spina bifida by history alone, all of whom died in the first few days of life.  + indicates 
individuals with DNA samples.  § refers to individuals included in linkage analysis.  
Individual 1075 is reported to have lumbosacral myelomeningocele; however, the 
medical records and radiographic studies are not currently available to confirm this 
diagnosis.  The red box denotes the recently ascertained branch. Individuals 128 and 129 
are reported to have hydrocephalus consistent with Chiari II malformation. 
Figure 3.1 Pedigree diagram of NTD family 8776 with newly ascertained branch. 
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Figure 3.2 Multipoint LOD plots for chromosomes 2 and 7 in extended family 8776. 
Multipoint logarithm of odds (LOD) plots for chromosomes 2 and 7 in extended family 
8776. Linkage results for chromosomes 2 (A) and chromosome 7 (B).  SNP linkage 
results using parametric and nonparametric linkage methods are plotted.  The genetic 
distance for the analyzed markers is given on the X-axis in cM.   
 103 
 
A. Chromosome 2 Haplotype 
1000 1001
D2S425
RS1050347
D2S1367
D2S2289
D2S1384
D2S2358
D2S1385
D2S434
205 177
141 141
207 209
235 235
270 278
2009
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
1023
290 294
C C
256 256
203 177
157 141
207 209
231 235
278 278
1024
294 294
T C
256 264
203 203
153 149
209 203
235 231
278 278
128
294 294
C C
264 256
203 177
149 141
203 209
231 235
278 278
1028
298 290
T T
272 256
203 177
149 141
209 209
231 235
274 278
1029
290 294
C T
264 272
177 197
145 153
209 209
231 247
270 278
129
294 290
T T
272 256
197 177
153 141
209 209
247 235
278 278
1005
294 294
T C
268 256
203 177
149 141
207 209
231 235
278 266
1006
0 0
T T
264 268
177 203
149 145
207 203
231 231
274 266
102
0 0
C T
256 264
177 177
141 149
209 207
235 231
266 274
103
0 0
C T
256 268
177 203
141 145
209 203
235 231
266 266
127
294 290
T C
256 256
203 203
153 157
209 207
235 231
278 278
126
294 294
C C
264 256
203 177
149 141
203 209
231 235
278 278
131
294 290
T T
0 0
197 203
153 149
209 209
247 231
278 274
3000
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
3001
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
2002
294 294
T T
264 268
199 203
153 149
203 207
0 0
262 278
2003
290 294
T C
260 256
205 177
141 141
207 209
235 235
266 278
294 298
T T
260 264
203 205
149 157
205 205
231 231
262 262
294 294
T C
268 256
203 177
149 141
207 209
231 235
262 278
1
294 294
T C
264 256
205 177
157 141
205 209
231 235
262 278
100
298 294
T C
264 256
205 177
157 141
205 209
231 235
262 278
195
298 294
T T
264 268
205 203
157 149
205 207
231 231
262 262
2008
290 294
T C
260 256
 
B. Chromosome 7 Haplotype 
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Figure 3.3 The 2q and 7p disease-associated haplotypes for family 8776. 
The haplotype results are consistent with autosomal dominant transmission with reduced penetrance as 
shown with the red bar segregating with affection status.  Only a subset of the markers is shown in 
these haplotypes. The circles surrounding the haplotype bars indicates where a critical recombinant 
haplotype resides that allowed narrowing of these minimum candidate intervals. 
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4.1 Abstract 
Native American myopathy (NAM) [MIM 255995], a putative autosomal recessive 
disorder, was first reported in the Lumbee Indians of North Carolina.  NAM features 
include congenital weakness and arthrogryposis, cleft palate, ptosis, short stature, 
kyphoscoliosis, talipes deformities, and susceptibility to malignant hyperthermia (MH) 
provoked by anesthesia.  This report documents the phenotypic complexity and natural 
history of this rare congenital disorder in fourteen individuals with NAM.  Findings 
include a previously unreported 36% mortality by age 18.  Based on this study, our 
conservative estimate for prevalence of NAM within the Lumbee population is 
~2:10,000; however, birth incidence remains unknown.   
 
4.2 Introduction 
4.2.1 Lumbee population 
The Lumbee people are a Native American group from the Lumber River region 
of south-central North Carolina [146]. The Lumbee have been culturally isolated for the 
past two centuries leading to frequent intra-tribe marriages.  Currently, the Lumbee Tribe 
of North Carolina is estimated to have more than 45,000 members making them the 
largest tribe east of the Mississippi River [147].  The origin of the Lumbee people is not 
well documented. One theory is that the Lumbee tribe descended from Sir Walter 
Raleigh’s Lost Colony of Roanoke Island [148].  
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4.2.2 Native American myopathy: Clinical Description 
In 1987, Bailey and Bloch first described Native American myopathy [MIM 
255995] in a 3 month old American Indian infant of Lumbee descent with multiple 
congenital anomalies including cleft palate, micrognathia, talipes equinus and 
arthrogryposis.  The infant had an episode of malignant hyperthermia (MH) while under 
general anesthesia for placement of a gastrostomy tube [153].  Later, in 1988, Stewart, 
Kahler, and Gilchrist described six Lumbee children affected with congenital myopathy, 
skeletal anomalies, and susceptibility to malignant hyperthermia [146]. These 6 children 
ranged in age from 5 to 13 years old and two were sibs with one of the patients a cousin 
to this sib pair. They had normal baseline creatine kinase levels.   Two of the children 
developed malignant hyperthermia during cleft palate repair.  Clinical features of this 
disorder described in the literature include short stature, cleft palate, high- arched palate, 
myopathic facies (malar hypoplasia, ptosis), scoliosis, congenital joint contractures, and 
talipes deformities [146,153-156].  
One of the greatest risks for patients with NAM is from MH crises during 
exposure to certain anesthetics.  MH is a potentially life threatening pharmacogenetic 
disorder of the skeletal muscle that is triggered in genetically predisposed individuals 
exposed to inhaled halogenated anesthetics and/or depolarizing muscle relaxants. 
Symptoms of MH can include hyperthermia, muscle hyperactivity/hypermetabolism, 
rhabdomyolysis, tachycardia, tachypnea, rigidity, and metabolic acidosis.  Succinylcoline 
and volatile anesthetics are often MH-triggering drugs in susceptible individuals [160]. If 
MH is not reversed, it can lead to severe tissue damage and death. Despite the high rate 
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of morbidity and mortality associated with NAM, little is known about the etiology and 
natural history of this condition. 
 
4.2.3 Genetics of NAM 
To date, the genetic etiology of NAM remains unknown. The Lumbee population 
is considered inbred based on a few common surnames and evidence of consanguinity 
within families (Powell, personal observation).  Given the cultural isolation and high-rate 
of consanguinity in the Lumbee population, it is likely that the genetic basis of NAM is 
due to a founder effect.  Founder effects can lead to a high frequency of recessive genetic 
disorders in an isolated or inbred population when members of the population harbor a 
disease-causing mutation inherited from a common ancestor. Because offspring of related 
parents from an isolated community share more alleles identical by descent, they will 
have a higher proportion of homozygous loci than the offspring of unrelated parents. 
These homozygous loci may harbor genetic mutations causing recessive diseases.  Two 
examples of recessive disease in individuals of Lumbee ancestry described in the 
literature are glutaric academia type 1 [242] and hyper IgM syndrome [243].  Stewart and 
colleagues also mentioned that the mode of inheritance for NAM appeared to be 
autosomal recessive [146].   
In this study, our aim is to further characterize both the natural history of the 
disease and the mode of inheritance for NAM.  
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4.3 Materials and Methods 
4.3.1 Clinical Ascertainment 
This study evaluated patients of Lumbee Indian descent affected with congenital 
muscle weakness who demonstrate two or more of the following phenotypic 
characteristics: myopathic facies, susceptibility to malignant hyperthermia, 
kyphoscoliosis and cleft palate.  Subjects included in this study were diagnosed with 
NAM by clinical geneticists at Duke University or at the University of North Carolina at 
Chapel Hill; these two large medical centers are the primary providers of medical 
genetics services to the Lumbee people.  Standardized family histories were conducted to 
provide information about potential inheritance patterns and whether consanguinity was 
present in the families. Clinical data describing the parents were obtained through 
recorded family history and clinical observations.  Data on patients were gathered from 
clinical evaluations and medical record review from The University of North Carolina at 
Chapel Hill and Duke University. Data were collected in compliance with Duke 
University and the University of North Carolina Institutional Review Boards. 
 
4.4 Results 
4.4.1 Natural history of Disease 
4.4.2 Mode of Inheritance and NAM pedigrees 
Fourteen Lumbee individuals affected with NAM were included in this study, 
denoted as individuals 1-14 in Table 4.1. There was no gender discrepancy. The study 
consisted of 7 females and 7 males, supporting an autosomal mode of inheritance for 
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NAM. Ten detailed family histories were available and pedigree analysis revealed 
consanguinity within three families for individuals 4, 8, and 11.Individual 4’s parents are 
3rd cousins, individual 8’s parents are 2nd cousins, and individual 11’s parents are first 
cousins once removed. Individuals 3 and 4 are half –sibs with the same mother.  The 
parents with clinical information available showed no evidence of NAM features (cleft 
palate, significant muscle weakness, talipes deformities, contractures). All NAM 
pedigrees show two unaffected parents of Lumbee descent having a child affected with 
NAM without any evidence of X-linked or dominant inheritance. Therefore, these 
pedigrees provide further evidence for NAM being an autosomal recessive condition, 
whereby the parents are carriers of a single copy of the recessive NAM mutation.   
 
4.4.3 Cytogenetic Studies 
Twelve patients had G-banded chromosome analysis of peripheral blood. Two 
patients (individuals 5 and 6) had a balanced interstitial paracentric inversion of 
chromosome 1 (q43q44).  Individual 5’s mother who is unaffected also was heterozygous 
for 46,XY inv(1)(q43q44). The ten other patients who had chromosome analysis 
performed were normal.  As children with cleft palate or a submucosal cleft are often 
evaluated for 22q deletion syndrome [MIM 606232], four patients (individuals 3, 5, 10, 
14) had testing for 22q deletion using fluorescence in situ hybridization (FISH) analysis.   
No deletion was present in any of the four tested.   
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4.4.4 Musculoskeletal and malignant hyperthermia 
All the patients were reported to have congenital non-progressive myopathy with 
myopathic facies. Four out of the fourteen patients had MH episodes giving a 29% 
frequency of MH among this study group (see Table 4.1). These MH reactions took place 
during surgery for talipes deformities or cleft palate repair. In all four patients presenting 
with MH, the medical team managed them by discontinuing the provoking anesthetic, 
aborting the surgery, and administering dantrolene, and all had a positive outcome with 
100% survival. However, individual 6’s sister, who was not included in this current study 
for lack of documented clinical history, died at age 2 years from a malignant 
hyperthermia crisis during surgery for talipes deformity repair. 
Muscle biopsies were performed on six patients to characterize the muscle 
pathology for diagnostic purposes. These biopsies showed non-specific myopathic 
changes with no evidence of mitochondrial abnormalities or central core disease. 
Additional diagnostic studies were done to evaluate muscle weakness including 
electromyography (EMG) and nerve conduction studies.   EMG was performed on four 
patients: 3 were normal, and individual 6 had prominent distal myopathy which may be 
attributable to a motor vehicle accident injury. Nerve conduction studies performed on 
two patients were normal.   
Scoliosis was observed in 9 out of the 14 patients (64%) as shown in Table 4.1; 
some individuals wore braces and others had surgical rod placement. Scoliosis progressed 
during both childhood and adult life causing increasing impairment of both lung function 
and mobility over time.  Patients with braces had scoliosis that progressed despite this 
intervention. Talipes deformities were a common presentation in the NAM patients with 
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10/14 (71%) having talipes equinovarus as reported in Table 4.1. Congenital joint 
contractures were observed in 12 of the 14 patients (86%; see Table 4.1).  
 
4.4.5  Dysmorphic features  
All patients observed in this study had myopathic facies. Figure 4.1 shows some 
of those common myopathic features. A myopathic face appears expressionless, 
consisting of bilateral ptosis, down-turned corners of the mouth with inability to elevate 
the corners of the mouth, and open-mouthed posture.  All of the patients had unusual eye 
morphology with a variety of manifestations: telecanthus, ptosis, short palpebral fissures, 
and/or downslanted palpebral fissures. Eight of the fourteen (57%) patients had ptosis 
(see Table 4.1). Two of the patients had posteriorly rotated ears.  Seven patients had 
micrognathia as reported in Table 4.1.  Four of the patients had facial hemangiomas in 
various sites including the forehead, glabella, nasal tip, eyelids, and upper lip.  Palate 
abnormalities were present in all 14 patients evaluated. Nine out of the 14 (64%) children 
had posterior cleft palate, five had a high-arched palate, and three had probable 
submucosal cleft palate (Table 4.1). Older patients develop a long and narrow face as 
shown in Figure 4.1 (F). 
 
4.4.6 Newborn and Toddler Period 
Three of the 14 patients died in the first year of life (21% mortality rate). Causes 
of death included severe pulmonary hypoplasia (patient 1) and apnea secondary to acute 
fulminant enterococcal pneumonia (patient 3); the cause of death for patient 5 is 
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unknown. Of the eleven patients seen in the newborn period, one was macrocephalic with 
a head circumference at or above the 97th centile and three of the patients had a head 
circumference greater or equal to the 90th centile (Table 4.1). Three of seven patients 
who had brain MRIs showed evidence of enlarged ventricles. Gastrointestinal issues were 
common in the first years of life including feeding problems in 10/14 of the patients 
(71%), aspiration, and gastroesophageal reflux in 5 patients (36%) (Table 4.1). Feeding 
problems were secondary to oral hypotonia, cleft palate and micrognathia and often 
caused poor postnatal weight gain.   Cryptorchidism was present in 5 of the 7 males 
(71%). All patients who survived the first few months of life had delays in motor 
development, likely due to their muscle weakness as shown in Figure 4.1C, where 
individual 2 requires support for ambulation at 2 years of age.  Distal contractures and 
equinovarus also contribute to delayed ambulation.  All patients seen in the newborn 
period had a myopathic face. Figure 4.1A and 1B show Individuals 9 and 2 at three 
months of age having myopathic facies with ptosis and open, down-turned mouth.   
 
4.4.7 Childhood 
Despite motor delays in the infant and toddler period, all patients seen later in 
childhood had normal intelligence.  Expressive language delay and hypernasal speech 
attributable to cleft palate, residual palatal fistulae, velopharyngeal insufficiency and oral 
hypotonia was still present in some children. By early childhood, head circumferences 
were closer to the mean than during the newborn period.  
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4.4.8 Adulthood 
 Two adults with NAM (individuals 6 and 13) had short stature with heights below 
the 3rd centile. These two adults had normal intelligence and both completed high school. 
Most patients during later childhood and adulthood were cachectic with significant 
muscle wasting.  In adulthood, the face is long with a prominent chin as illustrated in one 
adult patient shown in Figure 4.1 F. Despite individual 6’s severe development delay as a 
child (walked at 5 years of age and had language delay), as an adult he maintained a job 
as a barber for many years. This patient, who is currently 40 years old, is the oldest 
patient in this study.  He has mild scoliosis.  His back pain has become worse over the 
past few years; he has a foot drop, and now requires a walker to ambulate. It should be 
noted that in addition to having features of NAM, this patient was involved in a motor 
vehicle accident during adulthood.  It is unclear whether his chronic pain and foot drop 
are secondary to the accident or his underlying NAM.   Patient 13 is now 30 years old, 
has chronic respiratory failure with a permanent tracheostomy, and requires overnight 
continuous mechanical ventilatory support. Even though individual 13 has respiratory 
compromise, she delivered a normal healthy baby with low forceps delivery in 
2001[155].   
Progressive scoliosis appears to be a major cause of morbidity in adolescents and 
adults with NAM, contributing to restrictive lung disease and pulmonary insufficiency.  
The only individual to die after childhood was individual 11.  This was due to respiratory 
compromise with decreased lung volume from severe kyphoscoliosis and exacerbated by 
tobacco use.  Two other individuals 4 and 5 died of unknown causes. Overall, these 
fourteen individuals with NAM had by age 18 a 36% mortality rate (5/14 patients).  
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4.5 Discussion 
In this study, we report shared clinical features among 14 individuals of Lumbee 
Indian descent with Native American myopathy.  Many of the features of NAM are likely 
due to underlying muscle weakness in utero and postnatally.  For example, the neonatal 
arthrogryposis observed in patients with NAM may be caused by hypotonia and 
hyopokinesia in utero. The neonatal respiratory failure is likely to be secondary to one or 
all of the following: hypotonia, micrognathia, glossoptosis, gastroesophageal reflux, and 
aspiration. The feeding problems and failure to thrive may be secondary to the patient’s 
oral hypotonia, micrognathia and cleft palate. Feeding problems may be ameliorated in 
patients with special cleft palate nipples and bottles, feeding therapy, and treatment of 
gastroesophageal reflux.  The chronic respiratory compromise seen in adults is likely due 
to their myopathy and severe scoliosis that leads to restrictive lung disease.  
MH is a well known risk factor among the Lumbee Indian population 
[146,153,154].  Within our study, we found that four out of 14 patients (29%) had MH 
episodes, a similar frequency to two out of six patients (33%) observed in 1988 by 
Stewart and colleagues [146].  However, the true frequency of susceptibility to MH 
among these patients is likely to be much higher because the patients without episodes of 
MH either had no history of surgery or did not receive a MH-provoking anesthetic.   
 Anecdotal evidence suggests an increased frequency of congenital 
musculoskeletal anomalies [154] and a higher susceptibility to malignant hyperthermia in 
Native Americans of Lumbee background [153]. For example, in 1989 Meluch and 
colleagues reported a case study of an American Indian male of Lumbee descent who 
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underwent frontal craniotomy for resection of a pilocytic astrocytoma [154]. Subsequent 
surgeries for placement of ventriculoperitoneal shunts with halothane and isoflurane 
anesthesia triggered malignant hyperthermia crises. To address the MH susceptibility risk 
within the Lumbee people, clinicians in the Lumberton region and surrounding areas 
often will use non-halogenated non-volatile anesthetic management for their Lumbee 
patients (personal communication).  Furthermore, the above case report of a Lumbee 
male did not describe the patient as having any of the common features of NAM such as 
muscle weakness, skeletal abnormalities, or dysmorphic facies.  This finding suggests 
that the Lumbee people may have an isolated risk of MH without the presence of 
congenital myopathy. Two possible explanations for MH without congenital myopathy 
seen in the Lumbee population are: 1) individuals with isolated MH are heterozygous for 
the NAM genetic mutation whereas being homozygous for this mutation leads to both the 
congenital syndrome and MH; or 2) susceptibility to malignant hyperthermia is due to 
another genetic variant that is present in this population.   
The occurrence of both malignant hyperthermia and myopathy is not unique to 
Native American myopathy.   MH crises have been documented in patients with other 
myopathies such as myotonia fluctuans, Duchenne and Becker dystrophy, myotonia 
congenital, and myotonic dystrophy [244].   Malignant hyperthermia in patients with 
other musculoskeletal anomalies is not uncommon.  A review by Strazis and Fox of 503 
published MH cases identified a much higher frequency of congenital anomalies such as 
cleft palate, club foot, scoliosis, ptosis, and cryptorchidism  compared to the general 
surgical population [245]. 
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The frequency of NAM within the Lumbee Indian population is unknown.  We 
can make a minimum estimate of the current NAM prevalence based on our collected 
population, if we consider that at least 9 individuals affected with NAM are alive and the 
Lumbee tribe is estimated to be ~ 45,000 [147].   This estimated minimum prevalence of 
NAM within the Lumbee population would be 9/45,000 or 2/10,000.  The true prevalence 
of NAM, however, is likely to be much higher since many patients with NAM may not 
have been identified through our study.  Conversely, we may have underestimated the 
population size of the Lumbee tribe leading to a marginal inflation of estimated 
prevalence.  The high degree of infant mortality (21%) suggests that the birth incidence is 
likely much higher than the Lumbee population prevalence.  Underestimation of 
prevalence may also be due to phenotypic heterogeneity of NAM leading to non-
inclusion in the study of individuals who did not meet our phenotypic criteria. 
  The prevalence of NAM may also have been underestimated if affected 
individuals are diagnosed with other conditions. Since many of the clinical features of 
NAM resemble other congenital myopathies, it is likely that patients with NAM may 
have been diagnosed with another similar disorder such as King Syndrome, Noonan 
syndrome, or other myopathies.  King Syndrome (KS) [MIM 145600] is an autosomal 
dominant disorder characterized by dysmorphic facies (low-set ears), cryptorchidism, 
short stature, and susceptibility to MH. King Syndrome and NAM are both 
phenotypically heterogeneous with a myriad of clinical presentations, but the classic 
features for both are the congenital myopathy and malignant hyperthermia. While 
patients with KS have many similar clinical features of NAM,  they rarely have cleft 
palate, contractures, or clubbed feet [146].  Noonan syndrome [MIM 163950] is an 
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autosomal dominant dysmorphic syndrome characterized by hypertelorism, ptosis, low-
set posteriorly rotated ears with thickened helices, and a small pointed chin. While  
individuals with Noonan syndrome also have short stature and dysmorphic features that 
resemble NAM they frequently have structural cardiac defects not seen in NAM and 
typically do not have congenital myopathy, cleft palate or congenital joint contractures as 
seen in NAM.  Froster-Iskenius and colleagues described four children with similar 
features to NAM such as myopathic face, congenital contractures, ptosis, cleft palate, and 
susceptibility to malignant hyperthermia, but these patients also had congenital torticollis 
and neck and axillary webbing, which are not observed in NAM [158].  Some of the other 
diagnoses considered by physicians during evaluation of the patients in our series 
included: central core disease, neurogenic arthrogryposis, Freeman-Sheldon syndrome, 
amyoplasia, Trisomy 18, fetal akinesia sequence, Christian adducted thumb syndrome, 
and Gordon Syndrome ([MIM 114300] autosomal dominant distal arthrogryposis with 
cleft palate and club foot) [246].  
Cytogenetic studies were conducted for most patients in this study, in order to 
identify other potential causes for their multiple congenital anomalies. FISH analysis for 
22q deletion syndrome on four patients revealed no deletion. Two patients showed 
apparently balanced interstitial inversions of chromosome 1 (q43q44). The ten other 
patients who had chromosome analysis performed were normal. This inversion could be 
interpreted either as an unrelated finding or disrupting the causative gene region.  Based 
on the findings that individual 5’s unaffected mother is also heterozygous for the 
inversion and the lack of this inversion in other patients with NAM, it seems more 
plausible that the balanced inversion observed in two patients is not responsible for the 
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NAM phenotype and is most likely a benign polymorphism in the Lumbee population.  
Alternatively, NAM may result if this inversion causes a breakpoint in the putative NAM 
gene, and the other chromosome carries a point mutation. If this were the case, the other 
ten individuals with NAM who do not carry the inversion would require two copies of the 
other point mutation.   
Native American myopathy is a putative autosomal recessive disorder.  To clarify 
the inheritance patterns for NAM we examined several NAM pedigrees that all support 
autosomal recessive inheritance by the following findings:  1) None of the affected 
patients has an affected parent; 2) The majority of affected patients’ sibs are unaffected 3) 
equal ratio of affected females to males; 4) evidence of known consanguinity between the 
parents for some patients; and 5) all patients have parents of Lumbee ancestry.  
The high degree of consanguinity present within the population means it is 
plausible that any two Lumbee individuals affected with a recessive disease share genetic 
material from a common ancestor. Thus, this condition is an excellent candidate for 
homozygosity mapping to identify the NAM loci or gene [186,187].  Overall, the 
identification of the NAM disease locus or gene mutation could lead to understanding the 
molecular mechanisms behind the disease and provide potential genetic testing for 
Lumbee families.  
 
4.6 Summary 
In this study, we report shared clinical features among 14 individuals of Lumbee 
Indian descent with Native American myopathy.  All of the patients exhibited 
dysmorphic features including unusual eye morphology with ptosis, and/or downslanting 
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palpebral fissures. During the newborn period, numerous clinical features were 
commonly observed including congenital joint contractures, equinovarus, cleft palate, 
micrognathia, significant feeding difficulties, and cryptorchidism. Intellectual 
development was normal but motor development delayed. In childhood, additional 
clinical features were documented such as MH-crises, and severe scoliosis.  During the 
newborn period the mortality rate was documented to be 21%, and if extended to 
adulthood there was an overall 36% mortality rate. Pedigree inspection provided evidence 
in support of an autosomal recessive inheritance pattern for this condition, and the 
extensive consanguinity observed in these pedigrees suggests that a homozygosity 
mapping approach may be productive for gene identification studies. 
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 Table 4.1 Clinical description of patients with NAM 
Patient number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Natural history 
                            
sex F M F M M M F F F M M M F F 
age at diagnosis 1 d 2y 4m 84 d 2 d 1 d 30 y 22 d 1 d 6 d 1 d 14 y 1 d NK 9 d 
birth weight* 3-10% <3% 10% 10% <3% 50% 3-10% <3%  3-10% 3-10% 50% 3-10% NK <3% 
birth length*† NK†  3-10%* 10%* 10-25%* <3%* NK 10-25%* 75%* 50%* 75%* NK NK† NK 3-10%* 
head circumference*‡ 75%* 50%* 25%* 90-97%* 10%*  90%‡  25%* 50%* 90%* 90%* 90%‡  >97%* 25%‡  <3%* 
delayed motor development NK + NK + NK + + + + + + NK NK + 
feeding problems NK + + NK NK + + - + + + + + + 
GE Reflux NK - - NK + + + NK NK + NK NK + NK 
malignant hyperthermia  - + - + - + - - - - - - + - 
deceased (age) 1d No 5 m < 6 y 1 m No No No No No 18 y No No No 
 
    
   
  
 
   
 
Dysmorphology 
                            
Myopathic face + + + + + + + + + + + + + + 
ptosis + + - + NK + + + + NK + NK NK - 
downturned mouth - + + NK NK NK + + + NK NK NK + NK 
Cleft palate + HAP, SMC? + + + HAP HAP, SMC? + + + HAP, SMC? HAP + + 
micrognathia - + + - + - - + - + - + - + 
 
              
Muskoskeletal features                             
congenital joint contractures + + + + + NK + + + + + + NK + 
equinovarus + + + - + + + + + + - + NK - 
congenital scoliosis NK + NK + NK + + + + NK + + + - 
 
             
                                                 
NK (Not Known) 
*
 weight, length, and head circumference based on fetal-infant growth chart for preterm infants and reflect percentiles in the newborn period. 
†
 length measurement could not be obtained because feet were at her ears due to severe hip flexion.    
‡
 represents head circumference percentiles based on Nelhaus, G., Composite International and Interracial Graphs, PEDIATRICS 41: 106, 1968. 
CP (Cleft palate); SMC? (Probable Submucousal Cleft); HAP (High-arched palate) 
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Figure 4.1 Observed clinical features of patients with NAM 
 
 
A. Patient 9 at three months of age. Note ptosis, myopathic face, and cleft palate. 
 
 
 
 
 
 
 
 
B. Patient 2 at three months of age. Note myopathic face, forehead, nasal and philtrum 
hemangioma, and congenital talipes equinovarus. 
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C. Patient 2 at age 2 years.  Note myopathic face, down-turned open-mouthed posture, 
and inability to stand unassisted.  
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D. Patient 2 at age fourteen showing cachectic appearance with muscle wasting and 
camptodactyly demonstrated with attempt at finger extension. 
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E. Patient 8 at age ten years of age. Note ptosis, myopathic facies and camptodactyly. 
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F. Patient 6 at age thirty years old.  Note long face and prominent mandible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER 5  
 
Genomewide SNP chip homozygosity mapping defines critical region in singleton 
Native American myopathy families 
 
5.1 Abstract 
Native American myopathy (NAM) is an autosomal recessive congenital myopathy 
first reported in the Lumbee Indian people. Features of NAM include congenital 
weakness, cleft palate, ptosis, short stature and susceptibility to malignant hyperthermia. 
We identified five individuals with NAM from the Lumbee population, and hypothesized 
that these affected individuals have disease alleles shared identical-by-descent (IBD) 
inherited from common ancestry. To identify a NAM disease locus, homozygosity 
mapping methods were employed on a genomewide 10K single-nucleotide 
polymorphism (SNP) screen. To confirm regions of homozygosity identified in the SNP 
screen, microsatellite repeat markers were genotyped within those homozygous 
segments. The SNP data demonstrated five regions of shared homozygosity in individuals 
with NAM. The additional microsatellite genotyping data narrowed the region to one 
common segment of homozygosity spanning D12S398 to rs3842936 (5.6 Mb) mapping 
to 12q13.13-14.1. This study reports the first gene mapping of NAM using SNP-based 
homozygosity mapping in only a few affected individuals from simplex families and 
identified a putative NAM locus. Identifying the genetic basis of NAM may suggest new 
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genetic etiologies for other more common conditions such as cleft palate and malignant 
hyperthermia.  
 
5.2 Introduction 
The Native American myopathy [MIM 255995] is a congenital myopathy first 
described in the Lumbee people, a multi-racial group indigenous to Robeson County in 
south-central North Carolina. In 1987, Bailey and Bloch first described Native American 
myopathy in a 3-month old American Indian infant of Lumbee descent with multiple 
congenital anomalies including cleft palate, micrognathia, talipes equinus and 
arthrogryposis [153].   Later, Stewart et al described NAM in six Lumbee children and 
highlighted malignant hyperthermia as a feature of NAM that warrants medical concern 
in this myopathy [146].   Malignant hyperthermia (MH) is a potentially life-threatening 
pharmacogenetic disorder of the skeletal muscle that is triggered in genetically 
susceptible individuals exposed to inhaled anesthetics and/or depolarizing muscle 
relaxants.  Though clinical presentation of NAM is relatively heterogenous, some other 
typical features of NAM include muscle wasting and kyphoscoliosis secondary to 
congenital weakness, contractures, cleft palate, abnormal facies with ptosis and low-set 
ears, and talipes deformity [146,153-156].  
The Lumbee population is a relatively isolated population that is considered 
inbred based on a few common surnames and evidence of consanguinity within families 
(personal observation, C.P.). NAM pedigrees suggest an autosomal recessive pattern of 
inheritance, and clinical documentation in a few families shows unaffected parents 
having more than one child with affected with NAM (personal observation, C.P.). The 
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high degree of speculated consanguinity within this isolated population suggests that 
Lumbee individuals affected with NAM inherited identical genetic material containing 
the disease gene from a common ancestor. This phenomenon, whereby a couple transmits 
the same ancestral chromosomal segment to one of their offspring, is termed 
autozygosity.  Based on this rationale, homozygosity mapping may identify regions of 
autozygosity within the NAM families and facilitate mapping the NAM locus. 
Homozygosity mapping identifies genomic segments shared identical-by-descent 
among patients with recessive diseases from populations with limited migration into or 
out of the population and/or with high rates of consanguinity, allowing characterization 
of a genomic region that harbors the causative genetic mutation [186,187].  
Homozygosity mapping is a form of linkage disequilibrium (LD) mapping whereby the 
disease-causing gene is in LD with a conserved haplotype that arises from founder effects 
[187]. Founder effects occur when only a small number of individuals bring a 
chromosome with a disease mutation into a small isolated population and a subsequent 
increase in this population size will lead to a large proportion of individuals carrying this 
founder chromosome. Recombination events in this population over time lead to smaller 
segments of the original founder chromosome containing the disease gene, thereby 
facilitating productive homozygosity mapping studies. Since the development of dense 
whole genome SNP arrays, several rare recessive Mendelian loci and genes have been 
mapped [192,193,247] using homozygosity mapping approaches. We reasoned that 
whole genome SNP homozygosity mapping might facilitate identification of the NAM 
locus. 
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In this study, we conducted homozygosity mapping in NAM to identify a disease-
associated haplotype in which only simplex NAM families (as opposed to multiplex 
families) are available.  
 
5.3 Materials and Methods 
5.3.1 Clinical Description 
The typical clinical presentation of NAM includes abnormal facies with ptosis 
and low-set ears, muscle wasting and kyphoscoliosis. NAM subjects were of Lumbee 
Indian descent with congenital muscle weakness who demonstrate two or more of the 
following phenotypic characteristics: myopathic facies, susceptibility to malignant 
hyperthermia, kyphoscoliosis, and cleft palate.  Based on these criteria, five Lumbee 
families were included in this study. These families are from North Carolina and the 
probands were ascertained from the University of North Carolina at Chapel Hill’s 
Genetics Clinic and from Duke University’s Muscular Dystrophy Clinic. From these five 
families, 17 DNA samples were available.  All data and samples were collected following 
informed consent of subjects; this study was approved by the Duke University Medical 
Center Institutional Review Board. All families include at least an affected child and 
unaffected mother (family 2281).  Family 3012 also included a sampled unaffected father 
of the case, and families 2118, 3008, and 3013 include a sampled unaffected father and 
an unaffected sibling of the proband.  These families report no connection to one another 
within three degrees of relationship to the proband.   
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5.3.2 Genotyping Methods 
10K SNP Chip  
DNA was extracted from whole blood using the Puregene system (Gentra 
Systems, Minneapolis, MN).  Genotyping was performed on the Affymetrix 10K version 
2 Chip using the standard Affymetrix protocol (Affymetrix, Santa Clara, CA) on all 17 
individuals from the five families. Subjects’ DNA was treated with standard GeneChip 
Mapping 10K XbaI Assay protocol as described previously [191]. Data acquisition was 
performed by using the GeneChip GCOS software.  Data were checked for Mendelian 
errors and an inheritance check was performed using the software GeneSpring GT v1.0 
(Silicon Genetics). SNP data were evaluated for Mendelian inconsistencies using 
PedCheck [232] and SNPs demonstrating non-Mendelian inheritance were removed from 
the analyses. 
5.3.3 Homozygosity Mapping and Copy Number Variant Analysis 
The 10K SNP genotyping data for the families were imported into an Oracle 
database.  Once the data were merged into the database, SQL scripts were developed to 
query the Oracle database for homozygous SNPs shared amongst the individuals with 
NAM.  Regions with ≥ 3 consecutive homozygous SNPs were selected for follow-up 
with microsatellite repeat markers. 
SNP data available from the Affymetrix 10K SNP Chip was also used to evaluate 
for potential copy number variants (CNV) and loss of heterozygosity (LOH). The .cel 
files that provide intensity information for a given probe on an array were utilized in two 
different analysis tools (DChip (http://biosun1.harvard.edu/complab/dchip/) and 
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CNAT4.0 (http://www.affymetrix.com/products/software/specific/cnat.affx)), each of 
which makes two comparisons:  comparing copy number changes between cases and 
controls and characterizing loss of heterozygosity. In each case the SNPs were first 
viewed in groups of 5 in both a smoothed median and a Hidden Markov model. The SNP 
threshold was then gradually lowered to a single SNP using both algorithms.   
 
 
5.3.4 Fine Mapping with Microsatellites 
One or two polymorphic microsatellite markers that reside in each region of shared 
SNP homozygosity were selected to confirm each of the five regions. Once a 
homozygous locus was verified with the first pass of microsatellite genotyping, additional 
microsatellite markers were selected to narrow the minimum interval of shared 
homozygosity. Microsatellite markers were selected based on the highest heterozygosity 
(defined by Centre d’Etude du Polymorphisme Humain (CEPH) Genotype database, 
http://www.cephb.fr/cephdb/php/eng/search.php), spacing within the interval and the 
number of repeats.  The seventeen DNA samples from these families were organized into 
a list with a standardized order of samples to ensure the person performing the 
experiment was blinded to gender and family composition. Quality control (QC) 
standards were included at specified location and randomly selected duplicated 
individuals were used as internal QC’s.  DNA from patients’ blood samples was 
amplified with the microsatellite primers.  Genotyping was performed with 10 ng of 
DNA per reaction, utilizing a genotyping method on acrylamide gels previously 
described [248].  
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5.3.5 Sequencing of Candidate Genes 
UCSC’s “Known Genes” track was used to identify genes in the 12q region of 
interest. Primers were designed using Primer3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) with genomic sequence from UCSC’s bioinformatics 
website. We sequenced a subset of the DNA samples using the five case samples from 
2118 and 2281 because we expected all affected individuals would exhibit the same 
genetic mutation for NAM. PCR product was purified using Sephadex G-50 fine 
(Amersham Biosciences, Piscataway, NJ) and QuickStep2 SOPE Resin (Edge 
BioSystems, Gaithersburg, MD). The samples were then sequenced in both forward and 
reverse directions using the BigDye Terminator v3.1 Cycle Sequencing Ready Reaction 
kit (Applied Biosystems, Foster City, CA) and purified using Sephadex G-50 fine. 
Sequence analysis was performed using ABI 3100 Data Collection Software Version 1.01 
and ABI Sequencing Analysis 3.7. PCR products covered all the exons and respective 
intronic boundaries. The primers were designed to flank the exons and covered 25-50 
base pairs of sequence flanking the exons to include potential splicing regions.  All 
sequences for candidate genes ITGA7, PIP5K2C, PDE1B, and MLC1sa were visually 
inspected with this software to identify noteworthy variants. The sequence was compared 
to unaffected parents to ascertain if any genetic variant detected was transmitted or a de 
novo mutation.  
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5.4 Results 
5.4.1 Genetic Mapping  
The SNP screen identified five regions of homozygosity across 3 or more 
contiguous SNPs in the five NAM affected individuals (Table 5.1).  The longest 
homozygous haplotype length and largest number of contiguous homozygous SNPs was 
observed at 12q13.13-14.1.  
Coincidentally, a balanced paracentric inversion of chromosome 1 (q43-44) was 
observed in the proband of family 2118 (C. Powell, personal communication). Affected 
individuals without this inversion, however, do not share homozygous SNPs around this 
region of chromosome 1q, suggesting that this inversion is unlikely to contain the NAM 
gene. 
Ten microsatellite markers were selected to cover the five regions identified by 
the SNP screen.  These ten markers are described in Table 5.2.  The microsatellite repeat 
marker data narrowed the region of shared homozygosity to one region on chromosome 
12. The other four regions in chromosomes 2, 3, 5 and 6 were eliminated as potential 
regions of interest by heterozygous calls observed for the polymorphic microsatellite 
markers genotyped internal to the regions in the five patients with NAM.  The remaining 
region of shared homozygosity maps to 12q13.13-14.1 spanning a total homozygous 
segment of 5.6 Mb flanked by D12S398 and RS3842936 markers, a 0.3 Mb decrease 
from the SNP homozygosity mapping (Table 5.1). The 12q haplotypes for the five NAM 
families are shown in Figure 5.1. All three sampled unaffected siblings from families 
DUK 2118, 3008, and 3013 did not share any region of the 12q homozygous haplotype, 
and only one unaffected individual (100 from family 3008) was heterozygous for the 
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same alleles on the 12q haplotype as the affected proband (Figure 5.1).  The overall 
results confirm homozygosity in region 12q13.13 to 12q14.2 in the five individuals with 
NAM.  
No significant copy number variants were detected. Whole genome array-CGH, 
providing approximately 50-100K resolution, was performed on DNA from individual 1 
in family 2281 and no deletions in the five SNP segments described in Table 5.1 were 
noted. Loss of heterozygosity (LOH) estimates from CNAT4.0 identified a long stretch of 
LOH in SNPs at 12q supporting our findings from the homozygosity mapping.  
 
5.4.2 Candidate Genes 
The 12q13.13-14.1 chromosomal region is gene dense and contains 
approximately 135 known genes (UCSC Genome Browser http://genome.ucsc.edu/; 
NCBI Build 35). These genes were evaluated by a literature search using Online 
Mendelian Inheritance of Man (OMIM) and PubMed.  Four candidate genes were 
selected for sequence analysis based on their biological plausibility.  Integrin α-7 
(ITGA7) mutations have been shown to cause a human congenital myopathy [249]. 
MLC1sa is a myosin with a hexameric ATPase cellular motor protein that is expressed in 
both slow-twitch skeletal muscle and non-muscle tissue.  Two genes involved in calcium 
regulation were of interest because they might explain the molecular mechanisms for 
both the myopathy and malignant hyperthermia. These were PIP5K2C, a protein 
involved in actin cytoskeleton and phosphatidylinositol signaling, and PDE1B, a calcium/ 
calmodulin-stimulated cyclic nucleotide phosphodiesterase. All four genes were 
sequenced (ITGA7, MLC1sa, PIP5K2C, and PDE1B) but no coding mutations were 
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detected.  A known polymorphism for MLC1sa was detected in the mother (individual 
1001) for DUK family 2281.  She is heterozygous for the known deletion/insertion 
polymorphism rs3841624.  The other four individuals genotyped did not exhibit this 
polymorphism. 
 
5.5 Discussion 
 
 
In this genetic mapping study of NAM, whole genome SNP genotyping identified 
five shared homozygous segments in affected cases, with chromosome 12 having the 
largest homozygous segment. Fine mapping with microsatellite repeat markers eliminated 
four of the regions of interest and confirmed and narrowed our focus to a 5.6 MB region 
spanning D12S398 to RS3842936 at 12q13.13 to 12q14.1.  The 12q microsatellite data 
provided an elegant follow-up to the SNP data, as most of the parental polymorphic 
microsatellite data were heterozygous, allowing informative tracing of the allelic 
transmission patterns that contributed to the homozygous haplotype in the affected 
individuals. This shared homozygous haplotype supports our hypothesis of autozygosity 
for NAM. 
While these NAM mapping results provide evidence for a NAM disease gene on 
chromosome 12q, it is possible that this region represents chance homozygosity.  For 
instance, a homozygous genomic segment may not be autozygous because two copies of 
the genomic segment may be identical by chance mutation and recombination rates [250]. 
Moreover, estimates of chance IBD sharing within the Lumbee population are not 
possible at this time, because the expected allele frequencies for the Lumbee population 
  136 
are currently unavailable, and it is challenging to correctly specify the degree of 
relatedness or kinship coefficient for the NAM pedigrees. Despite having historical 
pedigrees for these five families, most of them only have pedigree structure extending to 
the grandparental generation, and it is probable that a significant founder effect within 
this population and unaccounted familial relatedness would lead to an underestimate of 
the extent of inbreeding. Moreover, homozygous segments have recently been identified 
in apparently outbred populations that are also thought to be from ancestral haplotypes 
[144,188-190]. This further limits our ability to calculate chance homozygosity because a 
certain degree of IBD sharing may be present within the general population that would be 
difficult to model at this time.  
Several homozygosity mapping studies have successfully identified a relevant 
disease gene [192,193,247,251], while others have observed allelic heterogeneity within 
consanguineous kindreds and therefore failed to map the underlying disease mutation 
[194-196]. Therefore, we cannot entirely exclude the possibility that the homozygosity 
observed at 12q13.13-14.1 is unrelated to the NAM phenotype. 
Once the narrowed homozygous 12q locus was characterized, we began 
identifying and testing candidate genes. Mutational screening was performed on these 
four biologically relevant candidate genes: ITGA7, PIP5K2C, PDE1B, and MLC1SA.  
Since NAM is considered a Mendelian disease, we expected to observe an obvious 
mutation leading to a functional change such as a premature termination codon, a 
frameshift mutation(s) or a missense mutation(s), and in the genes evaluated such 
functional mutations were not observed.  
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Individuals with NAM have a higher susceptibility to MH, a process appearing to 
result from abnormal calcium ion balance in skeletal muscle. This suggests that the NAM 
gene may affect calcium regulation. Predisposition to malignant hyperthermia is typically 
inherited as an autosomal dominant trait and has extensive genetic heterogeneity with six 
different malignant hyperthermia susceptibility (MHS) loci, designated as MHS1-6 [29-
37]. Two MHS genes have been identified, including RYR1 and CACNA1S.  MHS1 maps 
to 19q13.1 and is caused by mutations in the RYR1 gene [167,168]. MHS5 maps to the 
1q32 locus [175], and a putative causative mutation in the CACNA1S gene was identified 
in a single large French family [176]. MHS2 maps to 17q11.2 - q24 [170], and three 
families have mapped to the SCN4A gene but no mutation has been identified [165,171].  
The other MHS loci map to the following locations: MHS3 to 7q21-22 [172,173], MHS4 
to 3q13.1 [174], and MHS6 to 5p [175].   None of these MHS loci are in the homozygous 
regions identified in our SNP screen, suggesting a novel locus for the gene responsible 
for NAM. Because malignant hyperthermia is part of the phenotypic profile of NAM, we 
searched the 12q region for genes homologous to the MHS-associated genes RYR1, 
CACNL2A, and SCN4A.  We also searched for homology to the protein tyrosine 
phosphatase, non-receptor type II (PTPN11) gene that maps to 12q24.1, a gene associated 
with Noonan syndrome [MIM 163950] [252]. Noonan syndrome is an autosomal 
dominant disorder, and affected individuals have short stature and dysmorphic features 
that resemble NAM.  However, patients with Noonan syndrome frequently have 
structural cardiac defects not seen in NAM and typically do not have congenital 
myopathy, cleft palate or congenital joint contractures as seen in NAM. No homology 
was found in the region of interest on chromosome 12 for any of these genes.  
  138 
The 12q region is very gene dense, with well over 100 annotated genes in the 5.6 
Mb segment. Because of this, identifying the NAM gene may be a challenging 
undertaking.  Future efforts to identify the NAM gene might include ascertaining 
additional families to identify recombinant individuals, sequencing across the entire 
segment, or using stored muscle biopsies from NAM patients to identify candidate genes 
based on histological findings or RNA expression profiles.   
In addition to homozygosity mapping, the SNP data were used to screen for 
CNVs and LOH.  Although no deletions or amplifications were identified, it is still 
possible a smaller deletion exists on the 12q homozygous background that would be 
detected with denser arrays.  Importantly, the LOH predictions for the SNP chip data 
from the five individuals with NAM also identified 12q as having loss of heterozygosity. 
Therefore, this LOH approach could be used in other studies as a quick screening method 
to predict regions of shared homozygosity that then could be validated using more 
polymorphic markers such as microsatellites.  
 In summary, we utilized whole genome SNP-array technology to identify regions 
of shared homozygosity between five Lumbee individuals with NAM.  The SNP results 
were followed up by genotyping microsatellites to confirm and narrow the homozygosity 
to one critical region. Identification of the underlying genetic basis of NAM may lead to 
better treatments and presymptomatic identification of at-risk individuals for malignant 
hyperthermia.  Additionally, identification of the NAM gene may suggest new genetic 
etiologies for phenotypic components of other conditions such as cleft palate and 
malignant hyperthermia.  This study demonstrates how SNP screens can be used in 
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homozygosity mapping for rare Mendelian recessive diseases even when only one 
affected individual is available per family.  
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Table 5.1 Shared homozygous segments observed in affected individuals identified 
by SNP chip. 
Region SNPs flanking region Size (Mb) 
# Contiguous 
homozygous 
SNPs 
Physical 
Distance (Mb) 
2p11.2 rs725046 – rs1074883 2.8 6 86.3 -89.1 
3q21.3 rs977683 – rs725132 1.8 4 128.2-130.0 
5q13.2-q13.3 rs277939 – rs1363577 3.6  5 70.9-74.5 
6q22.1 rs3897507 – rs339346 1.1 3 116.1-117.3 
12q13.13-q14.1 rs373374 – rs3842936 5.9  18 51.2-57.1 
 
 
 
  
 
Table 5.2 Information on microsatellites used to evaluate regions of shared SNP homozygosity. 
Marker ID Chr Location (bp) Forward Primer Reverse Primer HET
α
 
D2S417 2 86899572 AGATGCTTGTGGTTTAGATGG ATAAAAGCATCTTTTACTGGCTG 72.34% 
D2S2216 2 88248932 GGGGTAAATTATTTCCAGCC TCCCTGACAAAGTGGGC 60.71% 
D3S3607 3 128682908 ACAGGCTCAGGCCCAC CTAAGAATAGCTTCCCAGAAACGG 64.29% 
D5S1982 5 73322387 AGACAGAATCTGGGGGCA TCTCTGGGCTGCTGGA 69.23% 
AFM268VH5 6 117775687 GCTCTGATAAATTTTTGAAAAGTG TGAGTATTAATTTCACTACATCCCT N/A 
D12S398 12 51483266 GGTGGATGGATGGATGAATA AGTGTTTGGACTGTCATTTGC 70.37% 
D12S1586 12 52433022 CTGCACCAAGGCAGGAAC AATTCCAGGCCCACACTTT 92.86% 
D12S1724 12 53156125 CTCTGGAGGCTGAGGTGG ATCCGTGCTGGTTCTATCTGTGTA 82.14% 
D12S1632 12 54701605 GCCTAATCAAGATGTCACCA GCTAGGGAGCCAATTCA 61.54% 
D12S1700 12 58302944 AGATGCTAATGCCATGACA CCCTGTGGATGACCAGTT 82.14% 
Table key: 
Chr = chromosome 
α= Heterozygosities from CEPH Genotype Database (http://www.cephb.fr/cephdb/php/eng/search.php) 
N/A= Heterozygosity information not available    
Location based on NCBI Build 35 (http://www.ncbi.nlm.nih.gov/)
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The disease-associated haplotype is outlined in black boxes and is consistent with an 
autosomal recessive inheritance pattern.  This diagram represents only a subset of the 
markers; several additional SNP markers demonstrated homozygosity in this region. The 
red arrows indicate key recombinant haplotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 The 12q13.13 to 12q14.1 haplotype for the five NAM families. 
  
 
CHAPTER 6  
Discussion of Future Directions and Potential Limitations of Projects 
 
The discussion which follows summarizes the research findings and comments on 
the potential limitations and future directions for the two projects investigating:  
 
1) Genetic susceptibility to neural tube defects in a large multiplex family 8776; 
2) Phenotypic features of NAM and homozygosity mapping outcomes for NAM.  
 
6.1.1 Genetic Susceptibility to Neural Tube Defects in Family 8776 
The first project involved genetic analysis of neural tube defects in one large 
family (family 8776) with multiple affected individuals from the NTD Collaborative 
Study.  Our original linkage findings from this family suggested two broad regions of 
interest for NTD susceptibility genes on chromosomes 2 and 7.  To follow up these 
linkage peaks, we ascertained the 1005/1006/102 branch and performed fine mapping 
that led to substantially narrowing the disease-associated haplotypes to 2q33.1-q35 and 
7p21.1-21.3 (Chapter 3). Unfortunately, however, we have been unable to map the 
underlying disease causing mutations. As with any study evaluating the genetics of 
complex disease, several factors may have affected our ability to successfully identify the 
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actual disease loci including:  1) genetic heterogeneity; 2) misspecification of the model 
of inheritance; 3) different environmental exposures; and 4) chance linkage findings.  
We considered several of these complicating factors in our efforts to map these 
NTD genes, for example the evidence for phenotypic and genetic heterogeneity was 
assessed by excluding individual 100, an individual with an unique NTD phenotype, a 
congenital dermoid cyst. All other affected individuals in this family displayed the 
lumbosacral myelomenginocele phenotype. However, the strongest evidence for linkage 
was obtained in analyses that included individual 100, suggesting a similar genetic 
susceptibility to NTDs in family 8776, irrespective of the exact NTD phenotype.      
Initial investigation of family 8776 did not indicate any obvious inheritance 
pattern and to avoid issues related to misspecification of the disease model both 
parametric and nonparametric or genetic model-free (allele sharing) methods were 
implemented. The strongest support for linkage was obtained when implementing 
nonparametric methods.   
The results from the haplotype analysis were suggestive of an autosomal 
dominant segregating disease in both the 2q and 7p regions of interest. Future genetic 
analysis of family 8776 would benefit from additional ascertainment of the last living 
affected individual 1075, who is shown in Figure 6.1  
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The plus (+) symbol means that DNA is available for that individual. The red ellipse 
represents that individual 1075 is the only affected individual within this family who is 
not currently sampled.  
 
 For example, if individual 1075 also carried the 2q and 7p haplotypes, both allele sharing 
and model-based methods would provide increased support for linkage.  Moreover, if an 
additional recombination event were observed, a further narrowing of the 2q and 7p 
interval could be achieved.  
 Notably, some of the presumed unaffected individuals, with presumably 
unaffected offspring, also carried significant portions of either the 2q and/or 7p 
haplotype.  For example, the 2q and 7p haplotypes are carried by the two unaffected 
offspring 103 and 126.  Individuals 2010 and 2016 in the grandparental generation also 
carry the 7p haplotype. According to our records, individual 2010, who has cerebral 
palsy, did not have any children.  Individuals 2016 and 2017 had 13 pregnancies, of 
which 6 resulted in live children with no documented NTD, while the remaining 7 (54%) 
pregnancies resulted in miscarriages—a much higher miscarriage rate than the expected 
15-20% chance of miscarriage observed in the general population. This increased 
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Figure 6.1 Pedigree plot of family 8776. 
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frequency of spontaneous abortions could be due to the 7p haplotype or any number of 
etiologies including an unrelated chromosomal anomaly, a teratogenic exposure, and/or a 
congenital malformation (e.g. anencephaly) in the fetus. 
Individuals 2010 and 2018, in the grandparental generation, and 5 offspring 
(1065, 1067, 1071, 1073, and 1089) of affected individual 1075, carry the 2q haplotype.  
Interestingly, individual 2018, who carries the 2q haplotype but doesn’t carry the 7p 
haplotype, had 6 normal children without any reported miscarriages.  These data on 
individuals 2016 and 2018 are suggestive that NTD risk may be modulated by epistatic 
interactions between the genes residing on chromosomes 2 and 7.   An alternative 
explanation may be that a gene on 2q may confer protection against spontaneous 
abortion, perhaps by leading to a less severe form of a NTD.  To explore the role of the 
2q and 7p haplotypes in disease susceptibility further, an avenue of future research may 
involve collecting DNA samples on the twelve surviving children of these branches of 
the family to evaluate whether they carry the disease-associated haplotypes and to 
determine their carrier frequency rate.   For example, if the live offspring from 2016 (who 
had 7 spontaneous abortions) carry the 7p haplotype at a lower frequency than expected 
by chance, it may provide further support that the 7p haplotype increase the risk of 
NTDs.   
Since chromosomal aberrations are observed in 2-16% of nonsyndromic NTDs 
[22], we evaluated family 8776 for chromosomal abnormalities using array-CGH, copy 
number variant detection on the 10K SNP chip data, and subtelomeric FISH.   Despite all 
three methods showing normal findings, the possibility remains that smaller cytogenetic 
abnormalities are present and were undetected in our analyses. Table 6.1 shows known 
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cytogenetic abnormalities in 2q and 7p regions associated with NTDs.  Interestingly, all 
of these aberrations were only associated with spina bifida and encephalocele and not 
with anencephaly or craniorachischisis [22]. Though encephalocele may or may not be 
associated with genetic susceptibility to open spina bifida, these abnormalities suggest 
that genes mapping to those segments may be involved with neural tube closure.  
Additionally, denser SNP chips are more frequently used for clinical diagnostic purposes, 
facilitating detection of more subtle chromosomal abnormalities.  Such diagnostic tests 
may lead to an expansion of the known NTD associated chromosomal aberrations, and 
perhaps will define smaller aberrations within the 2q and 7p locations.  
 
Table 6.1 Cytogenetic abnormalities in chromosomal 2q and 7p regions associated 
with NTDs. 
Chromosomal Abnormality Spina Bifida Encephalocele 
Trisomy 2 + + 
Trisomy 7 
 + 
Duplication 7p 
 + 
Deletion 2q24.3 
 + 
Deletion 2q35-36 +  
Table adapted from information from Lynch 2005[22].  
 
The chromosome 7 haplotype maps to an 8.2 Mb interval at 7p21.1-21.3, a region 
with approximately 9 annotated genes. Three of these genes (DGKB, ETV1, and MEOX2) 
have already been sequenced; the remaining 6 genes (NXPH1, ICA1 NDUFA4, PHF14, 
SCIN, ARL4A) should be evaluated in future sequencing efforts of family 8776.  
Particularly ICA1 (islet cell autoantigen 1), as there is an associated risk of maternal 
diabetes with having a child affected with a NTD, the ICA1 gene modulates expression of 
neuronal cells, it was down regulated in case lymphoblast cell lines (Chapter 3) and it is 
  148 
expressed in the fetus during Carnegie Stages 12 and 13 around the time of neural tube 
closure [241].  
The mapped 2q region has approximately 89 genes, of which 15 have been 
screened for obvious coding functional alterations. Also based on preliminary SAGE 
work coupled with biological plausibility additional genes are currently being sequenced 
in the 2q region which include: BMPR2, XRCC5 and ICA1L.  The sequencing efforts for 
family 8776 focused on the coding regions since obvious alterations in amino acid 
structure could be readily argued to have an effect on protein function because it is 
difficult to understand the functional consequence of non-coding variants when analyzing 
only one family.  However, intronic, promoter, and 3’ UTR variants may be functionally 
relevant to gene regulation in family 8776 and other NTD families.  
 Another project currently underway at Duke University is investigating the 
genetic basis of Chiari II malformations using family based gene mapping approaches. 
Since Chiari II malformation co-occurs with open spina bifida, any genetic mutations 
associated with Chiari II could also be tested in family 8776 and in our large collection of 
families with open spina bifida.  Alternatively, once an interesting genetic variant was 
detected in family 8776, the next steps would be to carry out association studies of this 
gene in the larger NTD data set as well as in the Chiari II population to determine the 
relevance of this gene in other families.     
 
6.1.2 Environmental Exposures and Other Potential Risk Factors for NTD 
After the identification of main genetic effects in Family 8776 and using the 
larger NTD dataset, it will be important to consider gene-environment interactions using 
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the data collected from the environmental risk factor questionnaire. Specifically folic acid 
status could be evaluated based on information on maternal perinatal intake of folic acid 
and daily multivitamins. Other potential risk factors to consider include maternal weight, 
maternal diabetes, smoking and medication use during pregnancy. The two critical 
regions with similar evidence in favor of linkage for family 8776 suggest that there may 
be polygenic effects; therefore, potential gene-gene and gene-environment interactions 
could be studied in several NTD families. 
Epigenetic mechanisms may also play a role in normal and dysregulated neural 
tube closure.  In family 8776, epigenetic mechanisms may be involved in disrupted 
neural tube closure. For instance, the sex ratios for transmitting members of the family to 
affected children has a 5:2 female to male ratio suggesting a stronger maternal 
transmission pattern.  Although this observation is not statistically significant and may 
reflect ascertainment biases toward maternal interviews, it illustrates the potential for 
maternal nutritional status in family 8776 affecting imprinting mechanisms and/or 
general methylation reactions that may increase the risk of having a child affected with an 
NTD.  At this time, no imprinted genes in the 2q and 7p regions of interest were noted 
[253].  If future studies reveal imprinted genes in these regions they should be evaluated.  
To estimate the degree of folate derivates consumed by women around the time of 
conception through the first month of pregnancy, a risk factor questionnaire with specific 
questions pertaining to folic acid, prenatal vitamins and multivitamins use was completed 
by NTD study participants.  Although these types of questionnaires are subject to recall 
bias, a rough measure of maternal folic acid status at the time of neural tube closure was 
obtained.  The folic acid questionnaire outcomes in family 8776 of the five mothers who 
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had a child affected with an NTD are illustrated in Table 6.2. All five mothers reported 
that they took folic acid, prenatal vitamins, or multivitamins first two months of 
pregnancy.  Individuals 1006, 1023, and 2021 reported taking prenatal or multivitamins 
for an NTD-affected pregnancy before 1990 when there was less public awareness of the 
role of folic acid in preventing NTDs. Thus, the amount of folic acid present in the 
multivitamin formulations at that time may have been inadequate for full protection 
against NTDs. It has been additionally difficult to determine if the mothers commenced 
taking folic acid prior to conception or more specifically, prior to neural tube closure.  To 
address this issue, the questionnaire has recently been changed to ask: “How far along 
before you knew you were pregnant?”  This question is a way to better estimate the 
mother’s actual folic acid intake at the time of neural tube closure, and the mothers in 
family 8776 have not been asked this question yet.  Another possible explanation is that 
the mothers from family 8776 had adequate folic acid consumption according to current 
recommendations, and this family may alternatively have genetic variant(s) conferring 
NTD risk that either lead to the intrauterine environment being folic acid resistant or 
increase the metabolism/excretion of folic acid or are completely unrelated to folic acid.  
 
Table 6.2 Folic acid questionnaire results for family 8776 
Mother Child 
Year 
Child 
Born 
FA 3m 
before 
preg? 
FA in first 
2m of 
preg? 
PV  3m 
before 
preg? 
PV in 
first 2m 
of preg? 
MV 
3m before 
preg? 
MV in first 
2m of 
preg? 
1001 1 1998 Yes yes no yes no No 
1001 100 1999 Yes yes no yes no No 
1006 102 1987 No no no yes yes No 
1023 128 1991 No no no yes no No 
1028 129 1983 No no no yes no No 
2021 1075 1957 No no no no yes Yes 
FA, folic acid; PV, prenatal vitamins; MV, multivitamins; m, months; preg, pregnancy 
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Recently, autoantibodies against folate receptors to placental membranes in 
women who had NTD-affected pregnancies were identified that may be blocking the 
cellular uptake of folate [89]. It would be interesting to examine if the mothers with 
affected children in family 8776 also express these autoantibodies, and more generally to 
investigate if the autoantibodies are correlated to all NTDs or only specific form of NTDs 
in a larger NTD dataset. The presence of other predisposing factors for NTD 
development in the presence of these autoantibodies to folate receptors is supported by 
the observation that two women with normal pregnancies also had autoantibodies against 
folate receptors. If these mothers from family 8776 demonstrate autoantibodies to folate 
receptors, it is possible that the chromosome 2 and 7 regions of interest may contain 
modifier genes that increase NTD risk in the developing fetus. Therefore, it would be 
additionally informative to collect serum on family members who also have children that 
are not affected by an NTD. Although the titer patterns of these autoantibodies is 
currently unknown, such that levels may change during different stages of pregnancy or 
alternatively, there may be variability from one pregnancy to the next. At this time, it is 
unclear whether these autoantibodies are environmental triggered or genetically 
determined or a combination of the two.  
 
6.1.3 Commentary on Future Genetic Studies of Human NTDs 
Since linkage often maps to large ~10-20 Megabase segments resulting in 
multiple interesting candidate genes, a staged approach has been commonly applied to 
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genetic analysis of complex human disorders. These staged approaches can involve fine 
mapping under the linkage peaks that is then followed by association analysis to provide 
more precise localization of candidate genes. At this time, only limited linkage data is 
available for human NTDs and of the 43 other multiplex families studied in the previous 
screen, none had strong evidence of linkage to the 2q and 7p regions, preventing 
association analysis in those regions. However, future whole genome linkage or 
association analysis within the ~330 multiplex and ~860 simplex American Caucasian 
families enrolled in the Duke NTD study may reveal promising genes mapping to the 2q 
and 7p region of interest.  In the field of human genetics, whole genome association 
(WGA) studies are becoming a more popular form of genetic analysis than traditional 
linkage studies, and it is therefore worthwhile to consider the rationale behind performing 
WGA studies in NTDs. Given the number of tests in a dense WGA, many regions of 
follow-up may be identified, and many of which will be false positive findings.   In order 
to reduce the number of false positives identified, WGA studies need to be adequately 
powered with large sample sizes, but replication samples are also needed. With the NTD 
study, even though enough sampled individuals exist to conduct WGA at this scale, it 
would be a very costly research endeavor and would require replication in another 
population or dataset to understand the broader significance of an association of 
polymorphism(s) with NTD susceptibility.  
 Moreover, the SNP arrays currently available for WGA may or may not be the 
most informative set for studying the genetic basis of NTDs. Many platforms 
preferentially select coding or exonic SNPs; however, this preference may lead to 
missing key promoter or intronic SNPs that may be functionally important for neural tube 
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closure. In addition, SNP selection for these platforms is based on the assumption that 
common diseases are caused by common variants with minor allele frequencies >5%, and 
this hypothesis may not hold true for more rare complex diseases, such as NTDs. I 
personally believe a combination of both common and rare SNPs predispose to NTDs 
and the constituent combination will vary in different populations and in different 
phenotypes.  From a more optimistic perspective, common SNPs may be in LD with 
some of the rare high risk SNPs such that WGA may still be a powerful tool for gene 
mapping studies in NTDs.  Moreover, the density of the arrays continue to increase with 
500K and 1M chips now available, and these denser chips may adequately capture more 
of the non-coding variation in the human genome.  
Overall, successful identification of an interesting NTD variant using linkage, 
association and/or sequencing approaches would provide valuable insight into the 
molecular mechanisms underlying NTDs, and may allow further investigation of these 
mechanisms in appropriate model organisms to elucidate therapeutic options to prevent 
and/or ameliorate disrupted neural tube closure. 
 
6.2 Native American Myopathy Study 
The second project studied Native American myopathy, a Mendelian congenital 
myopathy associated with high mortality and morbidity. For the purposes of this 
dissertation, we conducted a clinical evaluation (Chapter 4) and the first ever gene 
mapping study of NAM (Chapter 5).  
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6.2.1 NAM: Clinical Evaluation and Natural History of Disease 
Chapter 4 provides the most extensive clinical description of NAM to date, 
among fourteen individuals of Lumbee Indian descent.   In terms of the natural history of 
NAM, we were able to document for the first time the mortality rate for this condition, a 
rate of 36% by age 18. Also, we were able to document that malignant hyperthermia, a 
potentially dangerous condition, occurred in 29% of patients.  Moreover, pedigree 
inspection of the fourteen supported an autosomal recessive inheritance pattern for NAM 
suggesting that homozygosity mapping may be a productive approach for gene 
identification studies.  Overall, this information will further our understanding of the 
clinical presentation and natural history of NAM, and ideally lead to improved diagnosis 
and counseling of patients and their families in the Lumbee population.   
Although this clinical study of Lumbee Indian family members is the most 
extensive evaluation of NAM to date, future work to characterize the muscle pathology of 
patients with NAM is warranted.  Often the classification of muscular disorders is done 
through histopathological examination of skeletal muscle tissue from muscle biopsies. 
Although the muscle biopsy procedure is somewhat invasive, the information could not 
only contribute to the clinical categorization of the disease as NAM relates to other 
congenital myopathies, but also could be used for candidate gene selection. To avoid 
potential risks associated with new muscle biopsies, stored muscle biopsies on patients 
with NAM could alternatively be assessed. 
Furthermore, given the clinical risks associated with NAM, future work to 
identify the NAM gene is also warranted, as the identification of a susceptibility NAM 
gene could aid in genetic counseling for families with Lumbee ancestry.  Since the 
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original dataset for NAM included only two families and collecting more families would 
allow for a more powerful homozygosity mapping study, multiple clinical ascertainment 
strategies were employed for study recruitment of NAM families. These approaches 
included re-contacting families already involved in the study by telephone, referral from 
clinics, sending letters to physicians in Robeson County, and the posting of an 
advertisement on Lumbee affiliated web browsers.  Unfortunately, we had very limited 
success in our ascertainment strategies with only 3 new families being recruited, two of 
which were families previously seen by Cynthia Powell, a medical geneticist at the 
University of North Carolina at Chapel Hill.  Altogether five simplex families were 
available to us for homozygosity mapping studies. The challenges we encountered with 
attempts to recruit additional NAM families may reflect inherent culture fears within the 
Lumbee population towards genetic studies and/or a lack of diagnosis of NAM by 
physicians.  Future ascertainment could involve closer collaboration with the Lumbee 
Tribal government.   
 
6.2.2 Homozygosity Mapping in NAM 
Homozygosity mapping of the five affected NAM individuals using a genome-
wide 10K SNP screen identified five regions (2p, 3q, 5q, 6q, and 12q) of shared 
homozygosity, with 3 or more contiguous SNPs (Chapter 5).  Additional genotyping in 
these segments narrowed the interval to one region that also was the longest region of 
homozygosity on chromosome 12q13.13 to 12q14.1 (5.6 Mb segment).   
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The observation that 12q maps to the longest homozygosity segment is a 
potentially promising finding based on a study by Woods and colleagues, who evaluated 
the degree of homozygous segments in individuals with recessive disease whose parents 
were first cousins. They found the longest homozygous segment was the disease-
associated segment 17% of the time—a 12% increase over the expected 5% (1/20 
segments) [254].  Thus, since the 12q homozygous segment was the longest segment 
observed in the patients with NAM and the only confirmed homozygous segment, and 
because NAM appears to be following a recessive inheritance pattern, we are 
hypothesizing that the underlying susceptibility gene is localized on chromosome 12q. 
However, it is important to acknowledge the possibility that the 12q region 
represents chance autozygosity. At this time, estimates of chance IBD sharing within the 
Lumbee population are not possible because we do not know the expected allele 
frequencies of the markers genotyped for the Lumbee population and it is challenging to 
correctly specify the degree of relatedness within the NAM pedigrees to estimate the 
extent of expected IBD allele sharing.  In the future, ascertainment of additional NAM 
families or Lumbee individuals enrolled for other studies could be used to estimate allele 
frequencies.  However, misspecification of the degree of relatedness may remain a 
problem since the Lumbee population is likely to have experienced a significant founder 
effect and may have unspecified family relationships that could lead to an underestimate 
of the extent of IBD sharing.   
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6.2.3 Identification of NAM gene 
The NAM homozgosity mapping work revealed a 5.6 Mb segment shared among 
the five patients with NAM, mapping to 12q13.13 to 12q14.1. This region appears to be 
very gene dense with well over 100 annotated genes.  As a result, future sequencing 
efforts in this 12q region may be difficult. Thus far, ITGA7, PIP5K2C, PDE1B, and 
MLC1SA have been sequenced and no functional mutations were identified in these 
genes.  No other obvious candidate genes were noted in this region. Nonetheless, several 
approaches could be used in the future to help identify the causative mutation residing in 
the putative NAM locus such as ascertaining additional families to identify a recombinant 
individual and/or ascertaining individuals with MH only to possibly narrow the interval 
and localize the NAM gene.   Another approach to minimize sequencing efforts may be 
to use muscle biopsies from NAM patients to prioritize candidate genes based on 
histological finding or RNA expression profiles. Perhaps in the future more affordable 
sequencing platforms may become readily available such that determining the sequence 
across the entire 5.6 Mb segment would be feasible.   
Even though the homozygosity mapping to 12q appears promising for 
identification of a novel gene for NAM, the disease gene may map to another location. 
Several factors may have prevented the identification of the actual NAM locus such as 
genetic heterogeneity or a smaller homozygous segment flanking the disease gene in 
another region that falls outside of our 3 or more contiguous SNP threshold.  In addition, 
it is possible that the disease gene may be in a region with a paucity of SNP coverage on 
the 10K chip.  Based on the possibility of chance autozygosity at 12q, the MHS 
associated genes RYR1 and CACNA1S can still be considered potential candidate genes 
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for NAM. However, the 19q13.1 locus for the RYR1 gene did not reveal shared 
homozygosity among the five affected individuals with NAM (even between two 
contiguous SNPs). Nonetheless, it is still possible that one of the individuals may be 
heterozygous for the mutation rather than homozygous. Moreover, more than one 
mutation in the NAM gene may be segregating in the Lumbee population such that an 
individual with NAM could be a compound heterozygote. Although NAM presents with 
features similar to other diseases as described in Chapter 1, we believe this disorder is 
clinically distinct.  However, mutations in the MHS genes RYR1 or CACNA1S may still 
be responsible for the NAM phenotype and cannot be excluded, especially since both 
autosomal recessive and dominant mutations in RYR1 are associated with variable 
phenotypic presentations of congenital myopathies and/or malignant hyperthermia 
susceptibility.  Because mutations in the RYR1 cause the majority of known mutations 
associated with MHS and/or congenital myopathy, sequencing of the RYR1 gene in one 
of the individuals with NAM, who has a history of MH is being performed by 
PreventionGenetics (Marshfield, WI).  
Once the NAM gene is identified, future analysis could involve characterizing 
genotype-phenotype correlations to investigate whether an individual with one versus two 
mutated genes leads to differences in phenotypic presentation. Carrier testing may be 
particularly helpful if it is discovered that heterozygotes are at greater risk for malignant 
hyperthermia, a potentially life-threatening illness.  Moreover, to definitively determine if 
heterozygotes were susceptible to MH, the IVCT test could be done on muscle biopsy 
specimens to clarify the phenotype because MH will not be observed unless the patient 
has received halogenated agents or succinylcholine during anesthesia.  Overall, the 
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identification of a NAM gene could contribute to our understanding of the etiology of 
NAM and may provide an avenue for the development of a genetic test for this 
devastating disease.  
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